<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78972</article-id><article-id pub-id-type="doi">10.7554/eLife.78972</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Differentiated glioma cell-derived fibromodulin activates integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-274971"><name><surname>Sengupta</surname><given-names>Shreoshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274972"><name><surname>Mondal</surname><given-names>Mainak</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274973"><name><surname>Prasasvi</surname><given-names>Kaval Reddy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274974"><name><surname>Mukherjee</surname><given-names>Arani</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274975"><name><surname>Magod</surname><given-names>Prerna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-181759"><name><surname>Urbach</surname><given-names>Serge</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-267094"><name><surname>Friedmann-Morvinski</surname><given-names>Dinorah</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6394-9876</contrib-id><email>dino@tauex.tau.ac.il</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-50432"><name><surname>Marin</surname><given-names>Philippe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5977-7274</contrib-id><email>philippe.marin@igf.cnrs.fr</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-270908"><name><surname>Somasundaram</surname><given-names>Kumaravel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6228-9741</contrib-id><email>skumar1@iisc.ac.in</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dese585</institution-id><institution>Department of Microbiology and Cell Biology, Indian Institute of Science Bangalore</institution></institution-wrap><addr-line><named-content content-type="city">Bangalore</named-content></addr-line><country>India</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mhzgx49</institution-id><institution>School of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Tel Aviv</named-content></addr-line><country>Israel</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043wmc583</institution-id><institution>Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM</institution></institution-wrap><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mhzgx49</institution-id><institution>Sagol School of Neuroscience, Tel Aviv University</institution></institution-wrap><addr-line><named-content content-type="city">Tel Aviv</named-content></addr-line><country>Israel</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0202bj006</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>01</day><month>06</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e78972</elocation-id><history><date date-type="received" iso-8601-date="2022-03-25"><day>25</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-05-29"><day>29</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-04-06"><day>06</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.04.03.486893"/></event></pub-history><permissions><copyright-statement>© 2022, Sengupta et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Sengupta et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78972-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-78972-figures-v3.pdf"/><abstract><p>Cancer stem cells (CSCs) alone can initiate and maintain tumors, but the function of non-cancer stem cells (non-CSCs) that form the tumor bulk remains poorly understood. Proteomic analysis showed a higher abundance of the extracellular matrix small leucine-rich proteoglycan fibromodulin (FMOD) in the conditioned medium of differentiated glioma cells (DGCs), the equivalent of glioma non-CSCs, compared to that of glioma stem-like cells (GSCs). DGCs silenced for FMOD fail to cooperate with co-implanted GSCs to promote tumor growth. FMOD downregulation neither affects GSC growth and differentiation nor DGC growth and reprogramming in vitro. DGC-secreted FMOD promotes angiogenesis by activating integrin-dependent Notch signaling in endothelial cells. Furthermore, conditional silencing of <italic>FMOD</italic> in newly generated DGCs in vivo inhibits the growth of GSC-initiated tumors due to poorly developed vasculature and increases mouse survival. Collectively, these findings demonstrate that DGC-secreted FMOD promotes glioma tumor angiogenesis and growth through paracrine signaling in endothelial cells and identifies a DGC-produced protein as a potential therapeutic target in glioma.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer stem-like cells</kwd><kwd>differentiated bulk tumor cells</kwd><kwd>fibromodulin</kwd><kwd>angiogenesis</kwd><kwd>glioblastoma</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Somasundaram</surname><given-names>Kumaravel</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Department of Science and Technology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Somasundaram</surname><given-names>Kumaravel</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001852</institution-id><institution>Indo-French Centre for the Promotion of Advanced Research</institution></institution-wrap></funding-source><award-id>n° IFC/5603-C/2016/503</award-id><principal-award-recipient><name><surname>Somasundaram</surname><given-names>Kumaravel</given-names></name><name><surname>Marin</surname><given-names>Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id><institution>Israel Science Foundation</institution></institution-wrap></funding-source><award-id>Grant no.1315/15 and 1429/20</award-id><principal-award-recipient><name><surname>Friedmann-Morvinski</surname><given-names>Dinorah</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002915</institution-id><institution>Fondation pour la Recherche Médicale</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Marin</surname><given-names>Philippe</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Comprehensive proteomic investigation and functional studies unravel an essential role of differentiated glioma cell-secreted fibromodulin (FMOD) in regulating glioblastoma tumor growth by inducing angiogenesis by activating integrin-dependent Notch signaling in endothelial cells, highlighting FMOD as a potential therapeutic target.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tumors and their microenvironment form an ecosystem with many cell types that support tumor growth. The key constituents of this ecosystem include cancer stem cells (CSCs), non-cancer stem cells (non-CSCs) representing the differentiated cancer cells, and various other cell types present in the tumor stroma (<xref ref-type="bibr" rid="bib43">Prager et al., 2019</xref>). It is well established that the tumor-initiating capacity lies solely with CSCs, thereby making them the crucial architects of tumor–stroma interactions that favor tumor growth and progression (<xref ref-type="bibr" rid="bib46">Rheinbay et al., 2013</xref>). CSCs have a dichotomous division pattern as they are capable of self-renewal and give rise to differentiated cells that form the bulk of the tumor (<xref ref-type="bibr" rid="bib38">Olmeda and Ben Amar, 2019</xref>)<italic>.</italic> The indispensable role of CSCs, which usually constitute only a minority population within tumors, is well documented in many solid tumors (<xref ref-type="bibr" rid="bib20">Galli et al., 2004</xref>; <xref ref-type="bibr" rid="bib26">Ignatova et al., 2002</xref>; <xref ref-type="bibr" rid="bib52">Singh et al., 2004</xref>; <xref ref-type="bibr" rid="bib73">Yang et al., 2020a</xref>).</p><p>The tumor microenvironment is a vital driver of plasticity and heterogeneity in cancer (<xref ref-type="bibr" rid="bib9">Carnero and Lleonart, 2016</xref>; <xref ref-type="bibr" rid="bib24">Heddleston et al., 2010</xref>). The presence of hypoxic and necrotic regions is the hallmark of very aggressive tumors like glioblastoma (GBM), which have a highly vascular niche that supplies nutrients to cancer cells and makes a conducive environment for the tumor cells to thrive (<xref ref-type="bibr" rid="bib22">Hambardzumyan and Bergers, 2015</xref>; <xref ref-type="bibr" rid="bib25">Huang et al., 2016</xref>)<italic>.</italic> Paracrine signaling mediated by proteins secreted from tumor cells, particularly glioma stem-like cells (GSCs), helps acquire this highly vascular phenotype by attracting blood vessels and inducing pro-angiogenic signaling in endothelial cells through extracellular matrix (ECM) remodeling (<xref ref-type="bibr" rid="bib15">Dittmer and Leyh, 2014</xref>; <xref ref-type="bibr" rid="bib48">Rupp et al., 2016</xref>). A reciprocal relationship exists between GSCs and endothelial cells by which endothelial cells induce stemness phenotype in cancer cells through activation of Notch, sonic hedgehog (SHH), and nitric oxide synthase signaling pathways (<xref ref-type="bibr" rid="bib27">Jeon et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Yan et al., 2014</xref>; <xref ref-type="bibr" rid="bib80">Zhu et al., 2011</xref>), while GSCs drive vascularization of the tumor via endogenous endothelial cell stimulation, vascular mimicry, and GBM-endothelial cell transdifferentiation (<xref ref-type="bibr" rid="bib23">Hardee and Zagzag, 2012</xref>; <xref ref-type="bibr" rid="bib53">Soda et al., 2011</xref>). Recent reports have shown that CSCs induce high vascularization of tumors like GBM by migrating along blood vessel scaffolds to invade novel vascular niches, thereby ensuring surplus and continuous blood supply at their disposal (<xref ref-type="bibr" rid="bib44">Prager et al., 2020</xref>). In GBM, CD133+ and Nestin+ cells (representing GSCs) are located in close proximity to the tumor microvascular density (MVD), whereas a lower number of CD133- and Nestin- cells (representing differentiated glioma cells [DGCs]) are located in the vicinity of the blood vessels. It has also been reported that the depletion of brain tumor blood vessels causes a decrease in the number of tumor-initiating GSCs (<xref ref-type="bibr" rid="bib8">Calabrese et al., 2007</xref>).</p><p>While CD133 marker expression was reported to be associated with GSCs initially (<xref ref-type="bibr" rid="bib52">Singh et al., 2004</xref>; <xref ref-type="bibr" rid="bib20">Galli et al., 2004</xref>), later reports documented CD133- cells exhibiting GSC-like properties (<xref ref-type="bibr" rid="bib7">Beier et al., 2007</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Joo et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Ogden et al., 2008</xref>; <xref ref-type="bibr" rid="bib67">Wang et al., 2008</xref>). CXCR4-dependent SHH-GLI-NANOG signaling promotes stemness in GSCs. This study also showed that the miR302-367 cluster could suppress stemness and promote differentiation by targeting CXCR4/SDF1 (<xref ref-type="bibr" rid="bib16">Fareh et al., 2012</xref>). The above group subsequently showed that miR18A* promotes GSC stemness by activating Notch-dependent SHH-GL1-NANOG signaling, targeting DLL3, an autocrine inhibitor of Notch 1 signaling (<xref ref-type="bibr" rid="bib64">Turchi et al., 2013</xref>). In contrast to these observations, Dirkse et al. showed the existence of stem cell-associated heterogeneity in GBM, which results in tumor plasticity and is orchestrated by the microenvironment (<xref ref-type="bibr" rid="bib14">Dirkse et al., 2019</xref>).</p><p>Besides CSC self-renewal, their differentiation to form the bulk cancer cells also plays a crucial role in tumor growth and maintenance (<xref ref-type="bibr" rid="bib29">Jin et al., 2017</xref>). Epigenome unique to CSCs compared to differentiated cancer cells has been documented (<xref ref-type="bibr" rid="bib58">Suvà et al., 2014</xref>; <xref ref-type="bibr" rid="bib78">Zhou et al., 2018</xref>). Reciprocally, a set of four reprogramming transcription factors, POU3F2, SOX2, SALL2, and OLIG2, is identified in GBM that is sufficient to reprogram DGCs and create the epigenetic landscape of native GSCs, thus creating ‘induced’ CSCs (<xref ref-type="bibr" rid="bib58">Suvà et al., 2014</xref>). The epigenetic regulation forms the basis of cellular plasticity, which creates a dynamic equilibrium between CSCs and differentiated cancer cells (<xref ref-type="bibr" rid="bib49">Safa et al., 2015</xref>). Oncogene-induced dedifferentiation of mature cells in the brain was also reported using a mouse model of glioma, and the reprogrammed CSCs were proposed to contribute to the heterogeneous cell state populations observed in malignant gliomas (<xref ref-type="bibr" rid="bib17">Friedmann-Morvinski et al., 2012</xref>; <xref ref-type="bibr" rid="bib18">Friedmann-Morvinski and Verma, 2014</xref>). Lineage-tracing analyses revealed the reprogramming of DGCs to GSCs that act as a reservoir for initiating relapse of the tumors upon temozolomide chemotherapy (<xref ref-type="bibr" rid="bib3">Auffinger et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2012</xref>). Hypoxia has also been reported to reprogram differentiated cells to form CSCs in glioma, hepatoma, and lung cancer (<xref ref-type="bibr" rid="bib45">Prasad et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Wang et al., 2017</xref>). Spontaneous conversion of differentiated cancer cells to CSCs has also been reported in breast cancer (<xref ref-type="bibr" rid="bib31">Klevebring et al., 2014</xref>; <xref ref-type="bibr" rid="bib79">Zhou et al., 2019</xref>).</p><p>Collectively, these studies highlight the crucial role of CSCs in cellular crosstalk in the tumor niche and establish CSCs as critical drivers of tumorigenesis. However, the massive imbalance in the proportions of CSCs and non-CSCs or differentiated cancer cells in tumors raises several important questions. Considering that differentiated cancer cells constitute the bulk of tumors, do they have specific functions, or do they only constitute the tumor mass? Do they contribute to the complex paracrine signaling occurring within the tumor microenvironment? Do they support tumor growth by promoting CSC growth and maintenance? It has been recently shown in GBM that DGCs cooperate with GSCs through a paracrine feedback loop involving neurotrophin signaling to promote tumor growth (<xref ref-type="bibr" rid="bib69">Wang et al., 2018</xref>). While this study suggests a supporting role for differentiated cancer cells in tumor growth, the large proportion of them in tumors suggests a role in paracrine interactions with other stromal cells in the tumor niche.</p><p>We used quantitative proteomics to identify DGC-secreted proteins that might support their paracrine interactions within the tumor microenvironment. We show an essential role of fibromodulin (FMOD) secreted by DGCs in promoting tumor angiogenesis via a crosstalk with endothelial cells. FMOD promotes integrin-dependent Notch signaling in endothelial cells to enhance their migratory and blood vessel-forming capacity. These findings indicate that DGCs are crucial for supporting tumor growth in the complex tumor microenvironment by promoting multifaceted interactions between tumor cells and the stroma.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>DGC and GSC secretomes have distinct proteomes revealed by tandem mass spectrometry</title><p>While GSCs alone can initiate a tumor, the overall tumor growth requires functional interactions between GSCs and DGCs (<xref ref-type="bibr" rid="bib52">Singh et al., 2004</xref>; <xref ref-type="bibr" rid="bib69">Wang et al., 2018</xref>). To further understand the respective roles of GSCs vs. DGCs in tumor growth, we compared the conditioned medium (CM) derived from three patient-derived human GSC cell lines (MGG4, MGG6, and MGG8) (<xref ref-type="bibr" rid="bib66">Wakimoto et al., 2009</xref>) and their corresponding DGCs, using a quantitative proteomic strategy. Proteins in CMs were systematically analyzed by nano-flow liquid chromatography coupled to Fourier transform tandem mass spectrometry (nano-LC-FT-MS/MS), and their relative abundance in DGC vs. GSC CM was determined by label-free quantification. We found that 119 proteins are more abundant in GSC CM, while 185 proteins are more abundant in the DGC CM (p&lt;0.05, <xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Analysis of overrepresented functional categories among proteins exhibiting differential abundances in GSC vs. DGC CMs using Perseus with a p-value &lt;0.05 revealed that the DGC CM is enriched in proteins known to exhibit extracellular or cell surface localization, such as proteins annotated as ECM organization while terms related to DNA replication and many signaling pathways are enriched in GSC CM (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Quantitative proteomics shows a higher abundance of fibromodulin under the control of TGF-β signaling in the differentiated glioma cell (DGC) secretome.</title><p>(<bold>A</bold>) Volcano plot depicting relative protein abundance in glioma stem-like cell (GSC) (MGG4, MGG6, and MGG8) vs. their corresponding DGC conditioned media (CM). The black dots represent the nonsignificant proteins (p&gt;0.05), while the red (higher abundance in GSC CM) and green (lower abundance in GSC CM) dots represent the significant ones (p&lt;0.05) with a log<sub>2</sub> fold change cutoff of &gt;0.58 or &lt;−0.58. (<bold>B</bold>) Venn diagram showing the relationship between proteins upregulated in DGC CM and annotated extracellular matrix (ECM) proteoglycans. Of the common proteins shown below, fibromodulin (FMOD) exhibits the highest DGC/GSC ratio (indicated by the more intense red color). (<bold>C</bold>) Label-free quantification (LFQ) of FMOD, expressed as log<sub>2</sub> fold change in GSCs vs. DGCs CM. (<bold>D</bold>) RT-qPCR analysis shows upregulation of FMOD transcript in DGCs (red bars) compared to GSCs (blue bars). (<bold>E</bold>) Western blotting shows the presence of higher amounts of intracellular FMOD in DGCs compared with corresponding GSCs. (<bold>F</bold>) Western blotting shows the presence of higher amounts of FMOD in the DGC CM compared to GSC CM (top panel). Equal loading of the proteins assessed by Ponceau Red staining (bottom panel). (<bold>G</bold>) RT-qPCR analysis shows a reduction of FMOD transcript level in DGCs, but not in GSCs, upon treatment with SB431542 (10 μM), a TGF-β inhibitor. Red bars indicate FMOD expression, and blue bars represent TGM2 (a bonafide TGF-β pathway target gene) expression. (<bold>H</bold>) Western blotting shows the reduction of FMOD protein level in DGCs, but not in GSCs, upon treatment with SB431542 (10 μM) (intracellular, top, and secreted, bottom). Equal loading of the secreted proteins assessed by Ponceau Red staining. (<bold>I</bold>) Western blotting shows higher expression of pSAMD2 in DGCs than in GSCs, which is reduced by SB431542 treatment. (<bold>J</bold>) RT-qPCR shows significantly higher fold enrichment of pSMAD2 in the FMOD promoter, which is inhibited upon SB431542 treatment (10 μM). For panels (<bold>C</bold>), (<bold>D</bold>), (<bold>G</bold>), and (<bold>J</bold>), n=3, and p-value is calculated by unpaired <italic>t</italic>-test with Welch’s correction. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data1-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data2-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data3-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data4-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1E, F, H, I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data5-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata6"><label>Figure 1—source data 6.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data6-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata7"><label>Figure 1—source data 7.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data7-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata8"><label>Figure 1—source data 8.</label><caption><title>TGF-β is activated in glioblastoma (GBM) over normal samples in multiple datasets.</title><p>The table shows the gene set enrichment analysisGene Set Enrichment Analysis (GSEA) output, indicating significant positive enrichment of multiple TGF-β-related gene sets in GBM over normal in multiple publicly available datasets. Darker to lighter red indicates the highest to lowest normalized enrichment score (NES), while the symbol '%' and green color indicate the significant gene sets p-Value &lt;0.05 is considered significant. NA, not available.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data8-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata9"><label>Figure 1—source data 9.</label><caption><title>Source data used to generate <xref ref-type="supplementary-material" rid="fig1sdata8">Figure 1—source data 8</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data9-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata10"><label>Figure 1—source data 10.</label><caption><title>Mesenchymal gene expression signature and TGF-β signaling pathway are enriched in differentiated glioma cells (DGCs).</title><p>Gene Set Variance Analysis (GSVA) output indicates the molecular subtypes of the glioma stem-like cells (GSCs) and DGCs of MGG4, MGG6, and MGG8 (each in triplicates). The darkest red indicates the highest GSVA value for a subtype indicating the highest enrichment in that particular sample, with decreasing color intensity indicating a lower enrichment of the subtypes. The table also shows the GSVA score for the TGF-β hallmark gene set from MSigDb across the multiple data sets. The darkest red depicts the highest enrichment, and gradual lighter colors indicate gradually decreasing enrichment.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data10-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata11"><label>Figure 1—source data 11.</label><caption><title>Source data used to generate <xref ref-type="supplementary-material" rid="fig1sdata10">Figure 1—source data 10</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-data11-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Gene Ontology (GO) analysis of differentially abundant proteins in glioma stem-like cell (GSC) and differentiated glioma cell (DGC) conditioned medium (CM).</title><p>(<bold>A</bold>) Output of GO analysis of proteins exhibiting higher abundance in the GSC CM. (<bold>B</bold>) Output of GO analysis of proteins exhibiting higher abundance in DGC CM. The enrichment factor (plotted on the X-axis) is calculated by log (q-value). The q-value is a modified Fisher’s exact p-value provided by the UniProt Database for annotation, visualization, and integrated discovery enrichment analysis.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>The TGF-β pathway is activated in differentiated glioma cells (DGCs) over glioma stem-like cells (GSCs).</title><p>Gene set enrichment analysis (GSEA) output, represented by the enrichment plots, shows a significant negative enrichment of multiple TGF-β-related gene sets in GSCs compared to DGCs, suggesting activated TGF-β signaling in the DGCs. The depicted gene sets have a positive normalized enrichment score (NES) and significant false discovery rate (FDR) q-value, and p-value.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-figsupp2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig1-figsupp2-v3.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Fibromodulin (FMOD) expression and TGF-β signaling activation are significantly higher in mesenchymal glioblastoma (GBM) than in other subtypes.</title><p>(<bold>A</bold>) Box plots show significantly higher FMOD transcript levels in mesenchymal GBM samples over the other subtypes in the TCGA Agilent dataset. (<bold>B</bold>) Box plots show significantly higher enrichment of the TGF-β hallmark gene set from MSigDb in mesenchymal GBM samples over the other subtypes in the TCGA Agilent dataset. **** indicates the ANOVA p-value for (<bold>A</bold>) and (<bold>B</bold>). (<bold>C</bold>) Quantification of normalized relative luciferase units per second (RLU/s) of SBE-Luc transfected in MGG8-DGCs treated with DMSO or SB431542 (10 μM). (<bold>D</bold>) Quantification of normalized RLU/s of FMOD promoter Luc transfected in MGG8-DGCs treated with DMSO or SB431542 (10 μM). For panels (<bold>C</bold>) and (<bold>D</bold>), n=2, and p-values are calculated by unpaired <italic>t</italic>-test with Welch’s correction are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A–D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig1-figsupp3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig1-figsupp3-v3.tif"/></fig></fig-group></sec><sec id="s2-2"><title>TGF-β signaling controls the expression of FMOD in DGCs</title><p>The enrichment of the ECM annotation among proteins exhibiting higher abundance in DGC secretome prompted us to focus on ECM proteoglycans in line with their critical role in facilitating cancer cell signaling through their interaction with growth factor receptors, extracellular ligands and matrix components, and in promoting tumor–microenvironment interactions (<xref ref-type="bibr" rid="bib71">Winkler et al., 2020</xref>). Six ECM proteoglycans were found to be more abundant in DGC CM compared with GSC CM (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The role of five of them (LAMB2, SERPINEE1, ITGB1, TNC, and LAMA5) in tumor growth has been well established (<xref ref-type="bibr" rid="bib2">Angel et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Bartolini et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Long et al., 2016</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib74">Yang et al., 2020b</xref>). We thus focused on FMOD, which exhibited the highest DGC CM/GSC CM protein ratio. FMOD is a small leucine-rich repeat proteoglycan upregulated in GBM due to the loss of promoter methylation orchestrated by TGF-β1-dependent epigenetic regulation (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). FMOD promotes glioma cell migration through actin cytoskeleton remodeling mediated by an integrin-FAK-Src-Rho-ROCK signaling pathway but does not affect colony-forming ability, growth on soft agar, chemosensitivity, and glioma cell proliferation (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). We first confirmed the higher abundance of FMOD seen in DGC CM compared to GSC CM (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) both at the transcript level (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) and at the protein level (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>) in three GSC cell lines (MGG4, MGG6, and MGG8).</p><p>In line with our previous findings indicating that TGF-β signaling controls FMOD expression in glioma (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>), we next explored the possible role of this pathway in FMOD overexpression in DGCs. Gene set enrichment analysis (GSEA) of differentially regulated transcripts in GSC vs. DGC showed significant depletion of several TGF-β signaling pathway genes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), suggesting an enhanced TGF-β signaling in DGCs. Likewise, GSEA revealed an enrichment of several TGF-β signaling pathway genes in most GBM transcriptome datasets (<xref ref-type="supplementary-material" rid="fig1sdata8">Figure 1—source data 8</xref>), further supporting the activation of TGF-β signaling in DGCs that represent the bulk of GBMs. In addition, the DGCs used in this study that express a high level of FMOD showed enrichment in mesenchymal signature compared to GSCs (<xref ref-type="supplementary-material" rid="fig1sdata10">Figure 1—source data 10</xref>), consistent with the elevated TGF TGF-β signaling and FMOD levels we observed in the mesenchymal GBM subtype (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A B</xref>). Moreover, treating MGG8-DGCs with the TGF-β inhibitor (SB431542) significantly decreased luciferase activity of SBE–Luc (a TGF-β-responsive reporter and contains Smad-binding elements) and FMOD Promoter-Luc reporters (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C D</xref>). We also found higher levels of FMOD and TGM2 (a bonafide TGF-β target gene) transcripts and FMOD and pSMAD2 (an indicator of activated TGF-β signaling) proteins in MGG8-DGCs than MGG8-GSCs (<xref ref-type="fig" rid="fig1">Figure 1G–I</xref>). The addition of a TGF-β inhibitor (SB431542) significantly decreased transcript levels of FMOD and TGM2 and protein levels of FMOD and pSMAD2 in MGG8-DGCs (<xref ref-type="fig" rid="fig1">Figure 1G–I</xref>). Further, chromatin immunoprecipitation experiments revealed pSMAD2 occupancy on FMOD promoter in MGG8 DGCs that was significantly reduced by pretreating cells with SB431542 (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). These results demonstrate a predominant expression and secretion of FMOD by DGCs that are promoted by TGF-β signaling.</p></sec><sec id="s2-3"><title>Tumor growth requires FMOD secreted by DGCs</title><p>Toward exploring the possible role of DGC-secreted FMOD in glioma tumor growth, we first investigated the role of FMOD in GSC and DGC growth and interconversion between both cell populations in vitro using two human (MGG8 and U251) and two murine (AGR53 and DBT-Luc) glioma cell lines. We found that the absence of FMOD neither affected GSC growth and differentiation to DGC (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>) nor DGC growth and reprogramming to form GSCs (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>, <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>; more details in Appendix 1), consistent with our previous findings showing that FMOD does not affect glioma cell proliferation in vitro (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). In line with previous findings that DGCs cooperate with GSCs to promote tumor growth (<xref ref-type="bibr" rid="bib69">Wang et al., 2018</xref>), we then evaluated the ability of DGCs silenced for <italic>FMOD</italic> to support the growth of tumors initiated by GSCs in co-implantation experiments in a syngeneic mouse model using GSCs and DGCs derived from DBT-Luc glioma cells. Reminiscent of our observations in MGG8 cell line, DBT-Luc-DGCs express higher levels of <italic>FMOD</italic> than DBT-Luc-GSCs (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5C D</xref>). To silence the expression of <italic>FMOD</italic> in DBT-Luc-DGCs, we used a doxycycline-inducible construct that contains an inducible <italic>mCherry-shRNA</italic> downstream of the Tet-responsive element (<xref ref-type="bibr" rid="bib2">Angel et al., 2020</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). The scheme of the co-implantation experiment is described on <xref ref-type="fig" rid="fig2">Figure 2B</xref>. DBT-Luc-GSC cells were coinjected with either DBT-Luc-DGC/<italic>miRNT</italic> (nontargeting <italic>shRNA</italic>) or DBT-Luc-DGC/<italic>miRFMOD</italic> (<italic>FMOD shRNA</italic>). In both groups, 50% of the mice received doxycycline on alternated days from day 9 post-injection until the end of the experiment. Tumors in mice coinjected with DBT-Luc-GSCs and DBT-Luc-DGCs/<italic>miRNT</italic> grew much faster and reached a significantly larger size (measured by bioluminescence) than tumors in mice injected with DBT-Luc-GSCs alone regardless of doxycycline treatment (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>, compare black and purple lines with blue line; <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Notably, mice treated with doxycycline did show mCherry expression in tumors (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In contrast, injected DBT-Luc-DGC/<italic>miRFMOD</italic> cells failed to support the growth of tumors initiated by DBT-Luc-GSCs in doxycycline-treated mice compared to doxycycline-untreated mice (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>, compare red line with orange line; <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). While mice injected with DBT-Luc-GSCs+DBT-Luc-DGCs/<italic>miRFMOD</italic> (Dox+) showed an increase in tumor growth until the onset of doxycycline treatment (as seen in the rise in bioluminescence), subsequent tumor growth was drastically reduced. As expected, mice injected with DBT-Luc-DGCs alone developed substantially small tumors (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). The small tumors formed in animals injected with either DBT-Luc-GSC+DBT-Luc-DGC/<italic>miRFMOD</italic> (Dox+) or DBT-Luc-GSC alone expressed significantly less FMOD protein than other tumors (<xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7</xref>). These results indicate that FMOD secreted by DGCs is essential for the growth of tumors initiated by GSCs.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Differentiated glioma cell (DGC)-secreted fibromodulin (FMOD) is essential for tumor growth initiated by glioma stem-like cells (GSCs) in vivo in a co-implantation experiment.</title><p>(<bold>A</bold>) Diagram of the inducible <italic>shFMOD</italic> lentiviral construct. (<bold>B</bold>) Schema depicts the GSC-DGC co-implantation experiment in C57BL/6 mice (n = 5 per group). Mice were injected subcutaneously with a combination of DBT-Luc-GSCs and DBT-Luc-DGCs transduced with either <italic>miRNT</italic> (nontargeting) or miRFMOD lentiviruses. To induce <italic>miRNT</italic> or <italic>miRFMOD</italic> (and <italic>mCherry</italic>), mice received doxycycline (100 µl of 1 mg/ml per animal) as intraperitoneal injections at indicated times. The control groups were only injected with DBT-Luc-GSCs or DBT-Luc-DGCs and did not receive doxycycline. (<bold>C</bold>) In vivo imaging of the injected mice shows tumor growth over time by bioluminescence and mCherry fluorescence, according to the timeline shown in (<bold>B</bold>). (<bold>D</bold>) Quantification of the total radiance. The different colors represent the different groups of animals. Significant differences between each of the groups were calculated using ANOVA. The p-values for days 28 and 32 are shown. A detailed comparison of the p-values between different groups is provided in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-data1-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-data2-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Fibromodulin (FMOD) does not play a role in glioma stem-like cell (GSC) neurosphere formation/maintenance and differentiation in human GSCs.</title><p>(<bold>A</bold>) Western blotting shows FMOD protein levels in MGG8-GSC/shNT and MGG8-GSC/shFMOD cells. (<bold>B</bold>) Quantification of the number of neurospheres formed by MGG8-GSC/shNT and MGG8/shFMOD cells (spheres are divided into different sizes, 50–200, 200–440, and 400–800 μm<sup>2</sup>). (<bold>C</bold>) Limiting dilution assay output shows the neurosphere-forming capacity of MGG8-GSC/shNT (black line) and MGG8-GSC/shFMOD (red line) cells. (<bold>D</bold>) Representative images of neurospheres formed and differentiated monolayers by MGG8-GSC/shNT and MGG8-GSC/shFMOD cells. Magnification = ×4, scale bar = 200 μm. (<bold>E</bold>) RT-qPCR analysis shows the transcript levels of the four GSC reprogramming factors, OLIG2, SOX2, POU3F2, and SALL2 in MGG8-GSC/shNT (solid blue), MGG8-GSC/shFMOD (solid red), MGG8-DGC/shNT (striped blue), and MGG8-DGC/shFMOD (striped red) cells. For panels (<bold>B</bold>) and (<bold>E</bold>), n=3 and p-value calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-figsupp1-v3.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Difference in the level of fibromodulin (<italic>FMOD)</italic> expression between glioma stem-like cell (GSC) and differentiated glioma cell (DGC) of mouse glioma cell line AGR53 and confirmation of efficient conditional knockdown.</title><p>(<bold>A</bold>) RT-qPCR analysis shows <italic>FMOD</italic> transcript levels in AGR53-GSCs and AGR53-DGCs. (<bold>B</bold>) Western blotting shows intracellular FMOD protein levels in AGR53-GSCs and AGR53-DGCs. (<bold>C</bold>) Western blotting shows secreted FMOD protein levels in AGR53-GSCs and AGR53-DGCs. Ponceau staining is done to ensure equal loading. (<bold>D</bold>) RT-qPCR shows <italic>FMOD</italic> transcript levels in AGR53-DGC/<italic>miRNT</italic> and AGR53-DGC/<italic>miRFMOD</italic> cells, with or without doxycycline. (<bold>E</bold>) Western blotting shows FMOD protein levels in AGR53-DGC/<italic>miRNT</italic> and AGR53-DGC/<italic>miRFMOD</italic> cells, with or without doxycycline. For panels (<bold>A</bold>) and (<bold>D</bold>), n=2,and p-value calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-figsupp2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-figsupp2-v3.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Fibromodulin (FMOD) does not play a role in glioma stem-like cell (GSC) neurosphere formation and differentiation in murine GSCs.</title><p>(<bold>A</bold>) Quantification of the number of neurospheres formed by AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells with or without doxycycline treatment. (<bold>B</bold>) Limiting dilution assay output shows the neurosphere-forming capacity of AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells with or without doxycycline treatment. (<bold>C</bold>) Representative images of neurospheres formed by AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells with or without doxycycline treatment. Magnification = ×10, scale bar = 200 μm. (<bold>D</bold>) RT-qPCR analysis shows astrocytic marker transcript levels in AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells, with or without doxycycline treatment. Embryonic neuronal stem cells (ENSCs) were used as a negative control, and normal human astrocytes were used as a positive control. For panels (<bold>A</bold>) and (<bold>D</bold>), n=3, and p-value calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig2s3sdata1"><label>Figure 2—figure supplement 3—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A–D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-figsupp3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-figsupp3-v3.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Fibromodulin (FMOD) does not play a role in glioma stem-like cell (GSC) differentiation and reprogramming of murine GSCs.</title><p>(<bold>A</bold>) Representative images of neurospheres formed by AGR53-DGC/<italic>miRNT</italic> and AGR53-DGC/<italic>miRFMOD</italic> cells with or without doxycycline treatment. Magnification = ×4, scale bar = 100 μm. (<bold>B</bold>) RT-qPCR analysis shows the transcript levels of stem cell markers in AGR53-DGC/<italic>miRNT</italic> and AGR53-DGC/<italic>miRFMOD</italic> cells, with or without doxycycline treatment. Embryonic neuronal stem cells (ENSCs) were used as a positive control, and normal human astrocytes were used as a negative control. For panel (<bold>B</bold>), n=2, and p-value calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig2s4sdata1"><label>Figure 2—figure supplement 4—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-figsupp4-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-figsupp4-v3.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Validation of fibromodulin (FMOD) levels and knockdown in DBT-Luc mouse glioma cell line.</title><p>(<bold>A</bold>) RT-qPCR analysis shows the transcript levels of stem cell markers in DBT-Luc-GSCs and DBT-Luc-DGCs. (<bold>B</bold>) RT-qPCR analysis shows the transcript levels of astrocytic cell markers in DBT-Luc-GSCs and DBT-Luc-DGCs. (<bold>C</bold>) RT-qPCR analysis shows <italic>FMOD</italic> transcript levels in DBT-Luc-GSCs and DBT-Luc-DGCs. (<bold>D</bold>) Western blotting shows FMOD protein levels in DBT-Luc-GSCs and DBT-Luc-DGCs. (<bold>E</bold>) RT-qPCR analysis shows <italic>FMOD</italic> transcript levels in DBT-Luc-DGC/<italic>miRNT</italic> and DBT-Luc-DGC/<italic>miRFMOD</italic> cells, with or without doxycycline treatment. (<bold>F</bold>) Western blotting shows FMOD protein levels in DBT-Luc-DGC/<italic>miRNT</italic> and DBT-Luc-DGC/<italic>miRFMOD</italic> cells, with or without doxycycline treatment. (<bold>G</bold>) Confocal microscopy analysis shows mCherry expression (indicated by red) in DBT-Luc-DGC/<italic>miRNT</italic> and DBT-Luc-DGC/<italic>miRFMOD</italic> cells with doxycycline treatment. Magnification = ×4, scale bar = 200 μm. For panels (<bold>A</bold>), (<bold>B</bold>), (<bold>C</bold>), and (<bold>E</bold>), n=3 and p-value calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values less than 0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig2s5sdata1"><label>Figure 2—figure supplement 5—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A–G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-figsupp5-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-figsupp5-v3.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 6.</label><caption><title>Fibromodulin (FMOD) does not have a role in the de-differentiation of differentiated glioma cells (DGCs) to glioma stem-like cells (GSCs).</title><p>(<bold>A</bold>) Western blotting shows FMOD protein levels in U251-DGC/shNT and U251-DGC/shFMOD cells. (<bold>B</bold>) Representative images and quantification of monolayer cells and neurospheres formed by U251-DGC/shNT and U251-DGC/shFMOD cells. (<bold>C</bold>) Limiting dilution assay output shows the neurosphere-forming capacity of U251-DGC/shNT (black line) and U251-DGC/shFMOD (red line) cells. (<bold>D</bold>) RT-qPCR analysis shows the transcript levels of the four GSC reprogramming factors, OLIG2, SOX2, POU3F2, and SALL2, in U251-DGC/shNT (solid blue), U251-DGC/shFMOD (solid red), U251-GSC/shNT (striped blue), and U251-GSC/shFMOD (striped red) cells. For panels (<bold>B</bold>) and (<bold>D</bold>), n=3, and p-value calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001 respectively. ns, nonsignificance.</p><p><supplementary-material id="fig2s6sdata1"><label>Figure 2—figure supplement 6—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6A–D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-figsupp6-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-figsupp6-v3.tif"/></fig><fig id="fig2s7" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 7.</label><caption><title>Induction with doxycycline reduces fibromodulin (FMOD) level in mice injected with DBT-GSC-Luc+DBT-DGC-Luc/<italic>miRFMOD</italic> cells.</title><p>Western blotting shows FMOD protein levels in the subcutaneous tumors formed by DBT-GSC-Luc+DBT-DGC-Luc/<italic>miRNT</italic> and DBT-GSC-Luc+DBT-DGC-Luc/<italic>miRFMOD</italic> cells after administering doxycycline at regular intervals to the mice and in tumors formed by DBT-Luc-GSCs and DBT-Luc-DGCs, without doxycycline treatment.</p><p><supplementary-material id="fig2s7sdata1"><label>Figure 2—figure supplement 7—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig2-figsupp7-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig2-figsupp7-v3.tif"/></fig></fig-group></sec><sec id="s2-4"><title>FMOD induces angiogenesis of host-derived and tumor-derived endothelial cells</title><p>Tumor cell interactions with stromal cells are critical for glioma tumor growth (<xref ref-type="bibr" rid="bib42">Pine et al., 2020</xref>). Small leucine-rich proteoglycans such as FMOD promote angiogenesis in the context of cutaneous wound healing (<xref ref-type="bibr" rid="bib39">Pang et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Zheng et al., 2014</xref>). In addition, we previously found a significant enrichment of the term ‘angiogenesis’ among differentially regulated genes in FMOD-silenced U251 glioma cells (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). In light of these observations, we next examined the impact of FMOD on tumor angiogenesis. First, we tested the ability of glioma cell-derived FMOD to induce angiogenic network formation by immortalized human pulmonary microvascular endothelial cells (ST1). We used LN229 and U251 glioma cells, which express low and high levels of FMOD, respectively, for overexpression and silencing studies (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). We found that the CM derived from LN229 cells stably expressing FMOD (LN229/FMOD) induced more angiogenesis than LN229/Vector stable cells (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Further, the CM of FMOD-silenced U251 cells was less efficient in promoting angiogenesis than the CM of cells expressing nontargeting siRNA (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>) or shRNA (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). The addition of recombinant human FMOD (rhFMOD) to the CM of U251/siFMOD cells rescued its ability to induce angiogenesis (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). More importantly, the addition of rhFMOD directly to endothelial cells induced angiogenesis in the presence of a control antibody (IgG) but not in the presence of an FMOD neutralizing antibody ( <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Differentiated glioma cell (DGC)-secreted fibromodulin (FMOD) promotes angiogenesis of host-derived and tumor-derived endothelial cells.</title><p>(<bold>A</bold>) Representative images of in vitro network formation by ST1 cells treated with conditioned medium (CM) of LN229/Vector CM and LN229/FMOD. In the positive control condition (top right), cells are plated in complete endothelial cell media (M199) supplemented with endothelial cell growth factors (ECGS) and 20% fetal bovine serum (FBS), and in the negative control (top left), cells are plated in incomplete M199 (without serum and ECGS). Networks formed by ST1 cells treated with CM of LN229/Vector (left bottom) and LN229/FMOD (right bottom). Magnification = ×10, scale bar = 100 μm. (<bold>B</bold>) Quantification of the number of complete networks formed in (<bold>A</bold>). (<bold>C</bold>) Quantification of the number of networks formed by ST1 cells treated with CM of U251-DGC/siNT, U251-DGC/siFMOD, and U251-DGC/siFMOD + rhFMOD (400 nM) cells. (<bold>D</bold>) Quantification of the number of networks formed by ST1 cells treated with CM of MGG8-GSC, MGG8-DGC, MGG8-DGC/shNT, and MGG8-DGC/shFMOD supplemented with anti-FMOD or rhFMOD (400 nM) as indicated. (<bold>E</bold>) Representative images of in vitro network formation by primary human brain-derived microvascular endothelial cells (HBMECs). In the positive control condition (top right), HBMEC cells are plated in complete endothelial cell media (M199) supplemented with ECGS and 20% FBS, and in the negative control (top left), cells are plated in incomplete M199 without serum and ECGS. Networks formed by HBMEC cells treated with CM of MGG8-DGC/shNT, MGG8-DGC/shFMOD, and MGG8-DGC/shFMOD + rhFMOD (400 nM). Magnification = ×4, scale bar = 200 μm. (<bold>F</bold>) Quantification of the number of complete networks formed in (<bold>E). (G</bold>) RT-qPCR analysis showing transcript levels of CD31 (blue bars) and FMOD (orange bars) in ST1, MGG8-DGC/shNT, MGG8-DGC/shFMOD, MGG8-DGC-TDEC/shNT, and MGG8-DGC-TDEC/shFMOD cells. (<bold>H</bold>) Western blotting shows FMOD and CD31 protein levels in MGG8-DGC/shNT, MGG8-DGC/shFMOD, MGG8-DGC-TDEC/shNT, and MGG8-DGC-TDEC/shFMOD cells. (<bold>I</bold>) Representative images of in vitro network formation by ST1, MGG8-DGC-TDEC/shNT, and MGG8-DGC-TDEC/shFMOD upon bovine serum albumin (BSA) and rhFMOD (400 nM) treatments. Top panels: in the positive control conditions, ST1 or MGG8-DGC-TDEC cells are plated in complete endothelial cell media (M199) supplemented with ECGS and 20% FBS, and in the negative control conditions, ST1 or MGG8-DGC-TDEC cells are plated in incomplete M199 (without serum and ECGS). Bottom panels: networks formed by HBMEC cells treated with CM of MGG8-DGC-TDEC/shNT and MGG8-DGC-TDEC/shFMOD supplemented with either BSA or rhFMOD (400 nM). Magnification = ×4, scale bar = 200 μm. (<bold>J</bold>) Quantification of the number of complete networks formed in (<bold>I</bold>). For panels (<bold>B–D</bold>), (<bold>F</bold>), (<bold>G</bold>), and (<bold>J</bold>), n=3 and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction. p-Value &lt;0.05 was considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data1-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data2-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data3-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data4-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><label>Figure 3—source data 5.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data5-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata6"><label>Figure 3—source data 6.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data6-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata7"><label>Figure 3—source data 7.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data7-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata8"><label>Figure 3—source data 8.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data8-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata9"><label>Figure 3—source data 9.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data9-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata10"><label>Figure 3—source data 10.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3">Figure 3J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-data10-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Differentiated glioma cell (DGC)-secreted fibromodulin (FMOD) induces angiogenesis by endothelial cells of various origins.</title><p>(<bold>A</bold>) Representative images of in vitro network formation by ST1 cells treated with conditioned medium (CM) of U251-DGC/siNT, U251-DGC/siFMOD, and U251-DGC/siFMOD + rhFMOD (400 nM) cells. In the positive control condition (top second), cells are plated in complete endothelial cell media (M199) supplemented with endothelial cell growth factors (ECGS) and 20% fetal bovine serum (FBS), and in the negative control (top first), cells are plated in incomplete M199 (without serum and ECGS). Networks formed by ST1 cells treated with CM of U251-DGC/siNT, U251-DGC/siFMOD, and U251-DGC/siFMOD + rhFMOD (400 nM) cells. Magnification = ×10, scale bar = 100 μm. (<bold>B</bold>) Representative images and quantification of in vitro network formation by ST1 cells treated with CM of U251-DGC/shNT and U251-DGC/siFMOD cells. (<bold>C</bold>) Representative images and quantification of in vitro network formation by ST1 cells treated with incomplete M199 and bovine serum albumin (BSA), supplemented with anti-FMOD or IgG and incomplete M199 and rhFMOD (400 nM), supplemented with anti-FMOD or IgG. Magnification = ×10, scale bar = 100 μm. (<bold>D</bold>) Quantification of the number of networks formed by ST1 cells treated with CMs from MGG4, MGG6, and MGG8 GSCs and their corresponding DGCs. (<bold>E</bold>) Representative images and quantification of in vitro network formation by ST1 cells treated with CM of MGG8-DGC/siNT cells or with that of CM from MGG8-DGC/siFMOD cells, supplemented with either BSA or rhFMOD (400 nM). For panels (B–E), n=3, and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–E</xref> .</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig3-figsupp1-v3.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Fibromodulin (FMOD) induces migration and invasion, but not the proliferation of endothelial cells.</title><p>(<bold>A</bold>) Representative images (left) and quantification (right) from Boyden chamber assay show migration of ST1 cells treated with either rhFMOD (400 nM) or bovine serum albumin (BSA). Magnification = ×10, scale bar = 100 μm. (<bold>B</bold>) Representative images (left) and quantification (right) from Boyden chamber assay show migration of ST1 cells treated with conditioned medium (CM) from MGG8-DGC/shFMOD cells. Magnification = ×10, scale bar = 100 μm. (<bold>C</bold>) Representative images (left) and quantification (right) from Boyden chamber assay show invasion of ST1 cells treated with either rhFMOD (400 nM) or BSA. Magnification = ×10, scale bar = 100 μm. (<bold>D</bold>) Representative images (left) and quantification (right) from Boyden chamber assay show invasion of ST1 cells treated with CM from MGG8-DGC/shFMOD cells. Magnification = ×10, scale bar = 100 μm. (<bold>E</bold>) MTT cell proliferation assay shows proliferation of ST1 cells treated with either BSA or rhFMOD over a period of 96 hr. (<bold>F</bold>) Representative images (top) and quantification (bottom) of the number of networks formed by immortalized mouse brain-derived endothelial cells, B.End3, upon treatment with CM from MGG8-DGC/shNT, MGG8-DGC/shFMOD, MGG8-DGC/shFMOD + rhFMOD (400 nM). For all the panels, n=3, and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificant.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Source data to generate <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-figsupp2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig3-figsupp2-v3.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Fibromodulin (FMOD) induces glioblastoma (GBM) cells to undergo transdifferentiation.</title><p>(<bold>A</bold>) RT-qPCR analysis shows the transcript levels of CD31(blue bars) and FMOD (orange bars) in ST1 cells, U87, and U87-TDECs. (<bold>B</bold>) Western blotting shows FMOD and CD31 protein levels in ST1, U87, and U87-TDECs. (<bold>C</bold>) Representative images of in vitro network formation by U87 and U87 TDECs upon bovine serum albumin (BSA) and rhFMOD treatments. Magnification = ×10, scale bar = 100 μm. (<bold>D</bold>) Quantification of the number of networks formed in (<bold>C</bold>). For panels (<bold>A</bold>) and (<bold>D</bold>), n=3,and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificant.</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A–D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig3-figsupp3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig3-figsupp3-v3.tif"/></fig></fig-group><p>Both CMs derived from three DGCs and their corresponding GSCs also induced angiogenesis efficiently (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Further, pretreating cells with an FMOD antibody significantly reduced the ability of MGG8-DGC CM, but not that of MGG8-GSC CM, to induce angiogenesis (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The reduced ability of the FMOD antibody-pretreated DGC CM to promote angiogenesis was rescued by the exogenous addition of an excess of rhFMOD (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Moreover, CM derived from FMOD-silenced MGG8-DGCs was less efficient in promoting angiogenesis than the CM of shNT (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) or siNT (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>) transfected MGG-DGCs. The effect of FMOD silencing was rescued by adding exogenous rhFMOD (<xref ref-type="fig" rid="fig3">Figure 3D,</xref> <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Both rhFMOD and FMOD present in the CM collected from MGG8-DGC induced the migration and invasion but not the proliferation of ST1 cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–E</xref>). Further, CM from MGG8-DGC/shNT cells was more efficient than CM from MGG8-DGC/shFMOD cells in promoting angiogenic network formation by human brain-derived primary endothelial cells (HBMECs) and mouse brain-derived immortalized endothelial cells (B.End3) (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F</xref>). Again, the effect of FMOD silencing was rescued by adding rhFMOD (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F</xref>).</p><p>Vascular mimicry (VM) is one of the alternative mechanisms of angiogenesis wherein tumor-derived endothelial cells (TDECs) originate from GBM cells (<xref ref-type="bibr" rid="bib1">Angara et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Ricci-Vitiani et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Soda et al., 2011</xref>). To assess the ability of FMOD to induce TDECs derived from DGCs to form angiogenic networks, we used MGG8-DGC and U87 cells. MGG8-DGC/shNT cells grown in endothelial media (M199) under hypoxia (1% O<sub>2</sub>) differentiated to TDECS as evidenced by an increase in CD31 (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). MGG8-DGC/shFMOD also differentiated to form TDECs, albeit with less efficiency (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). Further, the addition of rhFMOD induced both MGG8-DGC/shNT-TDEC and MGG8-DGC/shFMOD-TDEC cells to form angiogenic networks efficiently (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>). Similarly, U87 cells differentiated to TDECs (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A B</xref>), which readily formed angiogenic networks in the presence of rhFMOD (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3C D</xref>). Collectively, these results demonstrate that DGC CM can induce angiogenesis and identify FMOD as a critical mediator of DGC-induced angiogenesis.</p></sec><sec id="s2-5"><title>FMOD activates integrin/FAK/Src-dependent Notch pathway in endothelial cells to induce angiogenesis</title><p>To dissect the signaling mechanisms underlying FMOD-induced angiogenesis, we subjected protein extracts derived from ST1 endothelial cells treated or not with rhFMOD to reverse phase protein array (RPPA). A total of 12 proteins exhibited differential abundance in a time-dependent manner in rhFMOD-treated ST1 endothelial cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). These include HES1, a downstream target of the Notch signaling pathway that has been shown to promote angiogenesis (<xref ref-type="bibr" rid="bib76">Zhao et al., 2017</xref>). We thus investigated the possible involvement of Notch signaling in FMOD-induced angiogenesis. The addition of rhFMOD induced luciferase activity of Notch-dependent CSL-Luc and HES-Luc reporters in ST1 cells but not in gamma-secretase inhibitor (GSI; a Notch pathway inhibitor) pretreated cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A B</xref>). The addition of rhFMOD also increased HES1 mRNA and protein levels in ST1 cells, an effect abolished by GSI pretreatment of cells (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). rhFMOD treatment also resulted in the translocation of NICD (Notch intracellular domain) from the cytosol to the nucleus, as shown by subcellular fractionation and confocal microscopy (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C D</xref>). Furthermore, rhFMOD failed to induce angiogenic network formation by GSI-pretreated ST1 cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). In addition, ST1 cells having a stable expression of NICD (ST1/NICD) showed enhanced angiogenic network formation than ST1 vector stable (ST1/Vector) cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–D</xref>). FMOD present in CM from MGG8-DGCs induced ST1/Vector cells, but not ST1/NICD cells, to form more angiogenic networks, suggesting that Notch activation in endothelial cells is an essential step in FMOD-induced angiogenesis.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Integrin/FAK/Src/JAG1-dependent Notch pathway activation in endothelial cells mediates fibromodulin (FMOD)-induced angiogenesis.</title><p>(<bold>A</bold>) Heatmap showing differentially regulated (log<sub>2</sub> fold change &gt;/&lt;0.2) proteins in ST1 cells treated with vehicle or rhFMOD (400 nM) for 10, 30, and 60 min, assessed by reverse phase protein array (RPPA). Red and green depict upregulated and downregulated proteins, respectively. The red arrows indicate HES1 and pFAK proteins. (<bold>B</bold>) RT-qPCR analysis shows HES1 transcript levels in ST1 cells treated with rhFMOD (400 nM) with or without gamma-secretase inhibitor (GSI; 10 μM). (<bold>C</bold>) Western blotting shows HES1 protein levels in ST1 cells treated with rhFMOD (400 nM) with or without GSI (10 μM). (<bold>D</bold>) Quantification of the number of networks formed by ST1 cells treated with rhFMOD (400 nM) with or without GSI (10 μM). (<bold>E</bold>) Western blotting shows phospho-FAK levels in ST1 cells treated with rhFMOD (400 nM) with or without RGD peptide (10 μM). (<bold>F</bold>) Quantification of the number of networks formed by ST1 cells pretreated with indicated small-molecule inhibitors (PP2 [10 μM], PP3 [10 μM], and PF573228 [FAK inhibitor; 10 μM], H1152 [ROCK1 inhibitor; 0.5 mM], and Rac1 inhibitor [10 μM]) followed by incubation with conditioned medium (CM) of LN229/Vector or LN229/FMOD cells. (<bold>G</bold>) RT-qPCR analysis shows HES1 transcript levels in ST1 cells treated with rhFMOD (400 nM) with or without RGD peptide (10 μM). (<bold>H</bold>) Western blotting shows HES1 protein levels in ST1 cells treated with rhFMOD (400 nM) with or without RGD peptide (10 μM). (<bold>I</bold>) Western blotting shows JAG1 protein levels in ST1/shNT and ST1/shJAG1 cells. (<bold>J</bold>) RT-qPCR analysis shows HES1 transcript levels in ST1/shNT and ST1/shJAG1 cells treated with rhFMOD (400 nM). (<bold>K</bold>) Western blotting shows HES1 protein levels in ST1/shNT and ST1/shJAG1 cells treated with rhFMOD (400 nM). (<bold>L</bold>) Quantification of the number of networks formed by ST1/shNT and ST1/shJAG1 cells treated with bovine serum albumin (BSA) or rhFMOD (400 nM). For panels (<bold>B</bold>), (<bold>D</bold>), (<bold>F</bold>), (<bold>G</bold>), (<bold>J</bold>), and (<bold>L</bold>), n=3, and the p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction are indicated. p-Value &lt;0.05 was considered significant with *, **, and *** representing <italic>p</italic>-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data1-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data2-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4C, E, H, I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data3-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data4-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data5-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data6-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data7-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata8"><label>Figure 4—source data 8.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4K</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data8-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata9"><label>Figure 4—source data 9.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4">Figure 4L</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-data9-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Fibromodulin (FMOD) induces activation of Notch signaling in endothelial cells.</title><p>(<bold>A</bold>) Quantification of normalized relative luciferase units per second (RLU/s) of CSL-Luc (Notch pathway-dependent reporter luciferase construct) and (<bold>B</bold>) HES-Luc (Notch pathway-dependent reporter [HES1 promoter] luciferase construct), transfected in ST1 cells and then treated with either rhFMOD or bovine serum albumin (BSA), each with or without gamma-secretase inhibitor (GSI) (10 μM). (<bold>C</bold>) Western blotting shows the protein levels of NICD, H3, and GAPDH (housekeeping) in the membrane and cytosolic fractions of ST1 cells treated with rhFMOD (400 nM). (<bold>D</bold>) Confocal microscopy analysis shows NICD protein levels in the cytoplasm and nuclei of the ST1 cells treated with either BSA or rhFMOD (400 nM) over days. (<bold>E</bold>) Quantification of normalized relative luciferase units per second (RLU/s) of CSL-Luc (Notch pathway-dependent reporter luciferase construct) and (<bold>B</bold>) HES-Luc (Notch pathway-dependent reporter [HES1 promoter] luciferase construct), transfected in ST1 cells, and then treated with either rhFMOD or BSA, each with or without RGD peptide (10 μM). For panels (<bold>A</bold>), (<bold>B</bold>), (<bold>E</bold>), and (<bold>F</bold>), n=3, and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificant.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>ST1 cells stably expressing NICD are independent of fibromodulin (FMOD) in forming angiogenic networks.</title><p>(<bold>A</bold>) Western blotting shows NICD protein levels in ST1/Vector control and ST1/NICD cells. (<bold>B</bold>) Confocal microscopy analysis shows the expression of NICD (green) in ST1/Vector control and ST1/NICD. Blue indicates H33342 (stains nuclei). Magnification = ×63, scale bar = 20 μm. (<bold>C</bold>) Representative images of networks formed by ST1/Vector control and ST1/NICD cells treated with conditioned medium (CM) from MGG8-DGC/shNT and MGG8-DGC/shFMOD cells. In the positive control condition, cells are plated in complete endothelial cell media (M199) supplemented with endothelial cell growth factors (ECGS) and 20% fetal bovine serum (FBS), and in the negative control, cells are plated in incomplete M199 (without serum and ECGS). (<bold>D</bold>) Quantification of the number of networks formed in (<bold>C</bold>). For panel (<bold>D</bold>), n=3, and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificant.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-figsupp2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-figsupp2-v3.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Fibromodulin (FMOD)–type I collagen interaction is crucial for FMOD-mediated activation of downstream signaling pathways.</title><p>(<bold>A</bold>) Quantification of normalized relative luciferase units per second (RLU/s) of CSL-Luc (Notch pathway-dependent reporter luciferase construct) and (<bold>B</bold>) HES-Luc (Notch pathway-dependent reporter [HES1 promoter] luciferase construct), transfected in ST1 cells, which are pretreated with the wildtype (WT peptide) or the mutant (Mut) peptide, and then incubated with either bovine serum albumin (BSA) or rhFMOD (400 nM). (<bold>C</bold>) Quantification of the number of networks formed by ST1 cells pretreated with the WT peptide or the Mut peptide and then incubated with either BSA or rhFMOD (400 nM). (<bold>D</bold>) Western blotting shows phospho-FAK and total FAK protein levels in ST1/shNT and ST/shITGB1 cells treated with rhFMOD (400 nM). (<bold>E</bold>) Western blotting shows phospho-FAK and total FAK protein levels in ST1/shNT and ST/shITGAV cells treated with rhFMOD (400 nM). (<bold>F</bold>) Western blotting shows phospho-FAK and total FAK protein levels in ST1/shNT and ST/shITGA6 cells treated with rhFMOD (400 nM). (<bold>G</bold>) Western blotting shows ITGB1 protein levels in ST1/shNT and ST/shITGB1 cells. (<bold>H</bold>) Western blotting shows ITGAV protein levels in ST1/shNT and ST/shITAV cells. (<bold>I</bold>) Western blotting shows ITGA6 protein levels in ST1/shNT and ST/shITGA6 cells. For panels (<bold>A</bold>–<bold>C</bold>), n=3, and p-values were calculated by unpaired <italic>t-</italic>test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A–I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-figsupp3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-figsupp3-v3.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Fibromodulin (FMOD)-mediated activation of Integrin-dependent Notch signaling in endothelial cells involves the integrin pathway downstream molecules FAK and Src.</title><p>(<bold>A</bold>) Quantification of normalized relative luciferase units per second (RLU/s) of CSL-Luc (Notch pathway-dependent reporter luciferase construct) and (<bold>B</bold>) HES-Luc (Notch pathway-dependent reporter [HES1 promoter] luciferase construct), transfected in ST1 cells pretreated with PF573228 (FAK inhibitor; 10 μM), and then incubated with bovine serum albumin (BSA) or rhFMOD (400 nM). (<bold>C</bold>) Quantification of normalized RLU/s of CSL-Luc (Notch pathway-dependent reporter luciferase construct) and (<bold>D</bold>) HES-Luc (Notch pathway-dependent reporter [HES1 promoter] luciferase construct), transfected in ST1 cells pretreated with PP2 (Src inhibitor, 10 μM), and PP3 (inactive structural analog to PP2, 10 μM) and then incubated with BSA or rhFMOD (400 nM). (<bold>E</bold>) RT-qPCR analysis shows HES1 transcript levels in ST1 cells pretreated with PF573228 (FAK inhibitor; 10 μM) and then incubated with BSA or rhFMOD (400 nM). (<bold>F</bold>) Western blotting shows HES1 protein levels in ST1 cells pretreated with PF573228 (FAK inhibitor; 10 μM) and then incubated with BSA or rhFMOD (400 nM). (<bold>G</bold>) RT-qPCR analysis shows HES1 transcript levels in ST1 cells pretreated with PP2 (Src inhibitor, 10 μM) and PP3 (inactive structural analog to PP2, 10 μM) and then incubated with BSA or rhFMOD (400 nM). (<bold>H</bold>) Western blotting shows HES1 protein levels in ST1 cells pretreated with PP2 (Src inhibitor, 10 μM) and PP3 (inactive structural analog to PP2, 10 μM) and then incubated with BSA or rhFMOD (400 nM). For panels (<bold>A</bold>–<bold>E</bold>) and (<bold>G</bold>), n=3, and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001 respectively. ns, nonsignificance.</p><p><supplementary-material id="fig4s4sdata1"><label>Figure 4—figure supplement 4—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A–H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-figsupp4-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-figsupp4-v3.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Fibromodulin (FMOD)-mediated crosstalk of integrin and Notch signaling pathways occurs via JAG1 upregulation.</title><p>(<bold>A</bold>) RT-qPCR analysis shows the transcript levels of SLL1, DLL3, JAG1, and JAG2 in ST1 cells pretreated with RGD peptide (10 μM) and then incubated with bovine serum albumin (BSA) or rhFMOD (400 nM). (<bold>B</bold>) RT-qPCR analysis shows the transcript levels of JAG1 in ST1 cells pretreated with PF573228 (FAK inhibitor; 10 μM) and then incubated with BSA or rhFMOD (400 nM). (<bold>C</bold>) RT-qPCR analysis shows the transcript levels of JAG1 in ST1 cells pretreated with PP2 (Src inhibitor, 10 μM) and PP3 (inactive structural analog to PP2, 10 μM), and then incubated with BSA or rhFMOD (400 nM). (<bold>D</bold>) Quantification of normalized relative luciferase units per second (RLU/s) of CSL-Luc (Notch pathway-dependent reporter luciferase construct) and (<bold>E</bold>) HES-Luc (Notch pathway-dependent reporter [HES1 promoter] luciferase construct), transfected in ST1/shNT and ST1/shJAG1 cells incubated with rhFMOD (400 nM). (<bold>F</bold>) RT-qPCR analysis shows the transcript levels of KLF8, FOXP1, ETS1, GATA4, and ATF2 in ST1 cells pretreated with RGD peptide (10 μM) and then incubated rhFMOD (400 nM). (<bold>G</bold>) Western blotting shows KLF8 protein levels in ST1/shNT and ST1/shKLF8 cells. (<bold>H</bold>) Western blotting shows JAG1 protein levels in ST1/shNT and ST1/shKLF8 cells incubated with rhFMOD (400 nM). For panels (<bold>A</bold>–<bold>F</bold>), n=3, and p-values were calculated by unpaired <italic>t</italic>-test with Welch’s correction, are indicated. p-Value &lt;0.05 is considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig4s5sdata1"><label>Figure 4—figure supplement 5—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A–H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-figsupp5-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-figsupp5-v3.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>Clinical relevance of the FMOD-JAG1-HES1 signaling.</title><p>(<bold>A</bold>) Dot plots show fibromodulin (FMOD) transcript levels in glioblastoma (GBM) samples over normal samples across multiple publicly available datasets. (<bold>B</bold>) Dot plots show HES1 transcript levels in GBM samples over normal samples across multiple publicly available datasets. (<bold>C</bold>) Dot plots show JAG1 transcript levels in GBM samples over normal samples across multiple publicly available datasets. (<bold>D</bold>) Correlation between transcript levels of FMOD and HES1 across multiple publicly available datasets. (<bold>E</bold>) Correlation between transcript levels of FMOD and JAG1 across multiple publicly available datasets. Data for JAG1 are not available in the dataset CCGA-RNA-Seq. For panels (<bold>A</bold>–<bold>C</bold>), significance was calculated using an unpaired <italic>t</italic>-test. The correlation coefficient was calculated using Pearson’s correlation coefficient test for panels (<bold>D</bold>) and (<bold>E</bold>). p-Value &lt;0.05 is considered significant with *, **, ***, and **** representing p-values &lt;0.05, 0.01, 0.001, and 0.00001, respectively.</p><p><supplementary-material id="fig4s6sdata1"><label>Figure 4—figure supplement 6—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6A–E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-figsupp6-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-figsupp6-v3.tif"/></fig><fig id="fig4s7" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 7.</label><caption><title>Clinical relevance of the FMOD-JAG1-HES1 signaling.</title><p>(<bold>A</bold>) Survival analysis using transcript levels of fibromodulin (FMOD) in multiple publicly available datasets. High FMOD mRNA levels (red lines) in patients show poorer survival than low FMOD patients (blue lines) in multiple publicly available datasets. (<bold>B</bold>) FMOD promoter hypomethylation (in CpGs cg03764585 and cg04704856) in patients shows poorer survival than low patients with FMOD promoter hypermethylation in multiple publicly available datasets. Significance was calculated using the log-rank test. p-Value &lt;0.05 is considered significant.</p><p><supplementary-material id="fig4s7sdata1"><label>Figure 4—figure supplement 7—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig4s7">Figure 4—figure supplement 7A B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig4-figsupp7-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig4-figsupp7-v3.tif"/></fig></fig-group><p>The increase in phosphorylated FAK (pFAK, FAK_Py397-R-V; the molecule downstream of integrin signaling) levels in rhFMOD-treated endothelial cells, as shown by RPPA (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), also suggested a possible role of integrin signaling in FMOD-induced angiogenesis. This is consistent with our previous findings indicating that FMOD activates integrin signaling via type I collagen to engage the FAK-Src-Rho-ROCK pathway and promote the migration of glioma cells (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). We first confirmed the activation of integrin signaling by FMOD, as assessed by increased pFAK in rhFMOD-treated ST1 cells, but not in cells pretreated with RGD peptide, an integrin inhibitor (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The addition of RGD peptide inhibited angiogenesis induced by LN229/FMOD CM (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Likewise, angiogenesis induced by LN229/FMOD CM was completely inhibited when ST1 cells were pretreated with inhibitors of FAK (FAKi) or Src (PP2), two signaling molecules downstream of integrin (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). These treatments also strongly reduced the basal level of angiogenesis elicited by the CM of LN229/Vector cells. In contrast, an inactive analog of Src inhibitor (PP3), as well as inhibitors of RAC1 and ROCK, failed to inhibit the ability of CM derived from LN229/FMOD cells to induce angiogenesis (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Our previous report also demonstrated that the interaction of FMOD with type I collagen is essential for integrin activation (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). The C-terminal region of FMOD comprises 11 leucine-rich-repeats (LRRs), of which the 11th repeat binds to type I collagen (<xref ref-type="bibr" rid="bib37">Oldberg et al., 2007</xref>). A synthetic interfering peptide (RLDGNEIKR) corresponding to the 11th<sup>h</sup> LRR of type 1 collagen, but not a modified peptide (RLDGNQIMR), competes with rhFMOD for binding to type I collagen to activate integrin signaling in glioma cells (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Oldberg et al., 2007</xref>). Consistent with these findings, rhFMOD-induced luciferase activity of CSL-Luc and HES-Luc (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A B</xref>) and angiogenesis by ST1 cells (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3C</xref>) were significantly inhibited by the interfering peptide, but not the modified peptide, suggesting a crucial role of type I collagen-dependent activation of integrin signaling in FMOD-induced angiogenesis. To identify the α and β subunits of integrin involved in FMOD-mediated activation of integrin signaling in endothelial cells, we chose ITGA6, ITGB1, and ITGAV for investigation based on the analysis of transcriptome data derived from laser capture-dissected microvessels from the human brain (more details in Appendix 1). Silencing either of the selected three integrin subunits in ST1 cells reduced significantly the ability of rhFMOD to activate integrin as assessed by reduced pFAK levels (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3D–I</xref>), thus demonstrating the involvement of αv/β1 and α6/β1 heterodimeric integrin receptors in FMOD activation of integrin signaling in endothelial cells.</p><p>Next, to examine a possible crosstalk between integrin and Notch signaling in FMOD-treated endothelial cells, we tested the effect of the RGD peptide on the ability of rhFMOD to induce Notch signaling. Pretreatment of ST1 cells with RGD peptide significantly reduced rhFMOD-elicited CSL-Luc and HES-Luc activation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E F</xref>). Likewise, pretreatment of cells with FAKi or PP2, but not PP3, significantly reduced rhFMOD-induced CSL-Luc and HES-Luc activity in ST1 cells (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A–D</xref>). Further, rhFMOD failed to increase HES1 transcript and protein levels in ST1 cells treated with either RGD peptide, FAKi, or PP2, but not in cells treated with PP3 (<xref ref-type="fig" rid="fig4">Figure 4G and H</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4E–H</xref>).</p><p>We next investigated the mechanistic link between integrin and Notch signaling in FMOD-treated ST1 cells. Since Notch activation by FMOD is sensitive to GSI treatment, we explored the activation of Notch ligands by integrin-FAK signaling in FMOD-treated cells. While the addition of rhFMOD induced DLL3 and JAG1 transcripts in ST1 cells, RGD peptide pretreatment abolished JAG1 induction (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A</xref>), suggesting that JAG1 might be a potential linking molecule. Consistently, pretreatment of cells with either FAKi or PP2, but not PP3, also abolished the ability of rhFMOD to induce JAG1 transcript in ST1 cells (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5B C</xref>). Further, JAG1 silencing significantly decreased rhFMOD-induced activity of CSL-Luc and HES-Luc reporters and HES1 transcript/protein levels in ST1 cells (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5D E</xref>, <xref ref-type="fig" rid="fig4">Figure 4I–K</xref>). JAG1 silencing also abolished the ability of rhFMOD to induce angiogenic networks by ST1 cells (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). In addition, rhFMOD induced the transcript levels of KLF8, a FAK-inducible transcription factor in ST1 cells, but not in RGD peptide pretreated cells (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5F</xref>). Further, KLF8 silencing in ST1 cells significantly reduced the ability of rhFMOD to increase JAG1 level (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5G H</xref>), suggesting that KLF8 activates JAG1 through an integrin-dependent pathway in FMOD-treated endothelial cells. Collectively, these results identify JAG1 as a molecular link between integrin and Notch signaling pathways in FMOD-treated endothelial cells and demonstrate a key role of integrin-FAK-JAG1-Notch-HES1 signaling in FMOD-induced angiogenesis.</p><p>To further explore the clinical relevance of these findings, we interrogated transcriptome datasets from multiple sources (more details in Appendix 1). We found a significant upregulation of transcript levels of FMOD, JAG1, and HES1 in GBM from various datasets (<xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6A–C</xref>). We also found a positive correlation between FMOD and HES1 transcripts and between FMOD and JAG1 transcripts in the majority of GBM datasets analyzed (<xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6D E</xref>), which further substantiates the functional link between FMOD, JAG1, and HES1. We also show that high FMOD transcript levels and hypomethylation of FMOD promoter are associated with poor prognosis in most datasets (<xref ref-type="fig" rid="fig4s7">Figure 4—figure supplement 7A B</xref>). These observations provide additional support for the activation of integrin-Notch signaling in FMOD-treated endothelial cells.</p></sec><sec id="s2-6"><title>DGC-secreted FMOD is required for the growth of murine and human GSC-initiated tumors</title><p>While GSCs alone can initiate a tumor, tumor growth requires continuous differentiation to form DGCs, which form the bulk of the tumor mass. In line with our co-implantation experiments (<xref ref-type="fig" rid="fig2">Figure 2</xref>), we sought to define the importance of FMOD secreted by DGCs generated through a differentiation program initiated by GSCs during tumor growth in vivo using a syngenic intracranial glioma mouse model. We injected AGR53-GSC-<italic>miRNT</italic> and AGR53-GSC-<italic>miRFMOD</italic> cells intracranially into C57/black mice and allowed them to form tumors. 13 days after intracranial injections, both groups received doxycycline as indicated (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The understanding is that as the tumors start growing, GSCs, in addition to their self-renewal, will start differentiating de novo to form DGCs, which would express high levels of <italic>FMOD</italic>. However, doxycycline treatment would inhibit <italic>FMOD</italic> expression, and thus one could investigate the importance of DGC-secreted FMOD in tumor growth. AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cell-initiated tumors showed a similar size 7 days after doxycycline treatment as shown by mCherry fluorescence (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>; day 21). However, upon subsequent follow-up, doxycycline administration significantly inhibited the growth of AGR53-GSC/<italic>miRFMOD</italic>-initiated tumors over time but not that of AGR53-GSC/<italic>miRNT</italic> tumors (<xref ref-type="fig" rid="fig5">Figure 5B, C and E</xref>). Further, doxycycline administration increased the survival of mice injected with AGR53-GSC/<italic>miRFMOD</italic> cells compared to AGR53-GSC/<italic>miRNT</italic> cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). AGR53-GSC/<italic>miRFMOD</italic>-initiated tumors showed decreased FMOD, mCherry, and GFP expression compared to AGR53-GSC/<italic>miRNT</italic>-initiated tumors (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). DBT-Luc GSC/<italic>miRFMOD</italic>, another murine glioma GSC cell line, produced similar results: FMOD silencing after doxycycline administration resulted in reduced tumor growth (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A B</xref>), increased mice survival (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), and decreased FMOD expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Conditional silencing of fibromodulin (<italic>FMOD)</italic> in differentiated glioma cells (DGCs) formed de novo by glioma stem-like cell (GSC)-initiated tumors inhibits tumor growth.</title><p>(<bold>A</bold>) Schema depicts the timeline of the intracranial orthotopic mouse glioma model using murine glioma stem cells (AGR53-GSC) in C57BL/6 mice (n = 10 per group). Mice were injected with AGR53-GSCs (1 × 10<sup>5</sup> cells per animal) transduced with either <italic>miRNT</italic> (nontargeting) or <italic>miRFMOD</italic> lentiviruses. Tumors were allowed to grow till day 13 and then <italic>miRNT</italic> or <italic>miRFMOD</italic> (and <italic>mCherry</italic>) were induced by doxycycline (100 µl of 1 mg/ml per animal) intraperitoneal injections at indicated times. Note that in vitro characterization shows that the highest knockdown of <italic>FMOD</italic> was obtained on the seventh day after doxycycline administration. First, in vivo imaging for mCherry expression depicting tumor size was done on day 21 post-injection, followed by imaging at regular intervals (as noted by the orange marks). (<bold>B</bold>) In vivo fluorescence (mCherry) imaging of mice injected with either AGR53-GSC/<italic>miRNT</italic> or AGR53-GSC/<italic>miRFMOD</italic> cells as per the timeline shown in (<bold>A). (C</bold>) The radiance efficiency for each time point in the two groups of animals as indicated was plotted. (<bold>D</bold>) Kaplan–Meier graph showing the survival of mice bearing tumors formed by AGR53-GSC/<italic>miRNT</italic> (Dox+) and AGR53-GSC/<italic>miRFMOD</italic> (Dox+) cells. (<bold>E</bold>) Hematoxylin and eosin staining shows a larger tumor (depicted by dark blue color due to extremely high cell density) in mice brain injected with AGR53-GSC/<italic>miRNT</italic> (Dox+) cells (top) compared to that of AGR53-GSC/<italic>miRFMOD</italic> (Dox+) cells (bottom). Magnification = ×0.8. (<bold>F</bold>) Confocal microscopy analysis showing FMOD expression in brains of mice injected with AGR53-GSC/<italic>miRNT</italic> (Dox+) and AGR53-GSC/<italic>miRFMOD</italic> (Dox+) cells. Red indicates FMOD, and blue indicates H33342 (stains nuclei). The merged images are shown for representation. Magnification = ×20, scale bar = 50 μm. (<bold>G</bold>) Brain sections showing areas of fluorescence (GFP, mCherry, and DAPI) for both AGR53-GSC/<italic>miRNT</italic> (Dox+) (left panel) and AGR53-GSC/<italic>miRFMOD</italic> (Dox+) (right panel) groups of animals. Note that the AGR53 cell line stably expresses GFP while mCherry expression is induced upon doxycycline addition. On day 13, prior to the administration of doxycycline, both AGR53-GSC/<italic>miRNT</italic> (left) and AGR53-GSC/<italic>miRFMOD</italic> (right) do not have any mCherry expression but have almost similar GFP expression. However, over time after the onset of doxycycline administration, both mCherry and GFP expression decreased in the <italic>miRFMOD</italic> group but not in the <italic>miRNT</italic> group. Merged images show an overlap of GFP and mCherry-positive tumor areas. Magnification = ×20, scale bar = 50 μm. For panel (<bold>C</bold>), the p-value was calculated by unpaired <italic>t</italic>-test with Welch’s correction, and for (<bold>D</bold>), the p-value was calculated by log-rank test. p-Value &lt;0.05 was considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig5-data1-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig5-data2-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig5-data3-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig5">Figure 5E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig5-data4-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig5">Figure 5F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig5-data5-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig5">Figure 5G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig5-data6-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Conditional silencing of fibromodulin (<italic>FMOD)</italic> in differentiated glioma cells (DGCs) formed de novo by glioma stem-like cell (GSC)-initiated tumors inhibits tumor growth in a murine glioma model.</title><p>(<bold>A</bold>) In vivo bioluminescence and fluorescence (mCherry) imaging of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells (1 × 10<sup>5</sup> cells per animal) in intracranial orthotopic mouse glioma model in C57BL/6 mice (n = 10 per group, total two groups). Tumors were allowed to grow till day 9, and then <italic>miRFMOD</italic> (and <italic>mCherry</italic>) were induced by doxycycline (100 µl of 1 mg/ml per animal) intraperitoneal injections in one group of <italic>miRFMOD</italic> mice (right). First, in vivo imaging for bioluminescence and mCherry expression depicting tumor size was done on day 5, followed by imaging at regular intervals. (<bold>B</bold>) Hematoxylin and eosin staining shows a larger tumor (depicted by dark blue color due to extremely high cell density) in mice brain injected with DBT-Luc-GSC/<italic>miRFMOD</italic> (Dox-) cells (left) compared to that of DBT-Luc-GSC/<italic>miRFMOD</italic> (Dox+) cells (right). Magnification = ×0.8. (<bold>C</bold>) Kaplan–Meier graph showing the survival of mice bearing tumors formed by DBT-Luc-GSC/<italic>miRFMOD</italic> (Dox-) and DBT-Luc-GSC/<italic>miRFMOD</italic> (Dox+) cells. (<bold>D</bold>) Confocal microscopy analysis showing FMOD expression in brains of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> (Dox-) and DBT-Luc-GSC/<italic>miRFMOD</italic> (Dox+). Red indicates FMOD, and blue indicates H33342 (stains nuclei). The merged images are shown for representation. Magnification = ×20, scale bar = 50 μm. For panel (<bold>C</bold>), the p-value was calculated by the log-rank test. p-Value &lt;0.05 was considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig5-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig5-figsupp1-v3.tif"/></fig></fig-group><p>To determine the relevance of our findings to the human pathology, we investigated the importance of DGC-secreted FMOD in the growth of tumors initiated by MGG8 and U251 cells using a xenograft mouse glioma model. The higher expression of CD133 confirmed the enrichment of CSCs in MGG8-GSC neurospheres compared to MGG8-DGCs (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We established orthotopic xenografts using MGG8-GSC/shNT and MGG8-GSC/shFMOD cells. Reminiscent of results obtained using transplantation of murine glioma cells, MGG8-GSC/shNT-transplanted mice readily developed intracranial tumors, whereas MGG8-GSC/shFMOD mice showed impaired tumor formation and increased mice survival (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>). Immunostaining and confocal microscopy analysis showed high expression of FMOD in MGG8-GSC/shNT tumors, while FMOD was barely detectable in MGG8-GSC/shFMOD tumors (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Likewise, U251/shFMOD cells that showed reduced FMOD protein levels compared to U251/shNT (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6A</xref>) developed smaller tumors, and mice bearing U251/shFMOD tumors had longer survival than those carrying U251/shNT tumors (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A–D</xref>). As expected, the expression of FMOD was more elevated in U251/shNT tumors than in U251/shFMOD tumors (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>). Collectively, these findings indicate that DGC-secreted FMOD is essential for the growth of both human and mouse glioma.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Growth of human glioma stem-like cell (GSC)-initiated tumors requires secreted fibromodulin (FMOD).</title><p>(<bold>A</bold>) Flow cytometry analysis shows the relative levels of CD133-positive cells in MGG8-GSCs compared to MGG8-DGCs. (<bold>B</bold>) Kaplan–Meier graph shows the survival of mice (n = 10 per group) injected intracranially with MGG8-GSC/shNT or MGG8-GSC/shFMOD cells (1 × 10<sup>5</sup> cells per animal). (<bold>C</bold>) Hematoxylin and eosin staining shows a larger tumor (depicted by dark blue color due to high cell density) in mice brain injected with MGG8-GSC/shNT cells (top) compared to that of MGG8-GSC/shFMOD cells (bottom). Magnification = ×0.8. (<bold>D</bold>) Confocal microscopy analysis shows FMOD expression in brains of mice injected with MGG8-GSC/shNT (top panel) and MGG8-GSC/shFMOD (bottom panel) cells. Red indicates FMOD, and blue indicates H33342 (stains nuclei). Magnification = ×20, scale bar = 50 μm. Statistical significance for panel (<bold>B</bold>) was calculated using the log-rank test. p-Value &lt;0.05 is considered significant.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig6-data1-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig6-data2-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig6-data3-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig6-data4-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Growth of human glioblastoma (GBM) cell-initiated tumors requires secreted fibromodulin (FMOD).</title><p>(<bold>A</bold>) In vivo bioluminescence imaging of two groups (n = 5 per group) of mice (NIH nu/nu) injected with either U251/shNT or U251/shFMOD cells (2.5 × 10<sup>6</sup> cells per animal). (<bold>B</bold>) The total radiance for each time points in the two groups of animals, as indicated, was plotted. (<bold>C</bold>) Kaplan–Meier graph showing the survival of mice bearing tumors formed by U251/shNT or U251/shFMOD cells. (<bold>D</bold>) Hematoxylin and eosin staining shows a larger tumor (depicted by dark blue color due to high cell density) in mice brain injected with U251/shNT cells (left) compared to that of U251/shFMOD cells (right). Magnification = ×0.8. (<bold>E</bold>) Confocal microscopy analysis showing FMOD expression in brains of mice injected with U251/shNT and U251/shFMOD cells. Red indicates FMOD, and blue indicates H33342 (stains nuclei). The merged images are shown for representation. Magnification = ×20, scale bar = 50 μm. For panel (<bold>B</bold>), the p-value using an unpaired <italic>t</italic>-test with Welch’s correction, and for panel (<bold>C</bold>), p-value was calculated using the log-rank test. p-Value &lt;0.05 was considered significant, with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig6-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig6-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Reduced angiogenesis in small tumors formed in FMOD-silenced conditions</title><p>Next, we investigated the cellular differentiation and angiogenesis in the tumors toward understanding the mechanism underlying reduced tumor growth in FMOD-silenced conditions. First, we measured the expression of CD133 and GFAP markers as the representation of GSCs and DGCs in the tumors formed in the animal models. The CD133-positive cells are much less in proportion compared to GFAP-positive cells in tumors formed by AGR53-GSC, DBT-Luc-GSCs, and MGG8-GSCs under FMOD nontargeting conditions (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A B</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A B</xref>, <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A B</xref>), in good correlation to the low proportion of GSCs seen in brain tumors (<xref ref-type="bibr" rid="bib52">Singh et al., 2004</xref>; <xref ref-type="bibr" rid="bib20">Galli et al., 2004</xref>; <xref ref-type="bibr" rid="bib8">Calabrese et al., 2007</xref>). Further, most GFAP-positive cells are also positive for FMOD expression compared to CD133-positive cells (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A C</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A C</xref>, <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A C</xref>), recapitulating the results we obtained in vitro, where FMOD is expressed specifically by DGCs (<xref ref-type="fig" rid="fig1">Figure 1</xref>). We also found a similar expression pattern of CD133 and GFAP markers in small tumors formed under FMOD-silenced conditions in all three tumor models (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D E</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2D E</xref>, <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3D E</xref>). The GFAP staining in these tumors confirms the occurrence of an efficient differentiation program even in FMOD-silenced conditions, which confirms our results obtained in vitro, where the absence of FMOD failed to affect the GSC differentiation to form DGCs (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). As expected, the small tumors formed in FMOD-silenced conditions showed substantially reduced FMOD staining (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D F</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2D F</xref>, <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3D F</xref>).</p><p>We next evaluated the extent of blood vessel formation by measuring the endothelial cell marker immunostaining in the tumors. The small size tumors formed by AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline treatment showed reduced staining for CD31 and von Willebrand factor (vWF) compared to AGR53-GSC/<italic>miRNT</italic> tumors (<xref ref-type="fig" rid="fig7">Figure 7A-C</xref>, <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4A–C</xref>). Tumors formed by DBT-Luc-GSC/<italic>miRFMOD</italic> cells in doxycycline-treated mice also showed significantly reduced CD31 staining compared to that measured in the absence of doxycycline treatment (<xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4D–F</xref>). Reminiscent of murine glioma tumors, tumors induced by MGG8-GSC/shFMOD cells also showed reduced CD31 staining compared to MGG8-GSC/shNT cells (<xref ref-type="fig" rid="fig7">Figure 7D–F</xref>). We then tested the extent of blood vessel formation by TDECs. In all three tumor models (AGR53-GSCs, DBT-Luc-GSCs, and MGG8-GSCs), blood vessels formed by TDECs were significantly reduced in tumors formed in FMOD-silenced conditions (<xref ref-type="fig" rid="fig7">Figure 7G–L</xref>, <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4G–I</xref>). These findings confirm our previous results obtained in vitro, where the absence of FMOD decreased the ability of host-derived endothelial cells and TDECs to form angiogenic networks (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). Next, we investigated the involvement of integrin-FAK-JAG1-Notch-HES1 signaling in FMOD-induced angiogenesis in the context of glioma tumors. Confocal microscopy analysis in tumors formed by AGR53-GSCs, DBT-Luc-GSCs, and MGG8-GSCs revealed a significant colocalization of the endothelial cell marker CD31 with FMOD, pFAK, JAG1, and HES1 markers in blood vessels (<xref ref-type="fig" rid="fig7s5">Figure 7—figure supplement 5A–C</xref>). From these results, we conclude that angiogenesis induced by DGC-secreted FMOD is essential for glioma tumor growth.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Reduced angiogenesis is characteristic of tumors initiated by fibromodulin (FMOD)-silenced glioma cells.</title><p>(<bold>A</bold>) Confocal microscopy analysis shows CD31 expression in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> or AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline administration to the mice. Red indicates CD31, and blue indicates H33342 (stains nuclei). Magnification = ×20, scale bar = 50 μm.(<bold>B</bold>) Quantification of the mean fluorescence intensity of CD31 in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> or AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline administration to the mice. (<bold>C</bold>) Quantification of the mean area of blood vessels in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> or AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline administration to the mice. (<bold>D</bold>) Confocal microscopy analysis showing CD31 expression in brain tumor sections of mice injected with MGG8-GSC/shNT or MGG8-GSC/shFMOD cells. Red indicates CD31, and blue indicates H33342 (stains nuclei). Magnification = ×20, scale bar = 50 μm. (<bold>E</bold>) Quantification of the mean fluorescence intensity of CD31 in brain tumor sections of mice injected with MGG8-GSC/shNT or MGG8-GSC/shFMOD cells. (<bold>F</bold>) Quantification of the mean area of blood vessels in brain tumor sections of mice injected with MGG8-GSC/shNT or MGG8-GSC/shFMOD cells. (<bold>G</bold>) Confocal microscopy analysis showing CD31 and GFP expression in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> or AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline administration to the mice. Red indicates CD31, green indicates GFP, and blue indicates H33342 (stains nuclei). The yellow arrow indicates the region exhibiting colocalization of CD31 and GFP. Magnification = ×20, scale bar = 50 μm. (<bold>H</bold>) Quantification of the colocalization coefficient of CD31 and GFP staining in the brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline injection to the mice. (<bold>I</bold>) The number of blood vessels with co-staining of CD31 and GFP was quantified in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline injection to the mice and plotted. (<bold>J</bold>) Confocal microscopy analysis showing CD31 and GFAP expression in brain tumor sections of mice injected with MGG8-GSC/shNT or MGG8-GSC/shFMOD cells. Red indicates CD31, green indicates GFAP, and blue indicates H33342 (stains nuclei). The yellow arrow indicates the region exhibiting colocalization of CD31 and GFAP. Magnification = ×20, scale bar = 50 μm. (<bold>K</bold>) Quantification of the colocalization coefficient of CD31 and GFAP staining in the brain tumor sections of mice injected with MGG8-GSC/shNT and MGG8-GSC/shFMOD cells. (<bold>L</bold>) The number of blood vessels with co-staining of CD31 and GFAP was quantified in brain tumor sections of mice injected with MGG8-GSC/shNT and MGG8-GSC/shFMOD cells and plotted. (<bold>M</bold>) A model depicting the functional interactions between different cell types in glioblastoma (GBM) tumors, which comprise a small proportion of glioma stem-like cells (GSCs), a massive number of differentiated glioma cells (DGCs), and stromal cells. FMOD, primarily secreted by DGCs, upregulates JAG1 through the activation of integrin signaling in endothelial cells. The higher expression of JAG1 causes the activation of the Notch signaling pathway, which results in the transcriptional upregulation of HES1 in endothelial cells. The integrin-dependent Notch pathway activation promotes angiogenesis and vascular mimicry, leading to glioma tumor growth. For panels (<bold>B</bold>), (<bold>C</bold>), (<bold>E</bold>), (<bold>F</bold>), (<bold>H</bold>), (<bold>I</bold>), (<bold>K</bold>), and (<bold>L</bold>), n=5, and p-value was calculated using an unpaired <italic>t</italic>-test with Welch’s correction. p-Value &lt;0.05 was considered significant, with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7">Figure 7A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-data1-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7">Figure 7B, C, H, I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-data2-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-data3-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata4"><label>Figure 7—source data 4.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7">Figure 7E, F, K, L</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-data4-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata5"><label>Figure 7—source data 5.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7">Figure 7G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-data5-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata6"><label>Figure 7—source data 6.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7">Figure 7J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-data6-v3.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata7"><label>Figure 7—source data 7.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7">Figure 7M</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-data7-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig7-v3.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Fibromodulin (<italic>FMOD</italic>) silencing does not hamper the differentiation potential of tumor cells in murine glioma models.</title><p>(<bold>A</bold>) Confocal microscopy analysis of brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> cells after the mice were administered with doxycycline. Red indicates FMOD, and green indicates GFAP (top panel). Confocal microscopy analysis of brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> cells after the mice were administered with doxycycline. Red indicates FMOD, and green indicates CD133 (bottom panel). Magnification = ×20, scale = 100 μm. (<bold>B</bold>) Quantification of mean fluorescent intensity of GFAP and CD133 in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> cells after the mice were administered with doxycycline. (<bold>C</bold>) Quantification of the colocalization coefficient of FMOD with CD31 and GFP in the brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> cells after the mice were administered with doxycycline. (<bold>D</bold>) Confocal microscopy analysis of brain tumor sections of mice injected with AGR53-GSC/<italic>miRFMOD</italic> cells after the mice were administered with doxycycline. Red indicates FMOD, and green indicates GFAP (top panel). Confocal microscopy analysis of brain tumor sections of mice injected AGR53-GSC/<italic>miRFMOD</italic> cells after the mice were administered with doxycycline. Red indicates FMOD, and green indicates CD133 (bottom panel). Magnification = ×20, scale bar = 100 μm. (<bold>E</bold>) Quantification of mean fluorescent intensity of GFAP and CD133 in brain tumor sections of mice injected with AGR53-GSC/<italic>miRFMOD</italic> cells after the mice were administered with doxycycline. (<bold>F</bold>) Quantification of the colocalization coefficient of FMOD with CD31 and GFP in the brain tumor sections of mice injected with AGR53-GSC/<italic>miRFMOD</italic> cells after the mice were administered with doxycycline. For panels (<bold>B</bold>), (<bold>C</bold>), (<bold>E</bold>), and (<bold>F</bold>), n=5, and the p-value was calculated by Student’s <italic>t</italic>-test. p-Value &lt;0.05 was considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig7-figsupp1-v3.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Fibromodulin (<italic>FMOD</italic>) silencing does not hamper the differentiation potential of tumor cells in murine glioma models.</title><p>(<bold>A</bold>) Confocal microscopy analysis of brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before the mice were administered with doxycycline. Red indicates FMOD, and green indicates GFAP (top panel). Confocal microscopy analysis of brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before the mice were administered with doxycycline. Red indicates FMOD, and green indicates CD133 (bottom panel). Magnification = ×2 0, scale bar = 100 μm. (<bold>B</bold>) Quantification of mean fluorescent intensity of GFAP and CD133 in brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before the mice were administered doxycycline. (<bold>C</bold>) Quantification of the colocalization coefficient of FMOD with CD31 and GFP in the brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before the mice were administered with doxycycline. (<bold>D</bold>) Confocal microscopy analysis of brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells after the mice were administered with doxycycline. Red indicates FMOD, and green indicates GFAP (top panel). Confocal microscopy analysis of brain tumor sections of mice injected DBT-Luc-GSC/<italic>miRFMOD</italic> cells after the mice were administered with doxycycline. Red indicates FMOD, and green indicates CD133 (bottom panel). Magnification = ×20, scale bar = 100 μm. (<bold>E</bold>) Quantification of mean fluorescent intensity of GFAP and CD133 in brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells after the mice were administered with doxycycline. (<bold>F</bold>) Quantification of the colocalization coefficient of FMOD with CD31 and GFP in the brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells after the mice were administered doxycycline. For panels (<bold>B</bold>), (<bold>C</bold>), (<bold>E</bold>), and (<bold>F</bold>), n=5, and the p-value was calculated by Student’s <italic>t</italic>-test. p-Value &lt;0.05 was considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A–F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-figsupp2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig7-figsupp2-v3.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Fibromodulin (<italic>FMOD</italic>) silencing does not hamper the differentiation potential of tumor cells.</title><p>(<bold>A</bold>) Confocal microscopy analysis of brain tumor sections of mice injected with MGG8/shNT. Red indicates FMOD, green indicates GFAP, and blue indicates H33342 (stains nuclei) (top panel). Confocal microscopy analysis of brain tumor sections of mice injected with MGG8/shNT. Red indicates FMOD, green indicates CD133, and blue indicates H33342 (stains nuclei) (bottom panel). Magnification = ×20, scale bar = 100 μm. (<bold>B</bold>) Quantification of mean fluorescent intensity of GFAP and CD133 in brain tumor sections of mice injected with DBT-Luc-GSC/miRFMOD cells before the mice were administered doxycycline. (<bold>C</bold>) Quantification of the colocalization coefficient of FMOD with CD31 and GFP in the brain tumor sections of mice injected with MGG8/shNT cells. (<bold>D</bold>) Confocal microscopy analysis of brain tumor sections of mice injected with MGG8/shFMOD cells. Red indicates FMOD, green indicates GFAP, and blue indicates H33342 (stains nuclei) (top panel). Confocal microscopy analysis of brain tumor sections of mice injected MGG8/shFMOD cells. Red indicates FMOD, green indicates CD133, and blue indicates H33342 (stains nuclei) (bottom panel). Magnification = ×20, scale bar = 100 μm. (<bold>E</bold>) Quantification of mean fluorescent intensity of GFAP and CD133 in brain tumor sections of mice injected with MGG8/shFMOD cell. (<bold>F</bold>) Quantification of the colocalization coefficient of FMOD with CD31 and GFP in the brain tumor sections of mice injected with MGG8/shFMOD cells. For panels (<bold>B</bold>), (<bold>C</bold>), (<bold>E</bold>), and (<bold>F</bold>), n=5, and the p-value was calculated by Student’s <italic>t</italic>-test. p-Value &lt;0.05 was considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively. ns, nonsignificance.</p><p><supplementary-material id="fig7s3sdata1"><label>Figure 7—figure supplement 3—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A–F</xref> .</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-figsupp3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig7-figsupp3-v3.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 4.</label><caption><title>Fibromodulin (<italic>FMOD</italic>) silencing affects angiogenesis and vascular mimicry in vivo.</title><p>(<bold>A</bold>) Confocal microscopy analysis shows von Willebrand factor (vWF) expression in the brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> (top panel) and AGR53-GSC/<italic>miRFMOD</italic> cells (bottom panel) after doxycycline administration. Red indicates vWF, and blue indicates DAPI (stains nuclei). (<bold>B</bold>) Quantification of mean fluorescent intensity of vWF in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline administration. (<bold>C</bold>) Quantification of mean average area of blood vessels in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> cells after doxycycline administration. (<bold>D</bold>) Confocal microscopy analysis shows CD31 expression in the brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before (top panel) and after (bottom panel) doxycycline administration. Red indicates CD31, and blue indicates H33342 (stains nuclei). (<bold>E</bold>) Quantification of mean fluorescent intensity of CD31 in brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before and after doxycycline administration. (<bold>F</bold>) Quantification of mean average area of blood vessels in brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before and after doxycycline administration. (<bold>G</bold>) Confocal microscopy analysis shows CD31 and GFP expression in the brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before (top panel) and after (bottom panel) doxycycline administration. Red indicates CD31, green indicates GFP, and blue indicates H33342 (stains nuclei). (<bold>H</bold>) Quantification of colocalization coefficient of CD31 and GFP staining in brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before and after doxycycline administration. (<bold>I</bold>) The number of blood vessels with co-staining of CD31 and GFP was quantified in brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before and after doxycycline administration. For panels (<bold>B</bold>), (<bold>C</bold>), (<bold>E</bold>), (<bold>F</bold>), (<bold>H</bold>), and (<bold>I</bold>) n=5, and p-values were calculated by Student’s <italic>t</italic>-test. p-Value &lt;0.05 was considered significant with *, **, and *** representing p-values &lt;0.05, 0.01, and 0.001, respectively.</p><p><supplementary-material id="fig7s4sdata1"><label>Figure 7—figure supplement 4—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4A–I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-figsupp4-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig7-figsupp4-v3.tif"/></fig><fig id="fig7s5" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 5.</label><caption><title>Fibromodulin (FMOD)-dependent activation of the integrin-FAK-JAG1-HES1 signaling axis is maintained in vivo.</title><p>(<bold>A</bold>) Confocal microscopy analysis showing the expression of CD31 and FMOD (top panel), CD31 and pFAK (second panel), CD31 and JAG1 (third panel), and CD31 and HES1 (bottom panel) in brain tumor sections of mice injected with AGR53-GSC/<italic>miRNT</italic> cells after doxycycline administration. Red indicates CD31, and green indicates FMOD (top panel), pFAK (second panel), JAG1 (third panel), and HES1 (bottom panel). (<bold>B</bold>) Confocal microscopy analysis showing the expression of CD31 and FMOD (top panel), CD31 and pFAK (second panel), CD31 and JAG1 (third panel), and CD31 and HES1 (bottom panel) in brain tumor sections of mice injected with DBT-Luc-GSC/<italic>miRFMOD</italic> cells before doxycycline administration. Red indicates CD31, and green indicates FMOD (top panel), pFAK (second panel), JAG1 (third panel), and HES1 (bottom panel). (<bold>C</bold>) Confocal microscopy analysis showing the expression of CD31 and FMOD (top panel), CD31 and pFAK (second panel), CD31 and JAG1 (third panel), and CD31 and HES1 (bottom panel) in brain tumor sections of mice injected with MGG8/shNT cells. Red indicates CD31, green indicates FMOD (top panel), pFAK (second panel), JAG1 (third panel), and HES1 (bottom panel), and blue indicates H33342 (stains nuclei).</p><p><supplementary-material id="fig7s5sdata1"><label>Figure 7—figure supplement 5—source data 1.</label><caption><title>Source data used to generate <xref ref-type="fig" rid="fig7s5">Figure 7—figure supplement 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78972-fig7-figsupp5-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-fig7-figsupp5-v3.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The importance of GSCs in tumor initiation, growth, immune escape, angiogenesis, invasion into the normal brain, and resistance to therapy is also well established (<xref ref-type="bibr" rid="bib4">Bao et al., 2006</xref>; <xref ref-type="bibr" rid="bib66">Wakimoto et al., 2009</xref>). GSCs are known for their ability to self-renew and differentiate to form DGCs, the bulk cells of tumors (<xref ref-type="bibr" rid="bib20">Galli et al., 2004</xref>; <xref ref-type="bibr" rid="bib26">Ignatova et al., 2002</xref>; <xref ref-type="bibr" rid="bib52">Singh et al., 2004</xref>; <xref ref-type="bibr" rid="bib58">Suvà et al., 2014</xref>; <xref ref-type="bibr" rid="bib73">Yang et al., 2020a</xref>). However, the role of DGCs in tumor growth remains poorly understood. The key requirement of tumor cells for self-maintenance in a novel tumor niche is the supply of nutrients. GSCs are known to promote the establishment of a highly vascularized microenvironment by being in close physical contact with endothelial cells (<xref ref-type="bibr" rid="bib8">Calabrese et al., 2007</xref>). In addition, GSC-secreted factors such as VEGF-A, GDF15, IL8, and miR21 also have been shown to induce tumor angiogenesis (<xref ref-type="bibr" rid="bib12">Conroy et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Sun et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Thirant et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Treps et al., 2017</xref>; <xref ref-type="bibr" rid="bib81">Zhu et al., 2021</xref>).</p><p>The massive proportion of DGCs in the tumor suggests that GSC-initiated angiogenesis might not be sufficient to meet the large nutrient requirement of the entire tumor. Wang et al. demonstrated that DGC-secreted BDNF is essential for GSC growth and maintenance through DGC-GSC paracrine signaling, which highlights the crucial role of DGC-secreted proteins in tumor formation (<xref ref-type="bibr" rid="bib69">Wang et al., 2018</xref>). Further, a possible interaction between DGCs and stromal cells, such as endothelial cells, cannot be ruled out. We hypothesized that in addition to GSCs, DGCs might play an essential role in autocrine and paracrine signaling involving different types of cells to augment tumor growth. This study demonstrates the existence of paracrine signaling between DGCs and endothelial cells, which promotes angiogenesis and glioma tumor growth.</p><p>Previously, we have demonstrated that FMOD is highly expressed in GBMs compared to normal brain tissues. The loss of FMOD expression hampers the migratory function of glioma cells but has no impact on glioma cell proliferation (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). This study identifies that FMOD is expressed exclusively by DGCs and further showed that FMOD is not needed for GSC/DGC growth and their plasticity to form one from the other. Given these facts, the inability of DGCs silenced for FMOD to support the growth of tumors initiated by GSCs was unexpected. However, it enlightened us that DGC-secreted FMOD has some essential yet unidentified functions supporting GSC-initiated tumor growth.</p><p>Here, we explored the mechanisms underlying the role of DGCs acting as critical support for GSC-initiated tumor growth. We demonstrate that DGC-secreted FMOD promotes tumor growth by inducing angiogenesis through integrin-dependent Notch signaling in endothelial cells, thus highlighting the importance of DGCs in tumor–stroma interactions that contribute to a sustainable niche for tumor growth. We further investigated the mechanism by which FMOD activates integrin-dependent Notch signaling in endothelial cells. Based on RPPA data that showed upregulation of HES1 in endothelial cells upon FMOD treatment, we demonstrated that activation of Notch signaling is essential for FMOD-induced angiogenesis. The importance of Notch signaling in glioma, especially in GSC growth and angiogenesis, is well documented (<xref ref-type="bibr" rid="bib6">Bazzoni and Bentivegna, 2019</xref>; <xref ref-type="bibr" rid="bib55">Stockhausen et al., 2010</xref>; <xref ref-type="bibr" rid="bib60">Teodorczyk and Schmidt, 2014</xref>). Similarly, activation of Notch signaling in endothelial cells has been involved in tumor development and angiogenesis (<xref ref-type="bibr" rid="bib21">Gridley, 2007</xref>; <xref ref-type="bibr" rid="bib32">Kofler et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">Phng and Gerhardt, 2009</xref>). RPPA data also showed an increase in pFAK in FMOD-treated glioma cells. Our previous study showed that FMOD acts on glioma cells via the integrin-FAK-Src-Rho axis to promote migration (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). This study demonstrates that FMOD-activated integrin signaling is essential for Notch pathway activation in ST1 cells. Integrin signaling in endothelial cells has been shown to play a crucial role in angiogenesis (<xref ref-type="bibr" rid="bib50">Short et al., 1998</xref>; <xref ref-type="bibr" rid="bib51">Silva et al., 2008</xref>). Based on our results indicating that FMOD-activated Notch signaling in endothelial cells is inhibited by GSI, we predicted that FMOD-elicited activation of the Notch pathway could involve Notch ligand-dependent process. Our experiments identified that JAG1 is the linker molecule that integrates integrin signaling to the Notch pathway. We also found a significant colocalization of endothelial cell marker CD31 with FMOD, pFAK, JAG1, and HES1 in blood vessels of tumors formed in mouse models. Finally, endothelial cells stably expressing NICD showed enhanced angiogenic network formation in an FMOD-independent manner, suggesting that Notch activation is an essential step in FMOD-induced angiogenesis. Thus, our results show that integrin-FAK-Src-KLF8-JAG1-dependent Notch signaling activation in endothelial cells mediates FMOD-induced angiogenesis.</p><p>Finally, in an orthotopic intracranial GBM mouse model, we show that conditional silencing of <italic>FMOD</italic> in newly generated DGCs during tumor growth leads to a significant reduction of tumor growth. Supporting our in vitro data indicating that FMOD is not required for GSC growth and differentiation, we found that the small tumors formed in FMOD-silenced conditions show differentiation of GSCs. However, these tumors exhibited poorly developed blood vasculatures of host-derived endothelial cells and TDECs. The lower tumor burden in the absence of FMOD might be attributed to insufficient nutrient supply to sustain tumor growth due to the reduced blood vessel density. Thus, our study establishes an essential role of paracrine signaling between the DGCs and the stroma in the context of tumor growth in the natural tumor niche complexity. It also demonstrates the importance of FMOD secreted by DGCs in promoting human glioma tumor growth in a mouse model. We propose a tumor evolution model (<xref ref-type="fig" rid="fig7">Figure 7M</xref>), whereby GSCs, in addition to their self-renewal, continuously differentiate to form DGCs, which secrete protein factors like FMOD that mediate paracrine signaling in the different cell types of the tumor, thus creating a niche favorable to tumor growth.</p><p>In conclusion, this study demonstrates that in addition to GSCs, DGCs have an essential role in tumor growth and maintenance. While the therapy-resistant and self-renewing GSCs trigger the early events of transformation and growth, DGCs, the proportion of which continues to increase during tumor growth, progressively become essential. Thus, targeting both CSCs and differentiated cancer bulk cells is vital to achieving a durable therapeutic response. The study also highlights the potential of GSC and DGC CM analysis to uncover novel targets in cancer therapy and the critical influence of DGC-secreted FMOD in glioma tumor growth.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Resource availability</title><p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact Dr. Kumaravel Somasundaram (skumar1@iisc.ac.in).</p></sec><sec id="s4-2"><title>Materials availability</title><p>This study did not generate any new unique reagents.</p></sec><sec id="s4-3"><title>Experimental model and subject details</title><p>Experiments were performed in C57&amp;BL/6J female mice and Athymic Nude female mice (6–8 weeks old) following the approval by the Institute Ethical Committee for Animal Experimentation (Institute Animal Ethics Committee [IAEC] Project Number: CAF/Ethics/752/2020). The mice were kept in a 12 hr light and dark cycle, fed ad libitum with a normal diet, and the experiments were done in the light phase of the cycle.</p></sec><sec id="s4-4"><title>Cell lines used</title><p>Primary human tumor-derived GSCs MGG4, MGG6, and MGG8 were extensively characterized and kindly gifted to us by Dr. Wakimoto, Massachusetts General Hospital, Boston, USA (<xref ref-type="bibr" rid="bib66">Wakimoto et al., 2009</xref>) . Characterization of AGR53 mouse-derived cell line has been described before (<xref ref-type="bibr" rid="bib2">Angel et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Friedmann-Morvinski et al., 2016</xref>). DBT-Luc cells were extensively characterized (<xref ref-type="bibr" rid="bib28">Jiang et al., 2014</xref>) and gifted to us by Dr. Dinesh Thotala, Washington University in St. Louis, St Louis, MO. ST1 endothelial cells were extensively characterized (<xref ref-type="bibr" rid="bib33">Krump-Konvalinkova et al., 2001</xref>) and gifted to us Dr. Ron Unger, Johannes Gutenberg University, Germany. B.End3 cell line was purchased from The American Type Culture Collection (ATCC, #CRL-2299, Certification of Analysis can be downloaded from <ext-link ext-link-type="uri" xlink:href="https://www.atcc.org/products/crl-2299">https://www.atcc.org/products/crl-2299</ext-link> with the lot# 70030469). The HBMECs were purchased from Cell Biologics, USA (#H-6023). The Certificate of Analysis can be found at <ext-link ext-link-type="uri" xlink:href="https://cellbiologics.com/index.php?route=product/product&amp;product_id=2959">https://cellbiologics.com/index.php?route=product/product&amp;product_id=2959</ext-link>. The U251 cell line was bought from the European Collection of Authenticated Cell Cultures (ECACC, # 09063001). The Certificate of Analysis can be found at <ext-link ext-link-type="uri" xlink:href="https://www.culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=09063001&amp;collection=ecacc_gc">https://www.culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=09063001&amp;collection=ecacc_gc</ext-link>. The U87 cell line was bought from the ECACC (#89081402). The Certificate of Analysis can be found at <ext-link ext-link-type="uri" xlink:href="https://www.culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=89081402&amp;collection=ecacc_gc">https://www.culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=89081402&amp;collection=ecacc_gc</ext-link>. The LN229 cell line was bought from ATCC (# CRL-2611, <ext-link ext-link-type="uri" xlink:href="https://www.atcc.org/products/crl-2611">https://www.atcc.org/products/crl-2611</ext-link>). All cell lines were obtained from the sources mentioned above within a year of experimentation, and additional yearly authentications were carried out wherever necessary. All cell lines are verified to be mycoplasma free by EZdetect PCR Kit for Mycoplasma Detection (HiMedia).</p></sec><sec id="s4-5"><title>Plasmids</title><p>The RAR3G vector (in which <italic>miRNT</italic> and <italic>miRFMOD</italic> are cloned for the inducible <italic>shRNA</italic> experiments) was previously described (<xref ref-type="bibr" rid="bib17">Friedmann-Morvinski et al., 2012</xref>). <italic>shRNA</italic> for <italic>FMOD</italic> (<italic>miRFMOD</italic>) was cloned following the <italic>mir30</italic> (<italic>miRNT</italic>)-inducible backbone under the <italic>TRE</italic> (tetracycline response element) promoter, which is placed downstream of the <italic>mCherry</italic> reporter gene. The <italic>m2RtTA</italic> transactivator is expressed from the same vector in the opposite direction under the EF1α promoter, and following a 2A peptide, the puromycin gene is placed for selection in vitro. The FMOD overexpression plasmid was bought from Origene, USA (#LY419579). NICD pCMV Neo/intracellular domain of human Notch1 (NIC-1) and CSL Luc were kind gifts from Prof. Thomas Kandesch, Department of Genetics, University of Pennsylvania School of Medicine. Hes-Luc plasmid was bought from Addgene, USA (#43806).</p></sec><sec id="s4-6"><title>Antibodies used</title><sec id="s4-6-1"><title>Primary antibodies</title><p>FMOD (Abgent AP9243b, 1:2000), FAK (Cell Signaling Technology 3285S, 1:1000), pFAK (Cell Signaling Technology #3283S, 1:500), GAPDH (Sigma #G8795, 1:20,000), Actin (Sigma A3854, 1:20,000), HES1 (Cell Signaling Technology #D6P2U, 11988S, 1:1000), vWF (Abcam #6994, 1:2000), CD31 (Cell Signaling Technology #89C2, mouse mAb 1:200 for IHC), JAG1 (Cell Signaling Technology, Jagged1 [D4Y1R] XP rabbit mAb #70109, 1:200 for IHC, 1:1000 for WB), FMOD (fibromodulin polyclonal antibody PA5-26250, Invitrogen, IHC 1:100, WB 1:1000), CD133 (recombinant anti-CD133 antibody-EPR20980-104 #ab216323 Abcam, Flow Cyt. 1:100, Prom1 monoclonal antibody-2F8C5, #MA1-219, IHC 1:100), SOX2 (Cell Signaling Technology #3579 rabbit mAb, IHC 1:100), GFAP (anti-GFAP antibody ab7260, Abcam ICC 1:200, recombinant anti-GFAP antibody [EPR1034Y] – mouse IgG2a [ab279290], IHC 1:200), NICD (NOTCH1 (cleaved Val1744) polyclonal antibody PA5-99448, WB 1:200), SMAD2 (Smad2 [D43B4] XP rabbit mAb #5339, WB 1:1000), pSMAD2 (phospho-SMAD2 [Ser465/Ser467] [E8F3R] rabbit mAb #18338, WB 1:1000), integrin beta-1 (Cell Signaling Technology #9699 rabbit mAb, WB 1:1000), integrin alphaV (Cell Signaling Technology #4711 rabbit Ab, WB 1:1000), integrin alpha-6 (recombinant anti-integrin alpha 6 antibody [EPR18124] [ab181551], WB 1:500), and KLF8 (anti-KLF8 antibody [ab168527], WB 1:500).</p></sec><sec id="s4-6-2"><title>Secondary antibodies</title><p>Goat anti-mouse HRP conjugate (Bio-Rad #170-5047, WB 1:5000), goat anti-rabbit (H+L) secondary HRP conjugate (Invitrogen, #31460, WB 1:5000), goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 488 (Invitrogen, #A-11029), goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 488 (Invitrogen, Cat# A-11034), goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 594 (Invitrogen, Cat# A-11032), goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 594 (Invitrogen, Cat# A-11037), goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 405 Plus (Invitrogen, #<ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/A48254">A48254</ext-link>), and goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 405 Plus (Invitrogen, Cat# <ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/A48255">A48255</ext-link>). All Alexa Fluor conjugated antibodies were used at a dilution of 1:500 for IHC and ICC.</p></sec><sec id="s4-6-3"><title>Recombinant protein</title><p>Fibromodulin (FMOD) (NM_002023) Human, Origene, Cat# TP306534.</p></sec></sec><sec id="s4-7"><title>Neurosphere culturing</title><p>The GSCs were obtained by dissecting GBM tumor tissue and then treating with trypsin, followed by a trypsin inhibitor. The chopped tissue was then passed through a cell strainer to remove the debris. The obtained filtrate was plated in ultra-low attachment plates using the stem cell for neurosphere formation media described next. Then, neurospheres were grown in Neurobasal medium (#21103049, Gibco) supplemented with 1× <sc>l</sc>-glutamine (#25030081, stock 200 mM, i.e., 100×, Gibco), heparin 2 μg/ml (#H3393 Sigma), 1× B27 supplement (#17504044, Gibco, stock concentration 50×), 0.5× N2 supplement (#17502048, Gibco, stock concentration 100×), 20 ng/ml rhEGF (#g5021, Promega), 2 ng/ml rhFGF-basic (#100-18B-100 μg, PeproTech), and penicillin and streptomycin. To make single-cell suspensions for re-plating, the spheres were chemically dissociated after 7 days of plating, using NeuroCult Chemical Dissociation Kit (mouse, #05707) from Stem Cell Technologies, according to the manufacturer’s instructions.</p></sec><sec id="s4-8"><title>Differentiation of GSCs to DGCs</title><p>For differentiation of GSCs to DGCs, fully grown neurospheres were collected from the ultra-low attachment plates (Corning, USA) and plated on normal cell culture dishes in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics, as mentioned earlier, for 15–20 days (<xref ref-type="bibr" rid="bib58">Suvà et al., 2014</xref>).</p></sec><sec id="s4-9"><title>Reprogramming of DGCs</title><p>The differentiated counterparts of GSCs and differentiated GBM cell lines were removed from 10% FBS containing DMEM, spun down twice in phosphate-buffered saline (PBS) to remove any trace of FBS, and plated on ultra-low attachment plates in Neurobasal medium containing all the supplements mentioned earlier and antibiotics for 7–10 days.</p></sec><sec id="s4-10"><title>Neurosphere assay</title><p>Viral infection was done in the GSCs using lentivirus transduction for nontargeting shRNA (shNT) or shRNA for the gene of interest. The small pellets of cells were collected 48 hr after viral infection, dissociated to form single cells, counted, and replated in six-well plates (3 × 10<sup>4</sup> cells/well) in complete Neurobasal medium. At the same time, cells were harvested and checked for specific gene manipulation (like knockdown verification). Media were replenished every 2–3 days, and neurosphere formation was monitored till the sixth or seventh day after replating. The number of neurospheres, sphere diameter, and size was analyzed using ImageJ software. Spheres having an area less than 50 µm<sup>2</sup> were excluded from the analysis.</p></sec><sec id="s4-11"><title>Limiting dilution assay</title><p>For each condition, 1, 10, 50, 100, and 200 GSCs (single cells) were plated in 10 wells each, respectively, of a 96-well plate, and sphere formation was assessed over the next 5–7 days. The number of wells not forming spheres was counted and plotted against the number of cells per well. Extreme limiting dilution assay was done using the ELDA software available online (<ext-link ext-link-type="uri" xlink:href="https://www.elda.at/cdscontent/?contentid=10007.854970&amp;portal=eldaportal">https://www.elda.at/cdscontent/?contentid=10007.854970&amp;portal=eldaportal</ext-link>).</p></sec><sec id="s4-12"><title>CM collection, concentration, and sample preparation for mass spectrometry</title><p>GSC cell lines were grown as neurospheres in a complete Neural Stem Cell medium containing glutamine, heparin, N2, B27, EGF, and FGF for 6 days. They were thoroughly washed using PBS and replated without disruption in Neural Stem Cell medium devoid of supplements and growth factors. 36 hr after plating in incomplete medium, the CM was collected, spun at 1500 rpm for 15 min, filtered using 0.45 µm syringe filters, and stored at –80°C. The DGCs were grown in complete DMEM supplemented with 10% FBS, then washed with PBS, and CM was collected after 36 hr in an incomplete medium and similarly stored.</p><p>The CM were concentrated using Centricons (3 kDa cutoff; Merck) from 8 ml to 100 μl, followed by precipitation of proteins with trichloroacetic acid (TCA 10% for 30 min at 4°C). Equal amounts of proteins from each condition were run on gradient (4–20%) SDS gels and stained with Colloidal Coomassie blue. The gels were then destained, and each lane was cut into five equal pieces. Proteins were digested in-gel using trypsin (Gold Promega, 1 μg per band, overnight at 30°C) as previously described (<xref ref-type="bibr" rid="bib62">Thouvenot et al., 2008</xref>).</p></sec><sec id="s4-13"><title>Mass spectrometry, protein identification, and relative quantification</title><p>Tryptic peptides were analyzed online by nano-flow liquid chromatography coupled to tandem-mass spectrometry using a Q-Exactive+ mass spectrometer (Thermo Fisher Scientific, Waltham, USA) coupled to an RSLC-U3000 HPLC (Thermo Fisher Scientific). Desalting and pre-concentration of samples were performed online on a PepMap pre-column (0.3 mm × 10 mm, Dionex). A gradient consisting of 2–25% B for 80 min, 25–40% B for 20 min, and finally 40–90% B for 5 min (A = 0.1% formic acid; B = 0.1% formic acid in 80% acetonitrile) at 300 nl/min was used to elute peptides from the capillary reverse-phase column (0.075 mm × 150 mm, Acclaim PepMap 100 C18, Thermo Fisher Scientific). Eluted peptides were electro-sprayed online at a voltage of 1.5 kV into the Q-Exactive+ mass spectrometer. A cycle of one full-scan mass spectrum (MS1, 375–1500 m/z) at a resolution of 70,000, followed by 12 data-dependent tandem-mass (MS2) spectra, was repeated continuously throughout the nano-LC separation. Parameters used for MS2 spectra were the resolution of 17,500, AGC target of 1e5, normalized collision energy of 28, and an isolation window of 1.2 m/z. Mass spectra were processed using the MaxQuant software package (v 1.5.5.1, <xref ref-type="bibr" rid="bib13">Cox and Mann, 2008</xref>) against the UniProtKB Reference proteome UP000005640 database for <italic>Homo sapiens</italic> (release 2018_11) and contaminant database. The following parameters were used: enzyme specificity set as trypsin/P with a maximum of two missed cleavages, oxidation (M) and acetyl (protein N-term) set as variable modifications, and carbamidomethyl (C) as fixed modification and a mass tolerance of 0.5 Da for fragment ions. The maximum false peptide and protein discovery rate was specified as 0.01. Match between runs was used to transfer identification from run to run. Relative protein quantification was performed using LFQ intensity in MaxQuant. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (<xref ref-type="bibr" rid="bib40">Perez-Riverol et al., 2022</xref>) partner repository with the dataset identifier PXD032958. For statistical analysis, missing values were defined using the imputation tool of the Perseus software (v. 1.6.1.1, <xref ref-type="bibr" rid="bib65">Tyanova et al., 2016</xref>).</p></sec><sec id="s4-14"><title>Lentivirus preparation and transduction of cells</title><p>HEK-293T cells were seeded in 60 mm or 90 mm poly-<sc>l</sc>-llysine-coated cell culture dishes. The cells were transfected with shRNA plasmid and helper plasmids psPAX2 and pMD2.G using Opti-MEM (Invitrogen #22600-050) medium and Lipofectamine (<ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/12566014">https://www.thermofisher.com/order/catalog/product/12566014;</ext-link> Invitrogen) when the cells were 60–70% confluent. 6 hr after transfection, the Opti-MEM medium was replaced by a fresh DMEM supplemented with 10% FBS. 60 hr post-transfection, the supernatant from the transfected cells was collected in 15 ml Falcon tubes, centrifuged at 5000 rpm for 10 min, filtered through 0.45 μm, and stored at –80°C for future use.</p><p>For the virus used in endothelial cells, DMEM was removed after 24 hr of transfection and changed to complete M199, and the virus was collected after 60 hr, as mentioned previously. The same method was used for the virus for GSCs (DMEM was changed to NBM). The shRNA construct number TRCN0000152163 from Sigma human TRC shRNA library was used for knockdown studies of human FMOD. The shRNA construct number TRCN000094248 from Sigma mouse TRC shRNA library was used for knockdown studies of mouse FMOD. A pooled lentivirus using the construct numbers TRCN000024441, TRCN000024441, TRCN000024441, and TRCN000024420 was used for knockdown studies of JAG1 in the ST1 cells.</p></sec><sec id="s4-15"><title>Endothelial cell culture</title><p>ST1 cells were grown in Medium 199 (Sigma #M4530) supplemented with 20% FBS and endothelial cell growth factor (ECGS) (Sigma #E2759), heparin, glutamine (1×) and 1× antibiotic-antimycotic solution (Sigma, # A5955, stock concentration 100×).</p></sec><sec id="s4-16"><title>Transdifferentiation of DGCs</title><p>The MGG8-DGCs were grown in Medium 199, having the same composition as mentioned above, for 3 days and subjected to hypoxia (1% O<sub>2</sub>) for 8 hr. The cells then formed transdifferentiated endothelial cells (TDECs), showed endothelial morphology (data not shown), were harvested for checking markers levels, and were also plated for the in vitro angiogenesis assay.</p></sec><sec id="s4-17"><title>NICD stable generation</title><p>For NICD stable cell line generation, the ST1 cells were transfected with NICD pCMV Neo/intracellular domain of human Notch1 (NIC-1) plasmid using Lipofectamine 200 (Invitrogen). They then were harvested 48 hr after transfection for Western blot and in vitro angiogenesis assay.</p></sec><sec id="s4-18"><title>RNA isolation, cDNA conversion, and real-time quantitative RT-PCR analysis</title><p>Total RNA from the cells was isolated from cells using the TRI reagent (#T9424 Sigma) according to the manufacturer’s instructions. Next, the integrity of the RNA was checked by running it on 2% MOPS-formaldehyde gel. RNAs were quantified by NanoDrop. 2 µg of total RNA were used for cDNA conversion using the high-capacity cDNA reverse transcription kit (Applied Biosystems, USA) according to the manufacturer’s protocol. The cDNAs were diluted in a ratio of 1:10 with nuclease-free water to make their final concentration 10 ng/µl. Subsequently, real-time quantitative PCR was done using the ABI Quant Studio 5 and 6 (Life Technologies, USA). The cDNA was used as a template, and DyNAmo Flash SYBR Green qPCR kit (#F-416L) was used. Gene-specific primer sets were used for the reaction (see table at the end) under the following conditions: 95°C for 15 min, 40 cycles of 95°C for 20 s, 60°C for 25 s, and 72°C for 30 s followed by the dissociation cycle for melt curve generation. Each sample was run either in duplicate or triplicate. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), ACTB (beta-actin), 18S rRNA, RPL35a (ribosomal protein L35a), and <italic>ATP5G1</italic> (ATP synthase, H+transporting, mitochondrial F0 complex, subunit C1 [subunit 9]) were used as reference genes for human gene expression analysis. For mouse gene expression analysis, cyclophilin was used as a housekeeping gene. ΔΔCT method was used to calculate gene expression, which was transformed to log2 ratio and then to absolute scale for plotting.</p></sec><sec id="s4-19"><title>Western blotting</title><p>For Western blotting analysis, cell pellets were lysed in RIPA lysis buffer (containing 1 mM sodium orthovanadate, 5 mM sodium fluoride, 1 mM phenylmethanesulfonyl fluoride, and 1× protease inhibitor cocktail, Sigma, USA), and proteins were isolated from the cells by spinning at 13,000 rpm for 30 min. The supernatant containing the proteins was collected. Protein concentrations were measured using Bradford’s reagent, and a standard BSA curve was used to determine the protein concentrations. Equal amounts of proteins from all conditions were mixed with protein loading dye (1×), denatured at 95°C for 15 min, loaded in each well of an SDS polyacrylamide gel, and the gel was run for around 8 hr. To prepare SDS- polyacrylamide gel, resolving and stacking gels were prepared at a concentration of 10–12 concentrations. The gel was run at 70–100 V, and then the proteins were transferred onto a polyvinyl fluoride (PVDF) membrane using the semi-dry transfer method. After the transfer, the membrane was blocked using 5% skimmed milk in 1× Tris-buffered saline-Tween (TBST) for 1 hr. Subsequently, the membrane was washed in TBST for 30 min and probed initially with primary antibodies in 5% BSA-TBST for 14–16 hr at 4°C. Then, the membrane was washed in TBST for 30 min, and the secondary antibody, diluted in 5% skimmed milk in TBST, was added and incubated at room temperature for 2–3 hr. Finally, the blot was washed and developed using PerkinElmer ECL Plus lightning and Bio-Rad Clarity and Clarity Plus ECL chemiluminescent reagent using GE Image Quant machine.</p></sec><sec id="s4-20"><title>Chromatin immunoprecipitation (ChIP)</title><p>ChIP assay was conducted with chromatin isolated from ST1 cells treated with 10 μM TGF-β RI inhibitor (SB431542) and DMSO for 6 hr. Briefly, after cross-linking, the nuclei were prepared and sonicated to generate chromatin fragments between 100 and 10,000 bp following the manufacturer’s protocol using the Simple Chromatin Immunoprecipitation kit (CST; Cat# 9003). The sheared chromatin was collected by centrifugation (10,000 × <italic>g</italic> for 10 min at 4°C), and a 10 μl aliquot was removed to serve as a positive input sample. Aliquots of 100-μl-sheared chromatin were incubated with 2 μg of the required antibody/antibodies followed by Protein G magnetic beads for the stipulated time. An equal amount of IgG and H3 antibodies was used as control. The eluted DNA was analyzed by quantitative PCR using the FMOD promoter-specific primer set ChIP-F/ChIP-R (in the list of primers) to amplify the desired region in the FMOD promoter. Conditions of linear amplification were determined empirically for this primer. The PCR conditions were as follows: 95°C for 5 min; 95°C for 30 s, 56°C for 30 s, and 72°C for 30 s for 35 cycles. PCR products were resolved by electrophoresis on a 2% agarose gel and visualized after ethidium bromide staining. Real-time qPCR was performed with the same eluted DNA. The conditions were as follows: 95°C for 3 min; 95°C for 10 s, 56°C for 30 s, 72°C for 30 s for 40 cycles and 72°C for 5 min. The Ct values of different conditions were normalized to Ct values in IgG control.</p></sec><sec id="s4-21"><title>Boyden chamber assay for cell migration</title><p>Trans-well assay was done in 24-well Boyden chambers with 8 μm pore size polycarbonate membranes (BD Biosciences, San Diego, USA). ST1 cells (5 × 10<sup>4</sup>) were resuspended in 500 μl serum-free Medium 199 and placed in the upper chamber. The lower chamber was filled with serum-free Medium 199 with 750 μl CM or 400 nM final concentration of recombinant protein dissolved in an incomplete medium (serving as a chemoattractant). After 24 hr of incubation, cells remaining on the upper surface of the membrane were removed with a wet cotton bud. The cells that migrated to the lower surface of the membrane were fixed in ice-cold methanol, stained with crystal violet, and imaged in a light microscope.</p></sec><sec id="s4-22"><title>Boyden chamber assay for cell invasion</title><p>Trans-well assay was done in 24-well Boyden chambers with 8 μm pore size polycarbonate membranes coated with Matrigel (BD Biosciences). ST1 cells (5 × 10<sup>4</sup>) were resuspended in 500 μl serum-free Medium 199 and placed in the upper chamber. The lower chamber was filled with serum-free Medium 199 with 750 μl CM or 400 nM final concentration of recombinant protein dissolved in an incomplete medium (serving as a chemoattractant). After 24 hr of incubation, cells remaining on the upper surface of the membrane were removed with a wet cotton bud. The cells that have invaded the lower surface of the membrane were fixed in ice-cold methanol, stained with crystal violet, and imaged in a light microscope.</p></sec><sec id="s4-23"><title>Cell proliferation assay (MTT assay)</title><p>1.5 × 10<sup>3</sup> ST1 cells were plated with 2% FBS-containing M199 Medium in each well of a 96-well plate. MTT assay was performed as per the established protocol. MTT was added to each well, and Formazan crystals formed after 3 hr of incubation were dissolved in DMSO, and the absorbance was measured at 420 nm. The first reading served as the untreated condition (0th time point). After this reading, the cells were treated with 400 nm rhFMOD or an equivalent concentration of bovine serum albumin (BSA), and readings were taken every 24 hr, till 96 hr. The cell viability was then plotted as a line graph.</p></sec><sec id="s4-24"><title>In vitro angiogenesis assay</title><p>ST1 endothelial cells were seeded in 96-well plates (10 × 10<sup>3</sup>–15 × 10<sup>3</sup> cells per well), coated with Geltrex (Invitrogen), and grown in Medium 199 (Sigma) without growth factors. Equal protein amounts (50–100 µg) from serum-free CM from different conditions were added on top of the cells. After 10–12 hr of incubation, endothelial cells form tube-like structures. Each complete circular structure was considered one complete network (well-connected and not broken at any place). The total number of networks for each condition was counted double-blindly. For positive control, cells were plated in complete endothelial cell media (Medium 199) supplemented with ECGS and 20% FBS, and in the negative control, cells were plated in incomplete Medium 199 (without serum and ECGS).</p></sec><sec id="s4-25"><title>Immunofluorescence staining of fixed cells</title><p>Cells were plated on coverslips in 12-well plates and allowed to attach. The cells were then fixed with 4% paraformaldehyde (PFA) and permeabilized using PBS supplemented with 0.25% Triton-X100. Cells were then washed with PBS and blocked using PBS supplemented with 1% BSA, 0.3% Triton X-100, and 5% goat serum for 2 hr at room temperature. After blocking, the primary antibody, diluted in the blocking buffer, was added to the coverslips overnight at 4°C. For dual staining, the primary antibodies (one anti-mouse and the other anti-rabbit) were simultaneously added to the samples in the required dilutions. After removing the primary antibody, cells were thoroughly washed with PBS three times for 5 min each. Fluorescence-conjugated secondary antibody was dissolved in the blocking buffer and added to the cells for 3 hr, after which the cells were washed three times with PBS for 5 min. The cells were stained with DAPI (1 µl/ml) for 5 min at room temperature. Coverslips were mounted on glass slides using glycerol as a mounting agent and imaged using a Zeiss LSM 880 confocal microscope.</p></sec><sec id="s4-26"><title>Luciferase reporter assay</title><p>Cells were seeded in six-well plates and co-transfected with the reporter luciferase construct and pCMV-beta gal (as control) using Lipofectamine according to the manufacturer’s instructions. 24–48 hr after transfection, cell extracts were made in reporter lysis buffer (Promega). Protein concentrations of the cell lysates were measured by Bradford assay reagent (Bio-Rad). 10 µg of protein were mixed with 30 µl of luciferase assay reagent (LAR) to determine the luciferase activity, and values were normalized to β-galactosidase activity units.</p></sec><sec id="s4-27"><title>Flow cytometry</title><p>The GSCs and DGCs are pelleted down and stained with live dead fluorescent stain (L34955 <ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/L34955?SID=srch-srp-L34955">LIVE/DEAD</ext-link> <ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/L34955?SID=srch-srp-L34955">Fixable Violet Dead Cell Stain Kit, for 405</ext-link> <ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/L34955?SID=srch-srp-L34955">nm</ext-link> <ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/L34955?SID=srch-srp-L34955">excitation</ext-link>) for 15 min at 37°C. Then, the cells are blocked using 10% FCS and 1% sodium azide in PBS. After blocking, the cells are washed with PBS thrice, incubated with the primary antibody for 2 hr at room temperature, washed again thrice, and incubated with the secondary antibody for 2 hr in the dark. The final pellet was washed thrice with PBS, dissolved in 200 μl 3% BSA in PBS, and analyzed using the BD FACS Verse flow cytometer. The data were analyzed using the FlowJo software.</p></sec><sec id="s4-28"><title>Reverse phase protein array analysis for the identification of differential protein expression upon FMOD treatment to endothelial cells</title><p>Untreated ST1 cells and cells treated for 10, 30, and 60 min with 400 nM rhFMOD were lysed using RPPA lysis buffer. Lysates were serially diluted in 5 twofold dilutions using lysis buffer and printed on nitrocellulose-coated slides using an Aushon Biosystem 2470 arrayer. Slides were probed with 304 validated primary antibodies followed by detection with appropriate biotinylated secondary antibodies. Slides were scanned, analyzed, and quantified using Array-pro Analyzer software (Media Cybernetics) to generate spot intensity (level 1 data). Signals were visualized by a secondary streptavidin-conjugated HRP antibody and DAB colorimetric reaction. The list of 304 antibodies can be found at <ext-link ext-link-type="uri" xlink:href="http://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-core/antibody-information-and-protocol.html">http://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-core/antibody-information-and-protocol.html</ext-link>.</p></sec><sec id="s4-29"><title>Cryo-sectioning of fixed mouse brain</title><p>Mice were perfused intracardiacally using 4% PFA solution, and the brains were harvested and stored in PFA for 12 hr and subsequently in 30% sucrose solution. The brains were then embedded in Poly-freeze solution (Sigma, #35059990) and sectioned into 20-μm-thick sections using a Leica Cryostat. The sections were stored at –80°C in Tissue Cutting Solution (TCS).</p></sec><sec id="s4-30"><title>Confocal microscopy-based immunofluorescence analysis of free-floating sections</title><p>The brain sections were removed from TCS, put in 96-well plates, and washed thoroughly with PBS for immunofluorescence. Then, the same protocol was followed for immunofluorescence staining of tissue sections as that followed for monolayer cells grown on coverslips. At the final step, after adding the secondary antibody, DAPI or H33342, and PBS washes, the sections were individually mounted on glass slides using the ProLong Glass Antifade Mountant (Invitrogen, #<ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/P36980">P36980</ext-link>) and covered by coverslips. Images were taken using the Zeiss LSM 880 confocal microscope using ×10, ×20, and ×40 objectives for various conditions.</p><p>For immunofluorescence of FFPE sections, an extra step of antigen retrieval was performed by de-paraffinizing the sections in xylene, then boiling in distilled water twice for 5 min each. After this, the rest of the steps from permeabilization to mounting the same steps were followed as that of immunofluorescence of free-floating sections.</p></sec><sec id="s4-31"><title>Scoring methods for confocal images</title><p>The areas of the blood vessels and the fluorescence intensities for all the fluorophores used in the tissue sections were measured using the Zeiss Black software (<ext-link ext-link-type="uri" xlink:href="https://www.zeiss.com/microscopy/int/products/microscope-software.html">https://www.zeiss.com/microscopy/int/products/microscope-software.html</ext-link>), converted to percentages, and plotted as bar diagrams. For determining the extent of vascular mimicry in the blood vessels of the tissues, the overlap of green (coming from GFP or GFAP staining of the tumor cells) and red (a measure of CD31 expression of the endothelial cells) forming yellow color was calculated as a measure of colocalization coefficients in the Zeiss Black software. The absolute values of the colocalization coefficients were plotted for each condition.</p></sec><sec id="s4-32"><title>Subcutaneous injection of DBT-Luc cells for the co-implantation mouse model</title><p>All animal procedures followed were approved by the Institute Ethical Committee for Animal Experimentation (Institute Animal Ethics Committee [IAEC] Project Number: CAF/Ethics/752/2020). Mouse cell line DBT-Luc-DGC, which grows as a monolayer cell line (stable for luciferase expression), was reprogrammed to form DBT-Luc-GSCs. A combination of 10<sup>5</sup> DBT-Luc-GSCs (without any <italic>shRNA</italic>) and 10<sup>6</sup> DBT-Luc-DGCs that carried either the <italic>miRNT</italic> or <italic>miRFMOD</italic> constructs (referred to as DBT-Luc-DGC/<italic>miRNT</italic> or DBT-Luc-DGC/<italic>miRFMOD,</italic> respectively) was injected subcutaneously in the mice. Two groups of mice (n = 5 each) received a combination of 10<sup>5</sup> DBT-Luc-GSCs+10<sup>6</sup> DBT-Luc-DGC/<italic>miRNT</italic> and another two groups (n = 5 each) received a combination of 10<sup>5</sup> DBT-Luc/GSCs +10<sup>6</sup> DBT-Luc-DGC/<italic>miRFMOD</italic> (only one of the two groups for both <italic>miRNT</italic> and <italic>miRFMOD</italic> received doxycycline). Doxycycline injection (intraperitoneal, 100 μg per animal) began on 9th day post the injection and was given on every day up to the 16<sup>th</sup> day, after which it was given on every alternate day till the end of the experiment. Since the doxycycline administration induced the <italic>mCherry</italic> expression along with the <italic>shRNA</italic> expression, the animals were imaged for both bioluminescence (marked by red on the timeline) and fluorescence (marked by orange on the timeline) on the days indicated in the timeline. Two other groups (n = 5 each) received either only 10<sup>5</sup> DBT-Luc-GSCs or 10<sup>6</sup> DBT-Luc-DGCs (not stables for any <italic>shRNA</italic>) as controls.</p></sec><sec id="s4-33"><title>Intracranial injection of GBM cells</title><p>Cells were harvested in incomplete DMEM or NBM depending on the cell type to be injected. 0.25 × 10<sup>6</sup> DGCs or 1 × 10<sup>5</sup> GSCs were injected intracranially (in the hippocampus, 2.5 mm deep) in each animal using a stereotaxic apparatus. The animals were imaged on the third day after injection and subsequently, every 5–6 days until the end of the experiment. In experiments using inducible shRNAs, doxycycline was injected every day for 10 days (from the 13th day after injection) and on every alternate day until the end of the experiment. MGG8-GSC (MGG8-GSC/shNT vs. MGG8-GSC/shFMOD), AGR53-GSCs (AGR53-GSC/<italic>miRNT</italic> vs. AGR53-GSC/<italic>miRFMOD</italic>), and DBT-Luc-GSCs (DBT-Luc-GSC/<italic>miRFMOD</italic>) cells were intracranially injected in this study.</p></sec><sec id="s4-34"><title>In vivo imaging</title><p>In vivo imaging was done for bioluminescence or fluorescence with the PerkinElmer IVIS Spectrum by using mild gas anesthesia (using isoflurane) for the animals.</p></sec><sec id="s4-35"><title>Hematoxylin and eosin staining</title><p>Brains from perfused mice were paraffin-embedded and sectioned using a microtome (Leica Biosystems, 5 μm sections). Sections were mounted on glass slides and removed from paraffin, rehydrated, and stained with Harris Hematoxylin (Merck, 6159380051046) for nuclear staining and Eosin Y (SDFCL, 44027G25) solution for cytoplasmic staining. The sections were then mounted using DPX mounting medium and imaged at 0.8× using a Lawrence and Mayo digital microscope.</p></sec><sec id="s4-36"><title>Gene set enrichment analysis (GSEA)</title><p>The differentially expressed genes between the GSC and DGC (as identified in GSE54792) were pre-ranked based on fold change and used as an input to perform GSEA. All the gene sets available in the Molecular Signature Database (MSigDB, roughly 18,000 gene sets) were used to run the GSEA. We filtered out the TGF-β pathway-related gene sets to identify that most of them were significantly enriched in the DGCs over the GSCs. Similarly, the same analysis was carried out in multiple publicly available GBM vs. normal samples datasets to show the significant enrichment of TGF-β gene sets in GBM over normal. We acknowledge our use of the GSEA software and MSigDB (<xref ref-type="bibr" rid="bib56">Subramanian et al., 2005</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/gsea/">http://www.broad.mit.edu/gsea/</ext-link>).</p></sec><sec id="s4-37"><title>Single sample GSEA (ssGSEA)</title><p>Gene set variation analysis (GSVA) was performed using ssGSEA to determine the enrichment of the different molecular subtypes of GBM in GSE54792 and also the enrichment of the TGF-β Hallmark gene set from MSigDb. The higher GSVA score indicates the highest enrichment, which gradually decreases.</p></sec><sec id="s4-38"><title>Survival analysis</title><p>Kaplan–Meier survival analysis was done using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).</p></sec><sec id="s4-39"><title>Heatmap generation</title><p>The heatmaps were generated using the Multiple Experiment Viewer (MEV) software (<ext-link ext-link-type="uri" xlink:href="http://www.tm4.org/mev.html">http://www.tm4.org/mev.html</ext-link>) version 4.8.1. LFQ values for protein expression from mass-spec data and mean pixel density for the RPPA were used as inputs for heatmap generation. A nonparametric <italic>t</italic>-test was performed with a false discovery rate (FDR) and a p-value cutoff of 0.05.</p></sec><sec id="s4-40"><title>Quantification and statistical analysis</title><p>Bar diagrams were generated using Microsoft Excel. The box plots were generated using GraphPad Prism 5.0 (GraphPad Software). The p-value was calculated by unpaired <italic>t</italic>-test with Welch’s correction or Student’s <italic>t</italic>-test done using Microsoft Excel indicated. ANOVA p-value was calculated using GraphPad Prism 5 software. Significance for Kaplan–Meier survival analysis as calculated by the log-rank test. Correlation coefficients were calculated using Pearson’s correlation coefficient using GraphPad Software. All experiments (except the ones involving the animal models) were done at least thrice with duplicates for each condition within the experiments. The data are represented as mean ± standard deviation. p-Value &lt;0.05 is considered significant with *, **, ***, and **** representing p-values &lt;0.05, 0.01, 0.001, and 0.00001, respectively. ns indicates nonsignificance.</p></sec><sec id="s4-41"><title>List of primers used in this study</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="top">1</td><td align="left" valign="top">FMOD</td><td align="left" valign="top">ACCTGCAGCTTGGAGAAGT</td><td align="left" valign="top">CAACACCAACCTGGAGAACC</td></tr><tr><td align="left" valign="top">2</td><td align="left" valign="top">SOX2</td><td align="left" valign="bottom">AACCCCAAGATGCACAACTC</td><td align="left" valign="top">GCTTAGCCTCGTCGATGAAC</td></tr><tr><td align="left" valign="top">3</td><td align="left" valign="top">SALL2</td><td align="left" valign="bottom">TAATCTCGGACTGCGAAGGT</td><td align="left" valign="top">TAGAACATGCGTTCTGGTGG</td></tr><tr><td align="left" valign="top">4</td><td align="left" valign="top">POU3F2</td><td align="left" valign="top">TGACGATCTCCACGCAGTAG</td><td align="left" valign="top">GGCAGAAAGCTGTCCAAGTC</td></tr><tr><td align="left" valign="top">5</td><td align="left" valign="top">OLIG2</td><td align="left" valign="top">CCAGAGCCCGATGACCTTTT</td><td align="left" valign="top">AGGACGACTTGAAGCCACTG</td></tr><tr><td align="left" valign="top">6</td><td align="left" valign="top">DLL4</td><td align="left" valign="top">CTGCGAGAAGAAAGTGGACAGG</td><td align="left" valign="top">ACAGTCGCTGACGTGGAGTTCA</td></tr><tr><td align="left" valign="top">7</td><td align="left" valign="top">DLL3</td><td align="left" valign="top">CACTCAACAACCTAAGGACGCAG</td><td align="left" valign="top">GAGCGTAGATGGAAGGAGCAGA</td></tr><tr><td align="left" valign="top">8</td><td align="left" valign="top">JAG1</td><td align="left" valign="top">TGCTACAACCGTGCCAGTGACT</td><td align="left" valign="top">TCAGGTGTGTCGTTGGAAGCCA</td></tr><tr><td align="left" valign="top">9</td><td align="left" valign="top">JAG2</td><td align="left" valign="top">GCTGCTACGACCTGGTCAATGA</td><td align="left" valign="top">AGGTGTAGGCATCGCACTGGAA</td></tr><tr><td align="left" valign="top">10</td><td align="left" valign="top">HES1</td><td align="left" valign="top">GGAAATGACAGTGAAGCACCTCC</td><td align="left" valign="top">GAAGCGGGTCACCTCGTTCATG</td></tr><tr><td align="left" valign="top">11</td><td align="left" valign="top">Mouse FMOD</td><td align="left" valign="top">CCCTTACCCCTATGAGCCC</td><td align="left" valign="top">GACAGTCGCATTCTTGGGGA</td></tr><tr><td align="left" valign="top">12</td><td align="left" valign="top">OSMR</td><td align="left" valign="top">CATCCCGAAGCGAAGTCTTGG</td><td align="left" valign="top">GGCTGGGACAGTCCATTCTAAA</td></tr><tr><td align="left" valign="top">13</td><td align="left" valign="top">ACSBG1</td><td align="left" valign="top">GAACATCTGGTGCACGGTATAG</td><td align="left" valign="top">GAGGAAGCTGGTGGAGTATTG</td></tr><tr><td align="left" valign="top">14</td><td align="left" valign="top">ALDH1L</td><td align="left" valign="top">GAGGAAGCTGGTGGAGTATTG</td><td align="left" valign="top">ACGGTTGGCTGAAAGAAGAA</td></tr><tr><td align="left" valign="top">15</td><td align="left" valign="top">S100B</td><td align="left" valign="top">CCCTGTAGAAGAGTCACCTGTA</td><td align="left" valign="top">GCTGTGGGTCTGTAGATGTATG</td></tr><tr><td align="left" valign="top">16</td><td align="left" valign="top">GFAP</td><td align="left" valign="top">CGGAGACGCATCACCTCTG</td><td align="left" valign="top">AGGGAGTGGAGGAGTCATTCG</td></tr><tr><td align="left" valign="top">17</td><td align="left" valign="top">MELK</td><td align="left" valign="top">TATGAAACGATTGGGACAGGTG</td><td align="left" valign="top">CCCTAGCGCATTCTTATCCATGA</td></tr><tr><td align="left" valign="top">18</td><td align="left" valign="top">NESTIN</td><td align="left" valign="top">GGAATCTCTGAGGTCTCTTGATG</td><td align="left" valign="top">TCTGCTCCTCCTCTTCTACTT</td></tr><tr><td align="left" valign="top">19</td><td align="left" valign="top">BMI1</td><td align="left" valign="top">CAAGAAGAGGTGGAGGGAATAC</td><td align="left" valign="top">CCAGAGAGATGGACTGACAAAT</td></tr><tr><td align="left" valign="top">20</td><td align="left" valign="top">KLF4</td><td align="left" valign="top">GTGCCCCGACTAACCGTTG</td><td align="left" valign="top">GTCGTTGAACTCCTCGGTCT</td></tr><tr><td align="left" valign="top">21</td><td align="left" valign="top">TWIST2</td><td align="left" valign="top">CCAAGGCTCTCAGAACAAGAA</td><td align="left" valign="top">GGAGACGTAAAGAACAGGAGTATG</td></tr><tr><td align="left" valign="top">22</td><td align="left" valign="top">PTGS2</td><td align="left" valign="top">TGAGCAACTATTCCAAACCAGC</td><td align="left" valign="top">GCACGTAGTCTTCGATCACTATC</td></tr><tr><td align="left" valign="top">23</td><td align="left" valign="top">S100A6</td><td align="left" valign="top">ATGGCATGCCCTCTGGATCAG</td><td align="left" valign="top">TTATTTCAGAGCTTCATTGTAGATC</td></tr><tr><td align="left" valign="top">24</td><td align="left" valign="top">Cyclophilin</td><td align="left" valign="top">CAGACGCCACTGTCGCTTT</td><td align="left" valign="top">TGTCTTTGGAACTTTGTCTG</td></tr><tr><td align="left" valign="top">25</td><td align="left" valign="top">ATP5G</td><td align="left" valign="top">CCAGACGGGAGTTCCAGAC</td><td align="left" valign="top">GACGGGTTCCTGGCATAGC</td></tr><tr><td align="left" valign="top">26</td><td align="left" valign="top">GAPDH</td><td align="left" valign="top">TTGTCAAGCTCATTTCCTGG</td><td align="left" valign="top">TGATGGTACATGACAAGGTGC</td></tr><tr><td align="left" valign="top">27</td><td align="left" valign="top">cPPT (for sequencing)</td><td align="left" valign="top">GAAGGAATAGAAGAAGAAGGT GGAGAG</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">28</td><td align="left" valign="top">KLF8</td><td align="left" valign="top">CCTGAAAGCTCACCGCAGAATC</td><td align="left" valign="top">TGCTTGCGGAAATGGCGAGTGA</td></tr><tr><td align="left" valign="top">29</td><td align="left" valign="top">FOXP1</td><td align="left" valign="top">CAAAGAACGCCTGCAAGCCATG</td><td align="left" valign="top">GGAGTATGAGGTAAGCTCTGTGG</td></tr><tr><td align="left" valign="top">30</td><td align="left" valign="top">ETS1</td><td align="left" valign="top">GAGTCAACCCAGCCTATCCAGA</td><td align="left" valign="top">GAGCGTCTGATAGGACTCTGTG</td></tr><tr><td align="left" valign="top">31</td><td align="left" valign="top">GATA4</td><td align="left" valign="top">GCGGTGCTTCCAGCAACTCCA</td><td align="left" valign="top">GACATCGCACTGACTGAGAACG</td></tr><tr><td align="left" valign="top">32</td><td align="left" valign="top">ATF2</td><td align="left" valign="top">GGTAGCGGATTGGTTAGGACTC</td><td align="left" valign="top">TGCTCTTCTCCGACGACCACTT</td></tr><tr><td align="left" valign="top">33</td><td align="left" valign="top">ITGB1</td><td align="left" valign="top">GGATTCTCCAGAAGGTGGTTTCG</td><td align="left" valign="top">TGCCACCAAGTTTCCCATCTCC</td></tr><tr><td align="left" valign="top">34</td><td align="left" valign="top">ITGA6</td><td align="left" valign="top">CGAAACCAAGGTTCTGAGCCCA</td><td align="left" valign="top">CTTGGATCTCCACTGAGGCAGT</td></tr><tr><td align="left" valign="top">35</td><td align="left" valign="top">ITGAV</td><td align="left" valign="top">AGGAGAAGGTGCCTACGAAGCT</td><td align="left" valign="top">GCACAGGAAAGTCTTGCTAAGGC</td></tr></tbody></table></table-wrap></sec><sec id="s4-42"><title>List of shRNAs used in the study (all IDs are of Sigma TRC whole-genome shRNA library)</title><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">S. no</th><th align="left" valign="bottom">Gene name</th><th align="left" valign="bottom">Clone 1</th><th align="left" valign="bottom">Clone 2</th><th align="left" valign="bottom">Clone 3</th><th align="left" valign="bottom">Clone 4</th><th align="left" valign="bottom">Clone 5</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">FMOD</td><td align="left" valign="bottom">TRCN0000153650</td><td align="left" valign="bottom">TRCN0000156734</td><td align="left" valign="bottom">TRCN0000152163</td><td align="left" valign="bottom">TRCN0000153199</td><td align="left" valign="bottom">TRCN0000151908</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">Mouse FMOD</td><td align="left" valign="bottom">TRCN0000094246</td><td align="left" valign="bottom">TRCN0000094245</td><td align="left" valign="bottom">TRCN0000094248</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">KLF8</td><td align="left" valign="bottom">TRCN0000015878</td><td align="left" valign="bottom">TRCN0000015879</td><td align="left" valign="bottom">TRCN0000015880</td><td align="left" valign="bottom">TRCN0000015881</td><td align="left" valign="bottom">TRCN0000015882</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">JAG1</td><td align="left" valign="bottom">TRCN0000033439</td><td align="left" valign="bottom">TRCN0000033440</td><td align="left" valign="bottom">TRCN0000033441</td><td align="left" valign="bottom">TRCN0000033442</td><td align="left" valign="bottom">TRCN0000033443</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">ITGA6</td><td align="left" valign="bottom">TRCN0000057773</td><td align="left" valign="bottom">TRCN0000057774</td><td align="left" valign="bottom">TRCN0000057775</td><td align="left" valign="bottom">TRCN0000057776</td><td align="left" valign="bottom">TRCN0000057777</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">ITGB1</td><td align="left" valign="bottom">TRCN0000275134</td><td align="left" valign="bottom">TRCN0000275133</td><td align="left" valign="bottom">TRCN0000275083</td><td align="left" valign="bottom">TRCN0000275135</td><td align="left" valign="bottom">TRCN0000275082</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">ITGAV</td><td align="left" valign="bottom">TRCN0000003238</td><td align="left" valign="bottom">TRCN0000003239</td><td align="left" valign="bottom">TRCN0000003240</td><td align="left" valign="bottom">TRCN0000003241</td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap></sec><sec id="s4-43"><title>List of inhibitors used</title><table-wrap id="inlinetable3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">S. no.</th><th align="left" valign="bottom">Inhibitor name</th><th align="left" valign="bottom">Target molecule</th><th align="left" valign="bottom">Catalog number</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Gamma-secretase inhibitor (GSI)</td><td align="left" valign="bottom">Gamma secretase</td><td align="char" char="." valign="bottom">565750 (Merck)</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">RGD Peptide</td><td align="left" valign="bottom">Integrins</td><td align="left" valign="bottom">A5082 (Sigma-Aldrich)</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">PP2</td><td align="left" valign="bottom">Src</td><td align="left" valign="bottom">P0042 (Sigma-Aldrich)</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">PP3</td><td align="left" valign="bottom">Structural analog to PP2</td><td align="char" char="." valign="bottom">529574 (Calbiochem)</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">H1152</td><td align="left" valign="bottom">ROCK1</td><td align="char" char="." valign="bottom">555550 (Calbiochem)</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">RAC1 inhibitor</td><td align="left" valign="bottom">RAC1</td><td align="left" valign="bottom">553502 (Sigma-Aldrich)</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">PF573228</td><td align="left" valign="bottom">FAK</td><td align="left" valign="bottom">PZ0117 (Sigma-Aldrich)</td></tr><tr><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">SB431542</td><td align="left" valign="bottom">TGFB RI</td><td align="left" valign="bottom">616464 (Sigma-Aldrich)</td></tr></tbody></table></table-wrap></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con3"><p>Animal Experiments, Formal analysis, Methodology, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Methodology, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Animal Experiments, Methodology</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Methodology, Resources, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Funding acquisition, Methodology, Resources, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The Institute Ethical Committee for Animal Experimentation (Institute Animal Ethics Committee [IAEC] Project Number: CAF/Ethics/752/2020).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of proteins exhibiting significantly different abundance in glioma stem-like cell (GSC) and differentiated glioma cell (DGC) secretomes.</title></caption><media xlink:href="elife-78972-supp1-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of significantly depleted gene sets from gene set enrichment analysis in glioma stem-like cell (GSC) vs. differentiated glioma cell (DGC) RNA-Seq Data (GSE54792).</title></caption><media xlink:href="elife-78972-supp2-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>ANOVA values between the different groups of the in vivo co-implantation mouse model experiment.</title></caption><media xlink:href="elife-78972-supp3-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of primers, shRNA clones, and inhibitors used in the study.</title><p>(A) List of primers used in this study. (B) List of shRNAs used in the study; all IDs are of Sigma TRC whole-genome shRNA library. (C) List of inhibitors.</p></caption><media xlink:href="elife-78972-supp4-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-78972-mdarchecklist1-v3.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Raw images for blots of figures and figure supplements.</title></caption><media xlink:href="elife-78972-data1-v3.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Label-free mass spectrometry data between the GSC and DGC showing protein ratios in the GSC and DGC secretome and p values are shown in Supplementary File 1 for proteins exhibiting significant differences in abundance in both conditions. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository with the dataset identifier PXD032958.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Somasundaram</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Functional genomics of glioblastoma: from epigenetics to proteomic investigation of tumor-initiating cell secretome</data-title><source>EBI PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD032958">PXD032958</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The results published here are in whole or part, based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at <ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>. We acknowledge the shRNA consortium (Dr. Subba Rao), IISc, India, for shRNA constructs. The Central Animal Facility (CAF), Indian Institute of Science is acknowledged for all animal experiments. SS acknowledges IISc for fellowship. KS acknowledges CEFIPRA DBT, DST, ICMR, and CSIR (Govt. of India) for research grants. Infrastructure supported by DST FIST, DBT-IISc partnership program, and UGC is acknowledged. KS is awarded J. C. Bose Fellowship from DST. This research was supported by grants to DFM from the Israel Science Foundation (1315/15 and 1429/20). PM was supported by grants from Fondation pour la Recherche Médicale and CEFIPRA (IFC/5603-C/2016/503). Mass spectrometry experiments were carried out using the facilities of the Montpellier Proteomics Platform (PPM, BioCampus Montpellier).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angara</surname><given-names>K</given-names></name><name><surname>Borin</surname><given-names>TF</given-names></name><name><surname>Arbab</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma</article-title><source>Translational Oncology</source><volume>10</volume><fpage>650</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.tranon.2017.04.007</pub-id><pub-id pub-id-type="pmid">28668763</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angel</surname><given-names>I</given-names></name><name><surname>Pilo Kerman</surname><given-names>O</given-names></name><name><surname>Rousso-Noori</surname><given-names>L</given-names></name><name><surname>Friedmann-Morvinski</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma</article-title><source>Oncogene</source><volume>39</volume><fpage>6990</fpage><lpage>7004</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01506-6</pub-id><pub-id pub-id-type="pmid">33077835</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auffinger</surname><given-names>B</given-names></name><name><surname>Tobias</surname><given-names>AL</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Dey</surname><given-names>M</given-names></name><name><surname>Lesniak</surname><given-names>MS</given-names></name><name><surname>Ahmed</surname><given-names>AU</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy</article-title><source>Cell Death and Differentiation</source><volume>21</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1038/cdd.2014.31</pub-id><pub-id pub-id-type="pmid">24608791</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Sathornsumetee</surname><given-names>S</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Hjelmeland</surname><given-names>AB</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>McLendon</surname><given-names>RE</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor</article-title><source>Cancer Research</source><volume>66</volume><fpage>7843</fpage><lpage>7848</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1010</pub-id><pub-id pub-id-type="pmid">16912155</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolini</surname><given-names>A</given-names></name><name><surname>Cardaci</surname><given-names>S</given-names></name><name><surname>Lamba</surname><given-names>S</given-names></name><name><surname>Oddo</surname><given-names>D</given-names></name><name><surname>Marchiò</surname><given-names>C</given-names></name><name><surname>Cassoni</surname><given-names>P</given-names></name><name><surname>Amoreo</surname><given-names>CA</given-names></name><name><surname>Corti</surname><given-names>G</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Bussolino</surname><given-names>F</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Corà</surname><given-names>D</given-names></name><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Marchiò</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer</article-title><source>Clinical Cancer Research</source><volume>22</volume><fpage>4923</fpage><lpage>4933</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2664</pub-id><pub-id pub-id-type="pmid">27143691</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazzoni</surname><given-names>R</given-names></name><name><surname>Bentivegna</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of Notch Signaling Pathway in Glioblastoma Pathogenesis</article-title><source>Cancers</source><volume>11</volume><elocation-id>E292</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11030292</pub-id><pub-id pub-id-type="pmid">30832246</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>D</given-names></name><name><surname>Hau</surname><given-names>P</given-names></name><name><surname>Proescholdt</surname><given-names>M</given-names></name><name><surname>Lohmeier</surname><given-names>A</given-names></name><name><surname>Wischhusen</surname><given-names>J</given-names></name><name><surname>Oefner</surname><given-names>PJ</given-names></name><name><surname>Aigner</surname><given-names>L</given-names></name><name><surname>Brawanski</surname><given-names>A</given-names></name><name><surname>Bogdahn</surname><given-names>U</given-names></name><name><surname>Beier</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles</article-title><source>Cancer Research</source><volume>67</volume><fpage>4010</fpage><lpage>4015</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4180</pub-id><pub-id pub-id-type="pmid">17483311</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>C</given-names></name><name><surname>Poppleton</surname><given-names>H</given-names></name><name><surname>Kocak</surname><given-names>M</given-names></name><name><surname>Hogg</surname><given-names>TL</given-names></name><name><surname>Fuller</surname><given-names>C</given-names></name><name><surname>Hamner</surname><given-names>B</given-names></name><name><surname>Oh</surname><given-names>EY</given-names></name><name><surname>Gaber</surname><given-names>MW</given-names></name><name><surname>Finklestein</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Frank</surname><given-names>A</given-names></name><name><surname>Bayazitov</surname><given-names>IT</given-names></name><name><surname>Zakharenko</surname><given-names>SS</given-names></name><name><surname>Gajjar</surname><given-names>A</given-names></name><name><surname>Davidoff</surname><given-names>A</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A perivascular niche for brain tumor stem cells</article-title><source>Cancer Cell</source><volume>11</volume><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.11.020</pub-id><pub-id pub-id-type="pmid">17222791</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnero</surname><given-names>A</given-names></name><name><surname>Lleonart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The hypoxic microenvironment: A determinant of cancer stem cell evolution</article-title><source>BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology</source><volume>38</volume><fpage>S65</fpage><lpage>S74</lpage><pub-id pub-id-type="doi">10.1002/bies.201670911</pub-id><pub-id pub-id-type="pmid">27417124</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Nishimura</surname><given-names>MC</given-names></name><name><surname>Bumbaca</surname><given-names>SM</given-names></name><name><surname>Kharbanda</surname><given-names>S</given-names></name><name><surname>Forrest</surname><given-names>WF</given-names></name><name><surname>Kasman</surname><given-names>IM</given-names></name><name><surname>Greve</surname><given-names>JM</given-names></name><name><surname>Soriano</surname><given-names>RH</given-names></name><name><surname>Gilmour</surname><given-names>LL</given-names></name><name><surname>Rivers</surname><given-names>CS</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Nacu</surname><given-names>S</given-names></name><name><surname>Guerrero</surname><given-names>S</given-names></name><name><surname>Edgar</surname><given-names>KA</given-names></name><name><surname>Wallin</surname><given-names>JJ</given-names></name><name><surname>Lamszus</surname><given-names>K</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Heim</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>CD</given-names></name><name><surname>VandenBerg</surname><given-names>SR</given-names></name><name><surname>Costello</surname><given-names>JF</given-names></name><name><surname>Moorefield</surname><given-names>S</given-names></name><name><surname>Cowdrey</surname><given-names>CJ</given-names></name><name><surname>Prados</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A hierarchy of self-renewing tumor-initiating cell types in glioblastoma</article-title><source>Cancer Cell</source><volume>17</volume><fpage>362</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.12.049</pub-id><pub-id pub-id-type="pmid">20385361</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>TS</given-names></name><name><surname>McKay</surname><given-names>RM</given-names></name><name><surname>Burns</surname><given-names>DK</given-names></name><name><surname>Kernie</surname><given-names>SG</given-names></name><name><surname>Parada</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A restricted cell population propagates glioblastoma growth after chemotherapy</article-title><source>Nature</source><volume>488</volume><fpage>522</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/nature11287</pub-id><pub-id pub-id-type="pmid">22854781</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>S</given-names></name><name><surname>Kruyt</surname><given-names>FAE</given-names></name><name><surname>Wagemakers</surname><given-names>M</given-names></name><name><surname>Bhat</surname><given-names>KPL</given-names></name><name><surname>den Dunnen</surname><given-names>WFA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma</article-title><source>Oncotarget</source><volume>9</volume><fpage>15721</fpage><lpage>15731</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24595</pub-id><pub-id pub-id-type="pmid">29644004</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title><source>Nature Biotechnology</source><volume>26</volume><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id><pub-id pub-id-type="pmid">19029910</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirkse</surname><given-names>A</given-names></name><name><surname>Golebiewska</surname><given-names>A</given-names></name><name><surname>Buder</surname><given-names>T</given-names></name><name><surname>Nazarov</surname><given-names>PV</given-names></name><name><surname>Muller</surname><given-names>A</given-names></name><name><surname>Poovathingal</surname><given-names>S</given-names></name><name><surname>Brons</surname><given-names>NHC</given-names></name><name><surname>Leite</surname><given-names>S</given-names></name><name><surname>Sauvageot</surname><given-names>N</given-names></name><name><surname>Sarkisjan</surname><given-names>D</given-names></name><name><surname>Seyfrid</surname><given-names>M</given-names></name><name><surname>Fritah</surname><given-names>S</given-names></name><name><surname>Stieber</surname><given-names>D</given-names></name><name><surname>Michelucci</surname><given-names>A</given-names></name><name><surname>Hertel</surname><given-names>F</given-names></name><name><surname>Herold-Mende</surname><given-names>C</given-names></name><name><surname>Azuaje</surname><given-names>F</given-names></name><name><surname>Skupin</surname><given-names>A</given-names></name><name><surname>Bjerkvig</surname><given-names>R</given-names></name><name><surname>Deutsch</surname><given-names>A</given-names></name><name><surname>Voss-Böhme</surname><given-names>A</given-names></name><name><surname>Niclou</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1787</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09853-z</pub-id><pub-id pub-id-type="pmid">30992437</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmer</surname><given-names>J</given-names></name><name><surname>Leyh</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Paracrine effects of stem cells in wound healing and cancer progression (Review</article-title><source>International Journal of Oncology</source><volume>44</volume><fpage>1789</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2385</pub-id><pub-id pub-id-type="pmid">24728412</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fareh</surname><given-names>M</given-names></name><name><surname>Turchi</surname><given-names>L</given-names></name><name><surname>Virolle</surname><given-names>V</given-names></name><name><surname>Debruyne</surname><given-names>D</given-names></name><name><surname>Almairac</surname><given-names>F</given-names></name><name><surname>de-la-Forest Divonne</surname><given-names>S</given-names></name><name><surname>Paquis</surname><given-names>P</given-names></name><name><surname>Preynat-Seauve</surname><given-names>O</given-names></name><name><surname>Krause</surname><given-names>K-H</given-names></name><name><surname>Chneiweiss</surname><given-names>H</given-names></name><name><surname>Virolle</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network</article-title><source>Cell Death and Differentiation</source><volume>19</volume><fpage>232</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/cdd.2011.89</pub-id><pub-id pub-id-type="pmid">21720384</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedmann-Morvinski</surname><given-names>D</given-names></name><name><surname>Bushong</surname><given-names>EA</given-names></name><name><surname>Ke</surname><given-names>E</given-names></name><name><surname>Soda</surname><given-names>Y</given-names></name><name><surname>Marumoto</surname><given-names>T</given-names></name><name><surname>Singer</surname><given-names>O</given-names></name><name><surname>Ellisman</surname><given-names>MH</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice</article-title><source>Science (New York, N.Y.)</source><volume>338</volume><fpage>1080</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1126/science.1226929</pub-id><pub-id pub-id-type="pmid">23087000</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedmann-Morvinski</surname><given-names>D</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dedifferentiation and reprogramming: origins of cancer stem cells</article-title><source>EMBO Reports</source><volume>15</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1002/embr.201338254</pub-id><pub-id pub-id-type="pmid">24531722</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedmann-Morvinski</surname><given-names>D</given-names></name><name><surname>Bhargava</surname><given-names>V</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of therapeutic targets for glioblastoma by network analysis</article-title><source>Oncogene</source><volume>35</volume><fpage>608</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.119</pub-id><pub-id pub-id-type="pmid">25961929</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>R</given-names></name><name><surname>Binda</surname><given-names>E</given-names></name><name><surname>Orfanelli</surname><given-names>U</given-names></name><name><surname>Cipelletti</surname><given-names>B</given-names></name><name><surname>Gritti</surname><given-names>A</given-names></name><name><surname>De Vitis</surname><given-names>S</given-names></name><name><surname>Fiocco</surname><given-names>R</given-names></name><name><surname>Foroni</surname><given-names>C</given-names></name><name><surname>Dimeco</surname><given-names>F</given-names></name><name><surname>Vescovi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma</article-title><source>Cancer Research</source><volume>64</volume><fpage>7011</fpage><lpage>7021</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1364</pub-id><pub-id pub-id-type="pmid">15466194</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gridley</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Notch signaling in vascular development and physiology</article-title><source>Development (Cambridge, England)</source><volume>134</volume><fpage>2709</fpage><lpage>2718</lpage><pub-id pub-id-type="doi">10.1242/dev.004184</pub-id><pub-id pub-id-type="pmid">17611219</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambardzumyan</surname><given-names>D</given-names></name><name><surname>Bergers</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glioblastoma: Defining Tumor Niches</article-title><source>Trends in Cancer</source><volume>1</volume><fpage>252</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2015.10.009</pub-id><pub-id pub-id-type="pmid">27088132</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardee</surname><given-names>ME</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mechanisms of glioma-associated neovascularization</article-title><source>The American Journal of Pathology</source><volume>181</volume><fpage>1126</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.06.030</pub-id><pub-id pub-id-type="pmid">22858156</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heddleston</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lathia</surname><given-names>JD</given-names></name><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Hjelmeland</surname><given-names>AB</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hypoxia inducible factors in cancer stem cells</article-title><source>British Journal of Cancer</source><volume>102</volume><fpage>789</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605551</pub-id><pub-id pub-id-type="pmid">20104230</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>WJ</given-names></name><name><surname>Chen</surname><given-names>WW</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches</article-title><source>Oncology Letters</source><volume>12</volume><fpage>2283</fpage><lpage>2288</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4952</pub-id><pub-id pub-id-type="pmid">27698790</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatova</surname><given-names>TN</given-names></name><name><surname>Kukekov</surname><given-names>VG</given-names></name><name><surname>Laywell</surname><given-names>ED</given-names></name><name><surname>Suslov</surname><given-names>ON</given-names></name><name><surname>Vrionis</surname><given-names>FD</given-names></name><name><surname>Steindler</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro</article-title><source>Glia</source><volume>39</volume><fpage>193</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1002/glia.10094</pub-id><pub-id pub-id-type="pmid">12203386</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>JB</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Joshi</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression</article-title><source>Cancer Research</source><volume>74</volume><fpage>4482</fpage><lpage>4492</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1597</pub-id><pub-id pub-id-type="pmid">24962027</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Perez-Torres</surname><given-names>CJ</given-names></name><name><surname>Thotala</surname><given-names>D</given-names></name><name><surname>Engelbach</surname><given-names>JA</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Cates</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Drzymala</surname><given-names>RE</given-names></name><name><surname>Rich</surname><given-names>KM</given-names></name><name><surname>Schmidt</surname><given-names>RE</given-names></name><name><surname>Ackerman</surname><given-names>JJH</given-names></name><name><surname>Hallahan</surname><given-names>DE</given-names></name><name><surname>Garbow</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A GSK-3β inhibitor protects against radiation necrosis in mouse brain</article-title><source>International Journal of Radiation Oncology, Biology, Physics</source><volume>89</volume><fpage>714</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2014.04.018</pub-id><pub-id pub-id-type="pmid">24969790</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer stem cells and differentiation therapy</article-title><source>Tumour Biology</source><volume>39</volume><elocation-id>e29933</elocation-id><pub-id pub-id-type="doi">10.1177/1010428317729933</pub-id><pub-id pub-id-type="pmid">29072131</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>SY</given-names></name><name><surname>Kong</surname><given-names>DS</given-names></name><name><surname>Lee</surname><given-names>JI</given-names></name><name><surname>Jeon</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Kang</surname><given-names>BG</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>SC</given-names></name><name><surname>Park</surname><given-names>WY</given-names></name><name><surname>Lee</surname><given-names>DS</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Nam</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas</article-title><source>Laboratory Investigation; a Journal of Technical Methods and Pathology</source><volume>88</volume><fpage>808</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2008.57</pub-id><pub-id pub-id-type="pmid">18560366</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klevebring</surname><given-names>D</given-names></name><name><surname>Rosin</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Lindberg</surname><given-names>J</given-names></name><name><surname>Czene</surname><given-names>K</given-names></name><name><surname>Kere</surname><given-names>J</given-names></name><name><surname>Fredriksson</surname><given-names>I</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Hartman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo</article-title><source>Breast Cancer Research</source><volume>16</volume><elocation-id>R72</elocation-id><pub-id pub-id-type="doi">10.1186/bcr3687</pub-id><pub-id pub-id-type="pmid">24998755</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kofler</surname><given-names>NM</given-names></name><name><surname>Shawber</surname><given-names>CJ</given-names></name><name><surname>Kangsamaksin</surname><given-names>T</given-names></name><name><surname>Reed</surname><given-names>HO</given-names></name><name><surname>Galatioto</surname><given-names>J</given-names></name><name><surname>Kitajewski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Notch signaling in developmental and tumor angiogenesis</article-title><source>Genes &amp; Cancer</source><volume>2</volume><fpage>1106</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1177/1947601911423030</pub-id><pub-id pub-id-type="pmid">22866202</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krump-Konvalinkova</surname><given-names>V</given-names></name><name><surname>Bittinger</surname><given-names>F</given-names></name><name><surname>Unger</surname><given-names>RE</given-names></name><name><surname>Peters</surname><given-names>K</given-names></name><name><surname>Lehr</surname><given-names>HA</given-names></name><name><surname>Kirkpatrick</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Generation of human pulmonary microvascular endothelial cell lines</article-title><source>Laboratory Investigation; a Journal of Technical Methods and Pathology</source><volume>81</volume><fpage>1717</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3780385</pub-id><pub-id pub-id-type="pmid">11742042</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>NP</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Huy</surname><given-names>NT</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Kwon</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel Biomarker Candidates for Colorectal Cancer Metastasis: A Meta-analysis of In Vitro Studies</article-title><source>Cancer Informatics</source><volume>15</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.4137/CIN.S40301</pub-id><pub-id pub-id-type="pmid">27688707</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondal</surname><given-names>B</given-names></name><name><surname>Patil</surname><given-names>V</given-names></name><name><surname>Shwetha</surname><given-names>SD</given-names></name><name><surname>Sravani</surname><given-names>K</given-names></name><name><surname>Hegde</surname><given-names>AS</given-names></name><name><surname>Arivazhagan</surname><given-names>A</given-names></name><name><surname>Santosh</surname><given-names>V</given-names></name><name><surname>Kanduri</surname><given-names>M</given-names></name><name><surname>Somasundaram</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration</article-title><source>Oncogene</source><volume>36</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.176</pub-id><pub-id pub-id-type="pmid">27212030</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogden</surname><given-names>AT</given-names></name><name><surname>Waziri</surname><given-names>AE</given-names></name><name><surname>Lochhead</surname><given-names>RA</given-names></name><name><surname>Fusco</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>JA</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Assanah</surname><given-names>M</given-names></name><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Sisti</surname><given-names>MB</given-names></name><name><surname>McCormick</surname><given-names>PC</given-names></name><name><surname>Canoll</surname><given-names>P</given-names></name><name><surname>Bruce</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas</article-title><source>Neurosurgery</source><volume>62</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1227/01.neu.0000316019.28421.95</pub-id><pub-id pub-id-type="pmid">18382330</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldberg</surname><given-names>A</given-names></name><name><surname>Kalamajski</surname><given-names>S</given-names></name><name><surname>Salnikov</surname><given-names>AV</given-names></name><name><surname>Stuhr</surname><given-names>L</given-names></name><name><surname>Mörgelin</surname><given-names>M</given-names></name><name><surname>Reed</surname><given-names>RK</given-names></name><name><surname>Heldin</surname><given-names>NE</given-names></name><name><surname>Rubin</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma</article-title><source>PNAS</source><volume>104</volume><fpage>13966</fpage><lpage>13971</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702014104</pub-id><pub-id pub-id-type="pmid">17715296</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olmeda</surname><given-names>F</given-names></name><name><surname>Ben Amar</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clonal pattern dynamics in tumor: the concept of cancer stem cells</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>15607</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-51575-1</pub-id><pub-id pub-id-type="pmid">31666555</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>N</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Small Leucine-Rich Proteoglycans in Skin Wound Healing</article-title><source>Frontiers in Pharmacology</source><volume>10</volume><elocation-id>1649</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01649</pub-id><pub-id pub-id-type="pmid">32063855</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Bandla</surname><given-names>C</given-names></name><name><surname>García-Seisdedos</surname><given-names>D</given-names></name><name><surname>Hewapathirana</surname><given-names>S</given-names></name><name><surname>Kamatchinathan</surname><given-names>S</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Frericks-Zipper</surname><given-names>A</given-names></name><name><surname>Eisenacher</surname><given-names>M</given-names></name><name><surname>Walzer</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D543</fpage><lpage>D552</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id><pub-id pub-id-type="pmid">34723319</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phng</surname><given-names>LK</given-names></name><name><surname>Gerhardt</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Angiogenesis: a team effort coordinated by notch</article-title><source>Developmental Cell</source><volume>16</volume><fpage>196</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.01.015</pub-id><pub-id pub-id-type="pmid">19217422</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pine</surname><given-names>AR</given-names></name><name><surname>Cirigliano</surname><given-names>SM</given-names></name><name><surname>Nicholson</surname><given-names>JG</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Linkous</surname><given-names>A</given-names></name><name><surname>Miyaguchi</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>L</given-names></name><name><surname>Singhania</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>TH</given-names></name><name><surname>Ramakrishna</surname><given-names>R</given-names></name><name><surname>Pisapia</surname><given-names>DJ</given-names></name><name><surname>Snuderl</surname><given-names>M</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Fine</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>964</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0057</pub-id><pub-id pub-id-type="pmid">32253265</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prager</surname><given-names>BC</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cancer Stem Cells: The Architects of the Tumor Ecosystem</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.12.009</pub-id><pub-id pub-id-type="pmid">30609398</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prager</surname><given-names>BC</given-names></name><name><surname>Bhargava</surname><given-names>S</given-names></name><name><surname>Mahadev</surname><given-names>V</given-names></name><name><surname>Hubert</surname><given-names>CG</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Glioblastoma Stem Cells: Driving Resilience through Chaos</article-title><source>Trends in Cancer</source><volume>6</volume><fpage>223</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.01.009</pub-id><pub-id pub-id-type="pmid">32101725</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>P</given-names></name><name><surname>Mittal</surname><given-names>SA</given-names></name><name><surname>Chongtham</surname><given-names>J</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hypoxia-Mediated Epigenetic Regulation of Stemness in Brain Tumor Cells</article-title><source>Stem Cells (Dayton, Ohio)</source><volume>35</volume><fpage>1468</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1002/stem.2621</pub-id><pub-id pub-id-type="pmid">28376560</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rheinbay</surname><given-names>E</given-names></name><name><surname>Suvà</surname><given-names>ML</given-names></name><name><surname>Gillespie</surname><given-names>SM</given-names></name><name><surname>Wakimoto</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>AP</given-names></name><name><surname>Shahid</surname><given-names>M</given-names></name><name><surname>Oksuz</surname><given-names>O</given-names></name><name><surname>Rabkin</surname><given-names>SD</given-names></name><name><surname>Martuza</surname><given-names>RL</given-names></name><name><surname>Rivera</surname><given-names>MN</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Kasif</surname><given-names>S</given-names></name><name><surname>Chi</surname><given-names>AS</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma</article-title><source>Cell Reports</source><volume>3</volume><fpage>1567</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.04.021</pub-id><pub-id pub-id-type="pmid">23707066</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci-Vitiani</surname><given-names>L</given-names></name><name><surname>Pallini</surname><given-names>R</given-names></name><name><surname>Biffoni</surname><given-names>M</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Invernici</surname><given-names>G</given-names></name><name><surname>Cenci</surname><given-names>T</given-names></name><name><surname>Maira</surname><given-names>G</given-names></name><name><surname>Parati</surname><given-names>EA</given-names></name><name><surname>Stassi</surname><given-names>G</given-names></name><name><surname>Larocca</surname><given-names>LM</given-names></name><name><surname>De Maria</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells</article-title><source>Nature</source><volume>468</volume><fpage>824</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1038/nature09557</pub-id><pub-id pub-id-type="pmid">21102434</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>T</given-names></name><name><surname>Langlois</surname><given-names>B</given-names></name><name><surname>Koczorowska</surname><given-names>MM</given-names></name><name><surname>Radwanska</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Hussenet</surname><given-names>T</given-names></name><name><surname>Lefebvre</surname><given-names>O</given-names></name><name><surname>Murdamoothoo</surname><given-names>D</given-names></name><name><surname>Arnold</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Biniossek</surname><given-names>ML</given-names></name><name><surname>Hyenne</surname><given-names>V</given-names></name><name><surname>Naudin</surname><given-names>E</given-names></name><name><surname>Velazquez-Quesada</surname><given-names>I</given-names></name><name><surname>Schilling</surname><given-names>O</given-names></name><name><surname>Van Obberghen-Schilling</surname><given-names>E</given-names></name><name><surname>Orend</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling</article-title><source>Cell Reports</source><volume>17</volume><fpage>2607</fpage><lpage>2619</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.012</pub-id><pub-id pub-id-type="pmid">27926865</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safa</surname><given-names>AR</given-names></name><name><surname>Saadatzadeh</surname><given-names>MR</given-names></name><name><surname>Cohen-Gadol</surname><given-names>AA</given-names></name><name><surname>Pollok</surname><given-names>KE</given-names></name><name><surname>Bijangi-Vishehsaraei</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs</article-title><source>Genes &amp; Diseases</source><volume>2</volume><fpage>152</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2015.02.001</pub-id><pub-id pub-id-type="pmid">26137500</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>SM</given-names></name><name><surname>Talbott</surname><given-names>GA</given-names></name><name><surname>Juliano</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Integrin-mediated signaling events in human endothelial cells</article-title><source>Molecular Biology of the Cell</source><volume>9</volume><fpage>1969</fpage><lpage>1980</lpage><pub-id pub-id-type="doi">10.1091/mbc.9.8.1969</pub-id><pub-id pub-id-type="pmid">9693360</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>D’Amico</surname><given-names>G</given-names></name><name><surname>Hodivala-Dilke</surname><given-names>KM</given-names></name><name><surname>Reynolds</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Integrins: the keys to unlocking angiogenesis</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>28</volume><fpage>1703</fpage><lpage>1713</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.108.172015</pub-id><pub-id pub-id-type="pmid">18658045</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>ID</given-names></name><name><surname>Squire</surname><given-names>JA</given-names></name><name><surname>Bayani</surname><given-names>J</given-names></name><name><surname>Hide</surname><given-names>T</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Cusimano</surname><given-names>MD</given-names></name><name><surname>Dirks</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Identification of human brain tumour initiating cells</article-title><source>Nature</source><volume>432</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature03128</pub-id><pub-id pub-id-type="pmid">15549107</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soda</surname><given-names>Y</given-names></name><name><surname>Marumoto</surname><given-names>T</given-names></name><name><surname>Friedmann-Morvinski</surname><given-names>D</given-names></name><name><surname>Soda</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Michiue</surname><given-names>H</given-names></name><name><surname>Pastorino</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>RM</given-names></name><name><surname>Kesari</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Transdifferentiation of glioblastoma cells into vascular endothelial cells</article-title><source>PNAS</source><volume>108</volume><fpage>4274</fpage><lpage>4280</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016030108</pub-id><pub-id pub-id-type="pmid">21262804</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>HW</given-names></name><name><surname>Foreman</surname><given-names>KL</given-names></name><name><surname>Gastfriend</surname><given-names>BD</given-names></name><name><surname>Kuo</surname><given-names>JS</given-names></name><name><surname>Palecek</surname><given-names>SP</given-names></name><name><surname>Shusta</surname><given-names>EV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptomic comparison of human and mouse brain microvessels</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>12358</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-69096-7</pub-id><pub-id pub-id-type="pmid">32704093</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockhausen</surname><given-names>MT</given-names></name><name><surname>Kristoffersen</surname><given-names>K</given-names></name><name><surname>Poulsen</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The functional role of Notch signaling in human gliomas</article-title><source>Neuro-Oncology</source><volume>12</volume><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nop022</pub-id><pub-id pub-id-type="pmid">20150387</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bihl</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal</article-title><source>Oncotarget</source><volume>8</volume><fpage>36137</fpage><lpage>36148</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16661</pub-id><pub-id pub-id-type="pmid">28410224</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suvà</surname><given-names>ML</given-names></name><name><surname>Rheinbay</surname><given-names>E</given-names></name><name><surname>Gillespie</surname><given-names>SM</given-names></name><name><surname>Patel</surname><given-names>AP</given-names></name><name><surname>Wakimoto</surname><given-names>H</given-names></name><name><surname>Rabkin</surname><given-names>SD</given-names></name><name><surname>Riggi</surname><given-names>N</given-names></name><name><surname>Chi</surname><given-names>AS</given-names></name><name><surname>Cahill</surname><given-names>DP</given-names></name><name><surname>Nahed</surname><given-names>BV</given-names></name><name><surname>Curry</surname><given-names>WT</given-names></name><name><surname>Martuza</surname><given-names>RL</given-names></name><name><surname>Rivera</surname><given-names>MN</given-names></name><name><surname>Rossetti</surname><given-names>N</given-names></name><name><surname>Kasif</surname><given-names>S</given-names></name><name><surname>Beik</surname><given-names>S</given-names></name><name><surname>Kadri</surname><given-names>S</given-names></name><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Wortman</surname><given-names>I</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells</article-title><source>Cell</source><volume>157</volume><fpage>580</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.02.030</pub-id><pub-id pub-id-type="pmid">24726434</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Hai</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Ming</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>e1063</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0957-3</pub-id><pub-id pub-id-type="pmid">30337536</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teodorczyk</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>MHH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Notching on Cancer’s Door: Notch Signaling in Brain Tumors</article-title><source>Frontiers in Oncology</source><volume>4</volume><elocation-id>341</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2014.00341</pub-id><pub-id pub-id-type="pmid">25601901</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thirant</surname><given-names>C</given-names></name><name><surname>Gavard</surname><given-names>J</given-names></name><name><surname>Junier</surname><given-names>MP</given-names></name><name><surname>Chneiweiss</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies</article-title><source>Proteomics. Clinical Applications</source><volume>7</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/prca.201200102</pub-id><pub-id pub-id-type="pmid">23229792</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thouvenot</surname><given-names>E</given-names></name><name><surname>Urbach</surname><given-names>S</given-names></name><name><surname>Dantec</surname><given-names>C</given-names></name><name><surname>Poncet</surname><given-names>J</given-names></name><name><surname>Séveno</surname><given-names>M</given-names></name><name><surname>Demettre</surname><given-names>E</given-names></name><name><surname>Jouin</surname><given-names>P</given-names></name><name><surname>Touchon</surname><given-names>J</given-names></name><name><surname>Bockaert</surname><given-names>J</given-names></name><name><surname>Marin</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid</article-title><source>Journal of Proteome Research</source><volume>7</volume><fpage>4409</fpage><lpage>4421</lpage><pub-id pub-id-type="doi">10.1021/pr8003858</pub-id><pub-id pub-id-type="pmid">18774838</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treps</surname><given-names>L</given-names></name><name><surname>Perret</surname><given-names>R</given-names></name><name><surname>Edmond</surname><given-names>S</given-names></name><name><surname>Ricard</surname><given-names>D</given-names></name><name><surname>Gavard</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles</article-title><source>Journal of Extracellular Vesicles</source><volume>6</volume><elocation-id>e1359479</elocation-id><pub-id pub-id-type="doi">10.1080/20013078.2017.1359479</pub-id><pub-id pub-id-type="pmid">28815003</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turchi</surname><given-names>L</given-names></name><name><surname>Debruyne</surname><given-names>DN</given-names></name><name><surname>Almairac</surname><given-names>F</given-names></name><name><surname>Virolle</surname><given-names>V</given-names></name><name><surname>Fareh</surname><given-names>M</given-names></name><name><surname>Neirijnck</surname><given-names>Y</given-names></name><name><surname>Burel-Vandenbos</surname><given-names>F</given-names></name><name><surname>Paquis</surname><given-names>P</given-names></name><name><surname>Junier</surname><given-names>MP</given-names></name><name><surname>Van Obberghen-Schilling</surname><given-names>E</given-names></name><name><surname>Chneiweiss</surname><given-names>H</given-names></name><name><surname>Virolle</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tumorigenic potential of miR-18A* in glioma initiating cells requires NOTCH-1 signaling</article-title><source>Stem Cells (Dayton, Ohio)</source><volume>31</volume><fpage>1252</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1002/stem.1373</pub-id><pub-id pub-id-type="pmid">23533157</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyanova</surname><given-names>S</given-names></name><name><surname>Temu</surname><given-names>T</given-names></name><name><surname>Sinitcyn</surname><given-names>P</given-names></name><name><surname>Carlson</surname><given-names>A</given-names></name><name><surname>Hein</surname><given-names>MY</given-names></name><name><surname>Geiger</surname><given-names>T</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Perseus computational platform for comprehensive analysis of (prote)omics data</article-title><source>Nature Methods</source><volume>13</volume><fpage>731</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3901</pub-id><pub-id pub-id-type="pmid">27348712</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakimoto</surname><given-names>H</given-names></name><name><surname>Kesari</surname><given-names>S</given-names></name><name><surname>Farrell</surname><given-names>CJ</given-names></name><name><surname>Curry</surname><given-names>WT</given-names></name><name><surname>Zaupa</surname><given-names>C</given-names></name><name><surname>Aghi</surname><given-names>M</given-names></name><name><surname>Kuroda</surname><given-names>T</given-names></name><name><surname>Stemmer-Rachamimov</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>TC</given-names></name><name><surname>Jeyaretna</surname><given-names>DS</given-names></name><name><surname>Debasitis</surname><given-names>J</given-names></name><name><surname>Pruszak</surname><given-names>J</given-names></name><name><surname>Martuza</surname><given-names>RL</given-names></name><name><surname>Rabkin</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors</article-title><source>Cancer Research</source><volume>69</volume><fpage>3472</fpage><lpage>3481</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3886</pub-id><pub-id pub-id-type="pmid">19351838</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sakariassen</surname><given-names>PØ</given-names></name><name><surname>Tsinkalovsky</surname><given-names>O</given-names></name><name><surname>Immervoll</surname><given-names>H</given-names></name><name><surname>Bøe</surname><given-names>SO</given-names></name><name><surname>Svendsen</surname><given-names>A</given-names></name><name><surname>Prestegarden</surname><given-names>L</given-names></name><name><surname>Røsland</surname><given-names>G</given-names></name><name><surname>Thorsen</surname><given-names>F</given-names></name><name><surname>Stuhr</surname><given-names>L</given-names></name><name><surname>Molven</surname><given-names>A</given-names></name><name><surname>Bjerkvig</surname><given-names>R</given-names></name><name><surname>Enger</surname><given-names>PØ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells</article-title><source>International Journal of Cancer</source><volume>122</volume><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1002/ijc.23130</pub-id><pub-id pub-id-type="pmid">17955491</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Wan</surname><given-names>WW</given-names></name><name><surname>Xiong</surname><given-names>SL</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer stem-like cells can be induced through dedifferentiation under hypoxic conditions in glioma, hepatoma and lung cancer</article-title><source>Cell Death Discovery</source><volume>3</volume><elocation-id>16105</elocation-id><pub-id pub-id-type="doi">10.1038/cddiscovery.2016.105</pub-id><pub-id pub-id-type="pmid">28179999</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Prager</surname><given-names>BC</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Kim</surname><given-names>LJY</given-names></name><name><surname>Gimple</surname><given-names>RC</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Morton</surname><given-names>AR</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Obara</surname><given-names>EAA</given-names></name><name><surname>Miller</surname><given-names>TE</given-names></name><name><surname>Song</surname><given-names>A</given-names></name><name><surname>Lai</surname><given-names>S</given-names></name><name><surname>Hubert</surname><given-names>CG</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Dixit</surname><given-names>D</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Zhai</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Dombrowski</surname><given-names>SM</given-names></name><name><surname>Hamerlik</surname><given-names>P</given-names></name><name><surname>Mack</surname><given-names>SC</given-names></name><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression</article-title><source>Cell Stem Cell</source><volume>22</volume><fpage>514</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.03.011</pub-id><pub-id pub-id-type="pmid">29625067</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Pang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SERPINE1 associated with remodeling of the tumor microenvironment in colon cancer progression: a novel therapeutic target</article-title><source>BMC Cancer</source><volume>21</volume><elocation-id>767</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-021-08536-7</pub-id><pub-id pub-id-type="pmid">34215248</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>J</given-names></name><name><surname>Abisoye-Ogunniyan</surname><given-names>A</given-names></name><name><surname>Metcalf</surname><given-names>KJ</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Concepts of extracellular matrix remodelling in tumour progression and metastasis</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5120</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18794-x</pub-id><pub-id pub-id-type="pmid">33037194</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>GN</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>YF</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>LL</given-names></name><name><surname>Yao</surname><given-names>XH</given-names></name><name><surname>Guo</surname><given-names>QN</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Cui</surname><given-names>YH</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Bian</surname><given-names>XW</given-names></name><name><surname>Guo</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway</article-title><source>The Journal of Pathology</source><volume>234</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/path.4349</pub-id><pub-id pub-id-type="pmid">24604164</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Targeting cancer stem cell pathways for cancer therapy</article-title><source>Signal Transduction and Targeted Therapy</source><volume>5</volume><elocation-id>e8</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-0110-5</pub-id><pub-id pub-id-type="pmid">32296030</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell</article-title><source>Medicine</source><volume>99</volume><elocation-id>e20944</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000020944</pub-id><pub-id pub-id-type="pmid">32629699</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Siegel</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Khosla</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>CR</given-names></name><name><surname>Jackson</surname><given-names>EN</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name><name><surname>Rich</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy</article-title><source>Oncogene</source><volume>26</volume><fpage>2563</fpage><lpage>2573</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210048</pub-id><pub-id pub-id-type="pmid">17099729</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Xue</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Notch Signaling Pathway Regulates Angiogenesis via Endothelial Cell in 3D Co-Culture Model</article-title><source>Journal of Cellular Physiology</source><volume>232</volume><fpage>1548</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1002/jcp.25681</pub-id><pub-id pub-id-type="pmid">27861873</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Jian</surname><given-names>J</given-names></name><name><surname>Velasco</surname><given-names>O</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ting</surname><given-names>K</given-names></name><name><surname>Soo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fibromodulin Enhances Angiogenesis during Cutaneous Wound Healing</article-title><source>Plastic and Reconstructive Surgery. Global Open</source><volume>2</volume><elocation-id>e275</elocation-id><pub-id pub-id-type="doi">10.1097/GOX.0000000000000243</pub-id><pub-id pub-id-type="pmid">25587509</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Alver</surname><given-names>BM</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Hlady</surname><given-names>RA</given-names></name><name><surname>Thompson</surname><given-names>JJ</given-names></name><name><surname>Schroeder</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>PH</given-names></name><name><surname>Sarkaria</surname><given-names>JN</given-names></name><name><surname>Robertson</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1420-6</pub-id><pub-id pub-id-type="pmid">29587824</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Stem Cells and Cellular Origins of Breast Cancer: Updates in the Rationale, Controversies, and Therapeutic Implications</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>820</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00820</pub-id><pub-id pub-id-type="pmid">31555586</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>TS</given-names></name><name><surname>Costello</surname><given-names>MA</given-names></name><name><surname>Talsma</surname><given-names>CE</given-names></name><name><surname>Flack</surname><given-names>CG</given-names></name><name><surname>Crowley</surname><given-names>JG</given-names></name><name><surname>Hamm</surname><given-names>LL</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hervey-Jumper</surname><given-names>SL</given-names></name><name><surname>Heth</surname><given-names>JA</given-names></name><name><surname>Muraszko</surname><given-names>KM</given-names></name><name><surname>DiMeco</surname><given-names>F</given-names></name><name><surname>Vescovi</surname><given-names>AL</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells</article-title><source>Cancer Research</source><volume>71</volume><fpage>6061</fpage><lpage>6072</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4269</pub-id><pub-id pub-id-type="pmid">21788346</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zang</surname><given-names>G</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1/2-c-Fos-LIF signaling</article-title><source>Cell Death Discovery</source><volume>7</volume><elocation-id>e3</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-020-00395-8</pub-id><pub-id pub-id-type="pmid">33431816</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>The role of FMOD on GSC, DGC growth, and their plasticity in vitro</title><p>Before studying the importance of DGC secreted FMOD on tumor growth, we decided to investigate its requirement for the GSC, DGC growth, and their plasticity to form the other type. We have earlier shown that FMOD is not required for the proliferation of established glioma cell lines (<xref ref-type="bibr" rid="bib35">Mondal et al., 2017</xref>). We used two human glioma cell lines, MGG8 and U251, two murine glioma cell lines, AGR53 (<xref ref-type="bibr" rid="bib2">Angel et al., 2020</xref>) and DBT-Luc (<xref ref-type="bibr" rid="bib75">Yuan et al., 2007</xref>).</p><p>MGG8-GSCs transduced with a small hairpin RNA targeting FMOD (MGG8-GSC/shFMOD) grew as neurospheres with equal efficiency as measured by neurosphere formation and limiting dilution assays and also differentiated to form DGCs as efficiently as control MGG8-GSCs transduced with non-targeting shRNA (MGG8-GSC/shNT) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>). As expected, the differentiation was accompanied by the downregulation of glioma reprogramming factors in both MGG8-GSC/shNT and MGG8-GSC/shFMOD cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In concordance with human GSCs, we found a higher expression of <italic>FMOD</italic> in AGR53-DGCs than AGR53-GSCs (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–C</xref>). To silence the expression of <italic>FMOD</italic> in AGR53-DGC, we used a doxycycline-inducible <italic>FMOD shRNA</italic> (<italic>miRFMOD</italic>) construct that contains an inducible <italic>mCherry-shRNA</italic> cassette downstream of the Tet-responsive element (<xref ref-type="bibr" rid="bib2">Angel et al., 2020</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Efficient silencing of <italic>FMOD</italic> in doxycycline-treated AGR53-DGC/<italic>miRFMOD</italic> cells was observed compared to AGR53-DGC/<italic>miRNT</italic> cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D E</xref>). Next, we investigated the impact of <italic>FMOD</italic> silencing on AGR53-GSC growth and differentiation to DGCs in vitro. Like human GSCs, AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> grew as neurospheres with equal efficiency both in the absence and presence of doxycycline (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A D</xref>). Further, both AGR53-GSC/<italic>miRNT</italic> and AGR53-GSC/<italic>miRFMOD</italic> differentiated efficiently to grow as a monolayer (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C</xref>). The differentiation resulted in the significant upregulation of astrocytic markers (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). These results confirm that FMOD is overexpressed in both human and murine DGCs but is not required for GSC growth and their differentiation to DGCs.</p><p>To study the role of FMOD on reprogramming of DGCs to form GSCs, AGR53-DGC and DBT-Luc DGC were tested for their ability to reprogram. DBT-Luc is a luciferase-expressing glioblastoma-derived cell line, which grows as a differentiated monolayer (referred to here onward as DBT-Luc-DGC) in an FBS-containing medium (<xref ref-type="bibr" rid="bib39">Pang et al., 2019</xref>). AGR53-DGC/<italic>miRNT</italic> and AGR53-DGC/<italic>miRFMOD</italic> (both in the absence and presence of doxycycline) cells grow as a monolayer efficiently and reprogrammed to form neurospheres (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>). The reprogramming resulted in the significant upregulation of stem cell markers (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>). Similarly, DBT-Luc-DGC could readily reprogram to form DBT-Luc neurospheres (DBT-Luc-GSC; data not shown) with concomitant upregulation of stem cell markers and downregulation of astrocyte markers (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A B</xref>). DBT-Luc-DGCs expressed higher levels of <italic>FMOD</italic> transcript and protein compared to DBT-Luc-GSCs (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5C D</xref>, respectively). To silence the expression of <italic>FMOD</italic> in DBT-Luc-DGC, we used the doxycycline-inducible <italic>shFMOD</italic> (<italic>miRFMOD</italic>) construct as explained above (<xref ref-type="bibr" rid="bib2">Angel et al., 2020</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). The addition of doxycycline resulted in downregulation of <italic>FMOD</italic> transcript and protein in DBT-Luc-DGC/<italic>miRFMOD</italic> but not in DBT-Luc-DGC/<italic>miRNT</italic> cells (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5E F</xref>). As expected, both DBT-Luc-DGC/<italic>miRFMOD</italic> and DBT-Luc-DGC/<italic>miRNT</italic> cells showed mCherry expression after doxycycline treatment (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5G</xref>, ). Both DBT-Luc-DGC/<italic>miRNT</italic> and DBT-Luc-DGC/<italic>miRFMOD</italic> (both in the absence and presence of doxycycline) cells reprogrammed to form neurospheres with equal efficiency (data not shown). We next explored the impact of FMOD silencing on the ability of U251 cells, an established human glioma cell line, to form neurospheres through reprogramming. U251 cells, which grow as differentiated monolayer cells (referred to here as U251-DGC) in an FBS-containing medium, can reprogram and form neurospheres enriched in CD133 expression (<xref ref-type="bibr" rid="bib59">Tao et al., 2018</xref>). Both U251-DGC/shNT and U251-DGC/shFMOD cells could reprogram with equal efficiency, as measured by neurosphere formation and limiting dilution assays (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6A–C</xref>). The neurospheres formed through reprogramming showed an upregulation of glioma reprogramming factors in U251-GSC/shNT and U251-GSC/shFMOD cells (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6D</xref>). Collectively, these observations indicate that FMOD is not required for GSC or DGC growth and differentiation or reprogramming processes.</p></sec><sec sec-type="appendix" id="s9"><title>Investigating integrin heterodimeric subunits that are required in rhFMOD-treated endothelial cells</title><p>Integrins are a family of α/β heterodimeric transmembrane adhesion receptors. To identify the integrin α and β subunits that are involved in rhFMOD activation of integrin signaling in endothelial cells, we resorted to an unbiased approach where we analyzed the transcriptome data of microvessels isolated through laser capture microdissection (LCM) from human brain samples (<xref ref-type="bibr" rid="bib54">Song et al., 2020</xref>). The transcript abundance of all integrins subunits α subunits (n = 19) and β subunits (n = 13) is shown in the following table. Three integrin subunits with maximum transcript abundance – ITGA6, ITGB1, and ITGAV – were chosen for testing. The ability of rhFMOD to induce pFAK levels in ST1 cells silenced for any of the above three integrins was investigated. The results show that all three integrins are essential for rhFMOD activation of integrin signaling in endothelial cells (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><table-wrap id="inlinetable4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="5">High-abundant integrins in endothelial cells<sup>*</sup></th></tr></thead><tbody><tr><td align="left" valign="top"><bold>S. no.</bold></td><td align="left" valign="top"><bold>Microvessel 1 FPKM (log2)</bold></td><td align="left" valign="top"><bold>Microvessel 2 FPKM (log2)</bold></td><td align="left" valign="top"><bold>Microvessel 3 FPKM (log2)</bold></td><td align="left" valign="top"><bold>Average FPKM (log2)</bold></td></tr><tr><td align="left" valign="top">ITGA6</td><td align="left" valign="top">191</td><td align="left" valign="top">68</td><td align="left" valign="top">249</td><td align="left" valign="top">169</td></tr><tr><td align="left" valign="top">ITGB1</td><td align="left" valign="top">78</td><td align="left" valign="top">26</td><td align="left" valign="top">151</td><td align="left" valign="top">85</td></tr><tr><td align="left" valign="top">ITGAV</td><td align="left" valign="top">57</td><td align="left" valign="top">91</td><td align="left" valign="top">61</td><td align="left" valign="top">70</td></tr><tr><td align="left" valign="top">ITGA7</td><td align="left" valign="top">23</td><td align="left" valign="top">28</td><td align="left" valign="top">76</td><td align="left" valign="top">42</td></tr><tr><td align="left" valign="top">ITGA1</td><td align="left" valign="top">30</td><td align="left" valign="top">4</td><td align="left" valign="top">79</td><td align="left" valign="top">38</td></tr><tr><td align="left" valign="top">ITGB8</td><td align="left" valign="top">19</td><td align="left" valign="top">41</td><td align="left" valign="top">15</td><td align="left" valign="top">25</td></tr><tr><td align="left" valign="top">ITGB5</td><td align="left" valign="top">39</td><td align="left" valign="top">9</td><td align="left" valign="top">21</td><td align="left" valign="top">23</td></tr><tr><td align="left" valign="top">ITGA5</td><td align="left" valign="top">13</td><td align="left" valign="top">11</td><td align="left" valign="top">38</td><td align="left" valign="top">20</td></tr><tr><td align="left" valign="top">ITGA10</td><td align="left" valign="top">11</td><td align="left" valign="top">9</td><td align="left" valign="top">40</td><td align="left" valign="top">20</td></tr><tr><td align="left" valign="top">ITGB1BP1</td><td align="left" valign="top">16</td><td align="left" valign="top">7</td><td align="left" valign="top">26</td><td align="left" valign="top">16</td></tr><tr><td align="left" valign="top">ITGA3</td><td align="left" valign="top">1</td><td align="left" valign="top">15</td><td align="left" valign="top">12</td><td align="left" valign="top">9</td></tr><tr><td align="left" valign="top">ITGA2</td><td align="left" valign="top">11</td><td align="left" valign="top">4</td><td align="left" valign="top">8</td><td align="left" valign="top">8</td></tr><tr><td align="left" valign="top">ITGA9</td><td align="left" valign="top">0</td><td align="left" valign="top">18</td><td align="left" valign="top">4</td><td align="left" valign="top">7</td></tr><tr><td align="left" valign="top">ITGB2</td><td align="left" valign="top">12</td><td align="left" valign="top">6</td><td align="left" valign="top">2</td><td align="left" valign="top">7</td></tr><tr><td align="left" valign="top">ITGB4</td><td align="left" valign="top">0</td><td align="left" valign="top">6</td><td align="left" valign="top">13</td><td align="left" valign="top">7</td></tr><tr><td align="left" valign="top">ITGB3BP</td><td align="left" valign="top">2</td><td align="left" valign="top">0</td><td align="left" valign="top">16</td><td align="left" valign="top">6</td></tr><tr><td align="left" valign="top">ITGAE</td><td align="left" valign="top">5</td><td align="left" valign="top">1</td><td align="left" valign="top">6</td><td align="left" valign="top">4</td></tr><tr><td align="left" valign="top">ITGB7</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">11</td><td align="left" valign="top">4</td></tr><tr><td align="left" valign="top">ITGB3</td><td align="left" valign="top">6</td><td align="left" valign="top">0</td><td align="left" valign="top">3</td><td align="left" valign="top">3</td></tr><tr><td align="left" valign="top">ITGA4</td><td align="left" valign="top">7</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">2</td></tr><tr><td align="left" valign="top">ITGAL</td><td align="left" valign="top">1</td><td align="left" valign="top">0</td><td align="left" valign="top">5</td><td align="left" valign="top">2</td></tr><tr><td align="left" valign="top">ITGA8</td><td align="left" valign="top">0</td><td align="left" valign="top">1</td><td align="left" valign="top">4</td><td align="left" valign="top">2</td></tr><tr><td align="left" valign="top">ITGAX</td><td align="left" valign="top">4</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">1</td></tr><tr><td align="left" valign="top">ITGAM</td><td align="left" valign="top">2</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">1</td></tr><tr><td align="left" valign="top">ITGA11</td><td align="left" valign="top">1</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top">ITGB1BP2</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">1</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top">ITGA2B</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top">ITGBL1</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top">ITGA9-AS1</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top">ITGAD</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top">ITGB2-AS1</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top">ITGB6</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top" colspan="5">*<xref ref-type="bibr" rid="bib54">Song et al., 2020</xref>.</td></tr></tbody></table></table-wrap></sec><sec sec-type="appendix" id="s10"><title>Bioinformatics analysis of FMOD, HES1, and JAG1 transcript levels in GBM: Classification, correlation, and prognosis</title><p>The transcript data of FMOD, HES1, and JAG1 in different data sets were used for deriving (1) transcriptional upregulation in GBM over the control brain, (2) survival prediction by Kaplan–Meier analysis, and (3) correlation between transcripts (see following table for more details). We used a total of 1885 samples that included GBMs (n = 1833) and control brain samples (n = 52). Wherever the data is not available (NA), the specific analysis is not carried out. A p-value &lt;0.05 is considered significant, with ****&lt;0.0001, ***&lt;0.001, **&lt;0.01, and *&lt;0.05. The nonsignificant data is denoted as ‘ns.’ The data is shown in <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref> and <xref ref-type="fig" rid="fig4s7">Figure 4—figure supplement 7</xref>.</p><table-wrap id="inlinetable5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="19">Expression, correlation, and survival of fibromodulin (FMOD), HES1, JAG1 in glioblastoma (GBM)</th></tr><tr><th align="left" valign="bottom" rowspan="2">S. no</th><th align="left" valign="bottom" rowspan="2">Datas et</th><th align="left" valign="bottom" rowspan="2">Source</th><th align="left" valign="bottom" rowspan="2">Control</th><th align="left" valign="bottom" rowspan="2">Survival information</th><th align="left" valign="bottom" rowspan="2">Control brain (n)</th><th align="left" valign="bottom" rowspan="2">GBM samples (n)</th><th align="left" valign="bottom" colspan="2">FMOD: GBM vs. control</th><th align="left" valign="bottom" colspan="2">HES1: GBM vs. control</th><th align="left" valign="bottom" colspan="2">JAG1: GBM vs. control</th><th align="left" valign="bottom" colspan="2">FMOD survival Kaplan–Meier</th><th align="left" valign="bottom" colspan="2">FMOD to HES1 correlation</th><th align="left" valign="bottom" colspan="2">FMOD to JAG1 correlation</th></tr><tr><th align="left" valign="bottom">log2 fold change</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">log2 fold change</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">log2 fold change</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Hazard ratio</th><th align="left" valign="bottom">Low vs. high p-value</th><th align="left" valign="bottom">R-value</th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">R-value</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">TCGA Affymetrix</td><td align="left" valign="bottom">TCGA</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">528</td><td align="char" char="." valign="bottom">6.87</td><td align="char" char="." valign="bottom">&lt;0.000</td><td align="char" char="." valign="bottom">8.98</td><td align="char" char="." valign="bottom">&lt;0.000</td><td align="char" char="." valign="bottom">8.64</td><td align="char" char="." valign="bottom">&lt;0.000</td><td align="char" char="." valign="bottom">1.40</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">&lt;0.0001</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="." valign="bottom">0.08</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">TCGA Agilent</td><td align="left" valign="bottom">TCGA</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">489</td><td align="char" char="." valign="bottom">1.42</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">0.98</td><td align="char" char="." valign="bottom">&lt;0.000</td><td align="char" char="." valign="bottom">2.04</td><td align="char" char="." valign="bottom">&lt;0.000</td><td align="char" char="." valign="bottom">1.34</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">0.36</td><td align="char" char="." valign="bottom">&lt;0.0001</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">Gravendeel</td><td align="left" valign="bottom">GSE16011</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">159</td><td align="char" char="." valign="bottom">1.9</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">1.42</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">1.84</td><td align="char" char="." valign="bottom">&lt;0.000</td><td align="char" char="." valign="bottom">2.01</td><td align="char" char="." valign="bottom">&lt;0.0001</td><td align="char" char="." valign="bottom">0.35</td><td align="char" char="." valign="bottom">&lt;0.0001</td><td align="char" char="." valign="bottom">0.12</td><td align="char" char="." valign="bottom">0.15</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">TCGA RNA Seq</td><td align="left" valign="bottom">TCGA</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">156</td><td align="char" char="." valign="bottom">2.91</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">1.01</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">2.32</td><td align="char" char="." valign="bottom">&lt;0.000</td><td align="char" char="." valign="bottom">1.31</td><td align="char" char="." valign="bottom">0.13</td><td align="char" char="." valign="bottom">0.22</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">0.58</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CGGA RNA Seq</td><td align="left" valign="bottom">CGGA</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">20</td><td align="left" valign="bottom">105</td><td align="char" char="." valign="bottom">12.94</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">9.62</td><td align="char" char="." valign="bottom">0.01</td><td align="left" valign="bottom" colspan="2">NA</td><td align="char" char="." valign="bottom">2.25</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">0.06</td><td align="char" char="." valign="bottom">0.58</td><td align="left" valign="bottom" colspan="2">NA</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">Lee Y</td><td align="left" valign="bottom">GSE13041</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">191</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">1.46</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">0.36</td><td align="char" char="." valign="bottom">&lt;0.0001</td><td align="char" char="." valign="bottom">0.29</td><td align="char" char="." valign="bottom">&lt;0.0001</td></tr><tr><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">Oh</td><td align="left" valign="bottom">GSE58401</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">105</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.33</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">0.25</td><td align="char" char="." valign="bottom">0.01</td></tr><tr><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">Bao</td><td align="left" valign="bottom">GSE48865</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">0.57</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">0.25</td><td align="left" valign="bottom">0.01</td></tr></tbody></table></table-wrap><p>For survival prediction based on the methylation status of FMOD promoter, the samples were divided into methylation high (above median β value) and low (below median β value) for two CpG IDs, cg03764585 and cg04704856, derived from TCGA and GSE48461 datasets. The data is presented in <xref ref-type="fig" rid="fig4s7">Figure 4—figure supplement 7</xref>.</p></sec></app><app id="appendix-2"><title>Appendix 2</title><table-wrap id="app2keyresource" position="anchor"><label>Appendix 2—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-FMOD (rabbit polyclonal)</td><td align="left" valign="bottom">Abgent</td><td align="left" valign="bottom">Cat# AP9243b; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10612142">AB_10612142</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-FAK (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#T9026; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477593">AB_477593</ext-link> RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2269034">AB_2269034</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho FAK (Tyr397) (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 3283; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2173659">AB_2173659</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (mouse monoclonal) unconjugated, clone GAPDH-71.1</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# G8795; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1078991">AB_1078991</ext-link></td><td align="left" valign="bottom">WB (1:20,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-actin (mouse beta monoclonal), horseradish peroxidase conjugated, clone AC-15</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A3854; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_262011">AB_262011</ext-link></td><td align="left" valign="bottom">WB (1:20,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HES1 (D6P2U) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 11988; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2728766">AB_2728766</ext-link></td><td align="left" valign="bottom">WB, IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Von Willebrand factor (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab6994; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_305689">AB_305689</ext-link></td><td align="left" valign="bottom">IHC (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD31 (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 89C2;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2160882">AB_2160882</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Jagged1 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 70109;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2799774">:AB_2799774</ext-link></td><td align="left" valign="bottom">IHC (1:200)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-FMOD (rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# PA5-26250;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2543750">:AB_2543750</ext-link></td><td align="left" valign="bottom">IHC (1:100)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD133 (rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab216323;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2847920">:AB_2847920</ext-link></td><td align="left" valign="bottom">Flow cytometry (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Prom1 (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# MA1-219;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2725113">:AB_2725113</ext-link></td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SOX2 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 3579;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2195767">:AB_2195767</ext-link></td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFAP (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab279290;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1209224">:AB_1209224</ext-link></td><td align="left" valign="bottom">ICC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFAP (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab7260;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_305808">AB_305808</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-NOTCH1 (rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# PA5-99448;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2818381">AB_2818381</ext-link></td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SMAD2 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 5339;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10626777">AB_10626777</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-pSMAD2 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 18338;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2798798">AB_2798798</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Integrin beta-1 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9699;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11178800">AB_11178800</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-integrin alpha-V (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 4711;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2128178">AB_2128178</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-integrin alpha 6 (rabbbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab18155</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">KLF8 antibody (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab168527</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse HRP conjugate (mouse polyclonal)</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# 170-5047;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11125753">AB_11125753</ext-link></td><td align="left" valign="bottom">WB (1:5000)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit (H+L) HRP conjugate (rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 31460;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_228341">:AB_228341</ext-link></td><td align="left" valign="bottom">WB (1:5000)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG (H+L), Alexa Fluor 488 (mouse polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A-11029;<break/>RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_138404">:AB_138404</ext-link></td><td align="left" valign="bottom">IHC and ICC<break/>(1:500)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit IgG (H+L), Alexa Fluor 488 (rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A-11034;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2576217">AB_2576217</ext-link></td><td align="left" valign="bottom">IHC and ICC<break/>(1:500)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG (H+L), Alexa Fluor 594 (mouse polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A-11032;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534091">AB_2534091</ext-link></td><td align="left" valign="bottom">IHC and ICC<break/>(1:500)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit IgG (H+L), Alexa Fluor 594<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A-11037;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534095">AB_2534095</ext-link></td><td align="left" valign="bottom">IHC and ICC<break/>(1:500)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit IgG (H+L), Alexa Fluor 405 Plus (rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A48254;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2890548">AB_2890548</ext-link></td><td align="left" valign="bottom">IHC and ICC<break/>(1:500)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG (H+L), Alexa Fluor 405 Plus (mouse polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A48255;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2890536">AB_2890536</ext-link></td><td align="left" valign="bottom">IHC and ICC<break/>(1:500)<break/>Secondary antibody</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Healthy adult C57BL/6 brain tissue</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Female, whole brain, isolated from the mice after perfusion for sectioning; check ‘Cryo-sectioning of fixed mouse brain’ section</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">GBM adult C57BL/6 brain tissue</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Female, whole brain, isolated from the mice after perfusion for sectioning; check ‘Cryo-sectioning of fixed mouse brain’ section</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">NU/J<break/>Healthy adult nude mice brain tissue</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Female, whole brain, isolated from the mice after perfusion for sectioning; check ‘Cryo-sectioning of fixed mouse brain’ section</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">NU/J<break/>GBM adult nude mice brain tissue</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Female, whole brain, isolated from the mice after perfusion for sectioning; check ‘Cryo-sectioning of fixed mouse brain’ section</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">GBM adult C57BL/6 subcutaneous tumor tissue</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Female, whole brain, isolated from the mice after perfusion for sectioning; check ‘Cryo-sectioning of fixed mouse brain’ section</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ℽ-Secretase inhibitor (GSI)</td><td align="left" valign="bottom">Merck</td><td align="char" char="." valign="bottom">565750</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RGD peptide (integrin inhibitor)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A8052; CAS# <ext-link ext-link-type="uri" xlink:href="https://www.sigmaaldrich.com/catalog/search?term=99896-85-2&amp;interface=CAS%20No.&amp;lang=en&amp;region=US&amp;focus=product">99896-85-2</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FAK inhibitor (PF-573228)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">PZ0117; CAS<ext-link ext-link-type="uri" xlink:href="https://www.sigmaaldrich.com/catalog/search?term=869288-64-2&amp;interface=CAS%20No.&amp;lang=en&amp;region=US&amp;focus=product"># 869288-64-2</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PP2 (Src inhibitor)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P0042; CAS# <ext-link ext-link-type="uri" xlink:href="https://www.sigmaaldrich.com/catalog/search?term=172889-27-9&amp;interface=CAS%20No.&amp;lang=en&amp;region=US&amp;focus=product">172889-27-9</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PP3 (negative control, structural analog of PP2)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">529574; CAS# 5334-30-5</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ROCK1 inhibitor</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">555550;<break/>CAS# 871543-07-6</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RAC1 inhibitor</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">553502;<break/>CAS# 1177865-17-6</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TGF-β-R1 inhibitor (SB431542)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">616464;<break/>CAS# 301836-41-9</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Fibromodulin (FMOD) (NM_002023) human</td><td align="left" valign="bottom">Origene</td><td align="left" valign="bottom">CAT# TP306534</td><td align="left" valign="bottom">Recombinant protein</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FMOD wild-type peptide (RLDGNEIKR)</td><td align="left" valign="bottom">Cellmano Biotech Limited, China</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Peptide, custom made upon order</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FMOD mutant peptide (RLDGNQIMR)</td><td align="left" valign="bottom">Cellmano Biotech Limited, China</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Peptide, custom made upon order</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">LN229</td><td align="left" valign="bottom">The American Type Culture Collection</td><td align="left" valign="bottom">#CRL-2611;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0393">CVCL_0393</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">U251-MG</td><td align="left" valign="bottom">European Collection of Authenticated Cell Cultures</td><td align="left" valign="bottom">#09063001;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0021">CVCL_0021</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MGG4, MGG6. MGG8</td><td align="left" valign="bottom">Kind gift from Dr. Wakimoto, Massachusetts General Hospital, Boston, USA</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">AGR-53</td><td align="left" valign="bottom">Kind gift from Dr. Dinorah Friedmann-Morvinski, Tel Aviv University, Israel</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom">DBT-Luc</td><td align="left" valign="bottom">Kind gift from Dr. Dinesh Thotala, Washington University in St. Louis, St Louis, MO, USA</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">ST1 (human pulmonary microvascular endothelial cells [HPMECs])</td><td align="left" valign="bottom">Kind gift from Dr. Ron Unger, Johannes Gutenberg University, Germany.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Human brain-derived microvascular endothelial cells (HBMECs)</td><td align="left" valign="bottom">Cell Biologics, USA</td><td align="left" valign="bottom">#H-6023</td><td align="left" valign="bottom">Primary Cell Line</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom">B.End3 mouse brain-derived immortalized endothelial cells</td><td align="left" valign="bottom">The American Type Culture Collection</td><td align="left" valign="bottom">#CRL-2299;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0170">CVCL_0170</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">U87-MG</td><td align="left" valign="bottom">European Collection of Authenticated Cell Cultures</td><td align="left" valign="bottom">#89081402;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0022">CVCL_0022</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">JAX:000664;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom">Female, 6–8 weeks old</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">NU/J (athymic nude)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">JAX 002019;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:002019">IMSR_JAX:002019</ext-link></td><td align="left" valign="bottom">Female, 6–8 weeks old</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">RAR3G (TetOn)</td><td align="left" valign="bottom">Dr. Dinorah Friedmann-Morvinski, Tel Aviv University</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">FMOD overexpression construct in the pcMV-entry backbone</td><td align="left" valign="bottom">Origene</td><td align="left" valign="bottom">#LY419579</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CSL Luc</td><td align="left" valign="bottom">Prof. Thomas Kandesch, Department of Genetics, University of Pennsylvania School of Medicine</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pHes1(2.5k)-luc</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat# 43806</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">NICD pCMV Neo/intracellular domain of human Notch1 (NIC-1)</td><td align="left" valign="bottom">Prof. Thomas Kandesch, Department of Genetics, University of Pennsylvania School of Medicine</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMD2.G</td><td align="left" valign="bottom">Dr. G.S. Rao, Indian Institute of Science</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">psPAX2</td><td align="left" valign="bottom">Dr. G.S. Rao, Indian Institute of Science</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VSVG</td><td align="left" valign="bottom">Dr. Dinorah Friedmann-Morvinski, Tel Aviv University</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pREV</td><td align="left" valign="bottom">Dr. Dinorah Friedmann-Morvinski, Tel Aviv University</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMDL</td><td align="left" valign="bottom">Dr. Dinorah Friedmann-Morvinski, Tel Aviv University</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">ImageJ (<ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij/">http://imagej.nih.gov/ij/</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MaxQuant software package</td><td align="left" valign="bottom">MaxQuant (<ext-link ext-link-type="uri" xlink:href="https://www.maxquant.org/">https://www.maxquant.org/</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014485">SCR_014485</ext-link></td><td align="left" valign="bottom">V 1.5.5.1</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Zen Black from Zeiss</td><td align="left" valign="bottom">Zen Black (<ext-link ext-link-type="uri" xlink:href="https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html">https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018163">SCR_018163</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">GraphPad Software (<ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">https://www.graphpad.com</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom">Version 6.01 for Windows</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">FlowJo (<ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="char" char="." valign="bottom">9.9.6 and v10</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Harris Hematoxylin</td><td align="left" valign="bottom">Merck</td><td align="char" char="." valign="bottom">6159380051046</td><td align="left" valign="bottom">Histological stain</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Eosin Y</td><td align="left" valign="bottom">SDFCL</td><td align="char" char="." valign="bottom">44027G25</td><td align="left" valign="bottom">Histological stain</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Reverse phase protein array (RPPA)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-core.html">https://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-core.html</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016649">SCR_016649</ext-link></td><td align="left" valign="bottom">M.D. Anderson Cancer Center, University of Texas, USA</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78972.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0202bj006</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2022.04.03.486893" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.03.486893"/></front-stub><body><p>The authors shed light on the role that differentiated glioma cells exerts in promoting cancer progression, revealing that the secreted fibromodulin by differentiated glioma cells is crucial in mediating angiogenesis in glioma via integrin-dependent Notch signaling. The results are important for gaining insight into the less concerned differentiated glioma cells in promoting cancer and would potentially enrich the treatment strategy for glioma.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78972.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0202bj006</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Chneiweiss</surname><given-names>Herve</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne University INSERM CNRS</institution></institution-wrap><country>France</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.03.486893">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.04.03.486893v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Non-cancer stem cell-derived Fibromodulin activates Integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Caigang Liu as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Mone Zaidi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Herve Chneiweiss (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Non-CSC as the key formulation needs to be specified and clearly clarified;</p><p>2) Statement regarding the biomarker of GSC in the Introduction part may require correction, and some important findings should be included as Reference;</p><p>3) Outline the reasons for the selection of the employed cell lines;</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1) Be more precise on why you select a cell type and a given method. May be some results are not absolutely needed and removing them could ease reading the manuscript</p><p>2) Justify why the patient-derived cell lines were not mainly used along the work and why you used &quot;circus&quot; cell lines such as U87 or U251.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78972.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Non-CSC as the key formulation needs to be specified and clearly clarified;</p></disp-quote><p>We understand the possibility that the use of &quot;non-cancer-stem cells (non-CSCs)&quot; may create confusion as it may sound like referring to stromal cells of cancer that are non-cancer cells of the tumor. This was rightly pointed out by reviewer # 2. After obtaining advice from Dr. Caigang Liu, reviewing Editor, we decided to use &quot;glioma stem-like cells&quot; (GSCs) and &quot;differentiated glioma cells&quot; (DGCs) in place of CSCs and non-CSCs respectively.</p><p>We also considered the Reference (Qiao X, et al. Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis. e<italic>Life</italic>. 2021 Jul 28;10:e65418) referred by Dr. Caigang Liu, reviewing Editor for formulating the non-CSCs. This is a good suggestion.</p><p>However, we thought it would be difficult to use this terminology as many GSC markers for glioma have been identified, resulting in heterogeneity within the GSC population.</p><disp-quote content-type="editor-comment"><p>2) Statement regarding the biomarker of GSC in the Introduction part may require correction, and some important findings should be included as Reference;</p></disp-quote><p>The statement regarding biomarker of GSC is addressed appropriately, taking the recommendations of Reviewer #2. Accordingly, references that reported the stemness properties of CD133- glioma cells (Beier et al., 2007; Chen et al., 2010; Joo et al., 2008; Ogden et al., 2008; Wang et al., 2008), involvement of miR302-367 cluster and miR18A* in the regulation of stemness (Fareh et al., 2012, Turchi et al., 2013), and the existence of stem cell-associated heterogeneity in GBM (Dirkse et al., 2019) are referred in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>3) Outline the reasons for the selection of the employed cell lines;</p></disp-quote><p>1) We have used three patient-derived GSC lines (MGG4, MGG6, and MGG8) for the initial discovery and in vitro validation of the DGC-specific expression of FMOD.</p><p>Please refer to Main Figure 1.</p><p>2) We have used one human patient-derived GSC line (MGG8) and two murine GSC lines (AGR53 and DBT-Luc) in an intracranial orthotopic mouse model experiment to prove the importance of FMOD induced angiogenesis in tumor growth. While MGG8 line silenced for FMOD using short hairpin RNA (shRNA) was used to prove the importance of FMOD in tumor angiogenesis and growth (Please refer to Main Figure 6), AGR53 and DBT-Luc lines carrying doxycycline-inducible shRNAs proved the importance of FMOD secreted by de novo generated DGCs from a GSC initiated tumor in angiogenesis and growth.</p><p>Please refer to Main Figure 5 and Main Figure 5—figure supplement 1, respectively.</p><p>3) We have also used the murine GSC line (DBT-Luc-GSC) for co-implantation experiment Please refer to Main Figure 2.</p><p>4) The only mouse model experiment carried out using the U251 cell line is now moved to the supplementary section as these cell lines are highly unrepresentative since they are grown for a long time in serum conditions, as recommended by reviewer # 2</p><p>Please refer to Main Figure 6—figure supplement 1.</p><p>5) The other places where the established glioma cell lines, LN229, U251, and U87 used, are in the main figure 3 and its figure supplements. In these experiments, we used these cells only as a source of secreted FMOD to study the angiogenesis-inducing property. However, we would like to point out that conditioned media from MGG4, MGG6, and MGG8 also showed the angiogenesis-inducing property of FMOD.</p><p>Please refer to Main Figure 3 and its figure supplements.</p><p>[Editors' note: we include below the reviews that the authors received from another journal, along with the authors’ responses.]</p><p>We thank the reviewers for their constructive comments, based on which we have revised the manuscript. All questions have been appropriately addressed and additional data have been included when requested. Please find below point-to-point responses to the reviewers’ comments describing how they were addressed.</p><disp-quote content-type="editor-comment"><p>Answers to comments from Reviewer 1</p><p>1) Large GBM or therapy-resistant GBM is characterized by at least three forms of neovascularization, angiogenesis, vasculogenesis, and vascular mimicry. This manuscript only dealt with angiogenesis. GSC is known to be involved in pericyte development to support angiogenesis and vasculogenesis. Recent reports also indicate the involvement of GSC in making vascular mimicry. The authors should at least show the effect of FMOD on vascular mimicry in vitro or in vivo (I believe the authors already have tissues from different conditions and staining for VM markers will prove the relationship).</p></disp-quote><p>In the first version, we showed the important role played by FMOD on tumor angiogenesis as measured by the ability of endothelial cells to form angiogenic networks. In the revised manuscript, we extended our studies to vascular mimicry, another form of neovascularization wherein the tumor cells transdifferentiate to form endothelial cells (TDECs) and obtain more nutrients.</p><p>– in vitro, we demonstrate that MGG8-DGCs and U87 readily differentiated to form TDECS when grown in M199 media, which correlated with increased CD31 expression and decrease in FMOD expression. Both TDECs formed angiogenic networks more efficiently in the presence of rhFMOD. <italic>These data are illustrated on Figures 3G-J and Supplementary Figure 15. See page no. 9, lines 259 to 271 for more detail in the revised manuscript.</italic></p><p>– in vivo, we demonstrate that large tumors formed by MGG8-GSC, AGR53-GSC, and DBTLuc-GSC in FMOD+ condition show the presence of TDECs, as evidenced by significant colocalization of CD31 and either GFAP (for MGG8) or GFP (for AGR53 and DBT-Luc) on blood vessels. This process was significantly reduced in small tumors formed by the above cells in FMOD-silenced conditions. <italic>These data are illustrated on Figures 7 G-L and Supplementary Figures 27G-I; see page no. 14, lines 422 to 428 for more detail in the revised manuscript.</italic></p><disp-quote content-type="editor-comment"><p>2) Larger GBM and recurrent GBM release many cytokines and attractants that mobilize and accumulate BMDPC in the tumor and cause vasculogenesis. The author should investigate or discuss the effect of FMOD on vasculogenesis.</p></disp-quote><p>We appreciate the suggestion of the reviewer to investigate the role of BMDPC and vasculogenesis. We tried to examine this phenomenon by staining the tumor sections using antiCD34 (a BMDPC-specific endothelial cell marker). While we found colocalization of CD34 and CD31 in a few locations on the blood vessels (the data are shown in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>), we are not comfortable with the quality of the CD34 antibody available. Hence, we would that these results are not included in the manuscript and to consider this line of investigation in the future.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Co-localization of BMDPC marker CD34 and endothelial marker CD31 in blood vessels.</title><p>A. Co-localization of the two markers in tumor sections of MGG8-GSC/shNT. B. Co-localization of the two markers in MGG8-GSC/shFMOD tumor sections. Yellow regions in the merged image of MGG8-GSC/shNT tumor section depicts the co-localization of CD34 and CD31. Scale = 50 µm, Magnification = 40X.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-sa2-fig1-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>3) ST1 is an endothelial cell line that originated from the lungs. These are not a replica of GBM or brain associated microvascular derived EC. The author should prove that there are no differences between EC from the brain and lungs in respect of in vitro angiogenesis with or without FMOD.</p></disp-quote><p>To address this issue, we have used two endothelial cell lines originating from human and murine brain -primary human brain microvascular endothelial cells (HBMECs) and murine immortalized brain endothelial cells (B.End3), respectively. Our results show that CM derived from MGG8 DGC/shNT is more efficient to promote formation of angiogenic networks by both B.End3 and HBMECs than CM derived from MGG8 DGC/shFMOD cells (Supplementary Figure 14F; Figures 3E and F). The effect of FMOD silencing was rescued by adding rhFMOD exogenously to both cell types (Supplementary Figure 14F; Figures 3E and F). This indicates that the pro-angiogenic effect of FMOD is conserved across endothelial cells, irrespective of their tissue of origin, and validates our initial findings using the human pulmonary microvascular endothelial cells (ST1). See page no. 9, lines no. 253 to 258 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4) If the development of GBM from GSC is related to DGC, then targeting GSC will not be the answer for therapeutic purposes. The authors should give a guideline on how to deal with the scenario in the clinical context. Antiangiogenic therapy is not fruitful, therefore, the guideline should emphasize breaking the link between DGC and GSC.</p></disp-quote><p>The present study demonstrates that in addition to GSCs, DGCs have an essential role in tumor growth and maintenance. While the therapy-resistant and self-renewing GSCs trigger the early events of transformation and growth, DGCs, the proportion of which continues to increase during tumor growth, progressively become essential. Thus, targeting both cancer stem cells and differentiated cancer bulk cells is crucial to achieve a durable response. The study also highlights the potential of GSC and DGC CM analysis to uncover novel targets in cancer therapy and the critical influence of DGC-secreted FMOD in glioma tumor growth. This aspect is discussed in the Discussion section. See page no. 17, lines no. 504 to 510 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Answer to comments from Reviewer 2</p><p>1) The manuscript is very hard to follow in places and takes leaps of logic. It would be far more helpful if the authors would focus on generating data to support a coherent story that is logically presented.</p></disp-quote><p>To address this issue, we have modified the manuscript to make it more coherent. The experiments showing that FMOD is not required for GSC growth and differentiation as well as DGC growth and reprogramming have been moved to supplementary information. These data are now illustrated on supplementary figures 6-11.</p><disp-quote content-type="editor-comment"><p>2) One issue is that the proteomics study seems a bit too easy that the authors happened to identify a protein that they have already studied. It would be better to do a secondary screen or some other prioritization.</p></disp-quote><p>The choice of FMOD from the proteomic data was motivated by the objective to identify proteins preferentially secreted by DGCs involved in ECM remodelling. This is the reason why we considered proteins enriched in the DGC secretome, compared to the GSC secretome, and annotated to be ECM proteoglycans (see the Venn diagram on Figure 1B). Among the six proteins exhibiting these characteristics, FMOD was the most enriched in the DGC secretome, compared to the GSC secretome. These results and our earlier work on FMOD led us to choose FMOD to further investigate its role in tumor formation by inducing ECM remodelling and associated phenotypes such as angiogenesis.</p><p>See page no. 5 and 6, lines no 148 to 165 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>3) One major concern is that GSC and DGC are cultured differently. It is not clear to me that FMOD is strictly connected to differentiated cells, but rather adherent cells grown in serum, which can induce ECM expression. The in vivo studies in Figure 2 are the best evidence but should be better developed.</p></disp-quote><p>Several lines of evidence support that “specific” FMOD expression in DGCs (compared with GSCs) is not due to specific culture conditions (grown as adherent cells in serum-containing medium):</p><p>1) Our previously published study (Mondal et al., 2017, Oncogene, 36, 71–83) showed a highly variable pattern of FMOD expression by several established adherent GBM cultures even though all cell lines used in the study were grown as adherent cultures in serum-containing medium. U251, U87, and U343 cells show very high FMOD expression while others like LN229 and LN18 cells show minimal or no detectable FMOD expression. This observation suggests that FMOD expression is not related to specific culture conditions such as the use of adherent cells and serum-containing media.</p><p>2) Both GSCs and DGCs (MGG8) are grown as a monolayer on Geltrex-coated cell culture dishes. In this condition, we show that (see <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> for detail):</p><p>a) FMOD RNA and protein (intracellular and secreted) are still more abundant in DGCs than in GSCs (see panels A and B of <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>).</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Figure 2: GSCs and DGCs grown as adherent cultures retain expression of their unique markers.</title><p>A. Real-time qRT-PCR analysis showing FMOD mRNA upregulation in DGCs over GSCs. B. Western blotting showing FMOD protein overexpression, both in the total cellular proteome (left) and the secretome (right) of DGCs vs. GSCs. C. Real-time qRT-PCR analysis showing downregulated expression of four reprogramming factors in DGCs compared with GSCs. D. Expression of SSEA1, FMOD, CD133, and GFAP in GSCs vs. DGCs in adherent conditions. E. Flow cytometry analysis showing and enrichment of CD133-positive cells in the GSC cultures compared with DGC cultures.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78972-sa2-fig2-v3.tif"/></fig><p>b) RNA level of four reprogramming factors are upregulated in GSCs, compared with DGCs (see panel C of <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>).</p><p>c)Confocal staining of SSEA1, <italic>SOX2</italic>, and CD133 show that they are upregulated in GSCs, while GFAP and FMOD are upregulated in DGCs (see panel D of <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>).</p><p>d) FACS analysis of CD133 expression by GSCs and DGCs shows an enrichment of CD133 positive-cells in the GSC monolayer but not in the DGCs (see panel E of <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>).</p><p>Our results show that even when GSCs and DGCs are grown in adherent conditions, DGCs express higher levels of FMOD than GSCs. Thus, the DGC-specific expression of FMOD compared to GSC is not related to adherent growth conditions.</p><p>3) We also demonstrate that in FMOD+ tumors (in all three orthotopic tumors using AGR53, DBT-Luc, and MGG8 GSCs), FMOD colocalizes with GFAP, further supporting that preferential FMOD expression and secretion by DGCs takes place in vivo<italic>.</italic></p><p>These data are illustrated on Supplementary Figures 24, 25, and 26;. See page no. 14, lines no. 405 to 414 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4) FMOD has been strongly connected to TGF-β signaling (and invasion and angiogenesis). It is not clear from the studies how the proposed signaling integrates into the prior modeling of protein function.</p></disp-quote><p>As suggested by the reviewer, we firmly believe that FMOD expression in DGCs is under the control of TGF-β signaling. In the revised manuscript, the following aspects have been addressed:</p><p>1) GSEA analysis of DEGs (differentially regulated genes) in GSCs over DGCs (Suva et al., 2014, 157, 580-594, Cell) showed a significant depletion of many gene sets associated to TGF-β signaling (Supplementary Figure 2).</p><p>2) GSEA analysis of GBM DEGs (GBM/Control) showed a significant enrichment of many gene sets associated to TGF-β signaling (Supplementary Figure 3)</p><p>3) FMOD and TGM2 RNA levels are more elevated in DGCs than in GSCs, and decreased upon treatment of cells with the TGF-β inhibitor (SB431542) (Figure 1G)</p><p>4) FMOD (intracellular and secreted, Figure 1H) and pSMAD (Figure 1I) levels are more elevated in DGCs than in GSCs, and decreased upon treatment of cells with the TGF-β inhibitor SB431542</p><p>5) TGF-β1-induced luciferase activities of SBE-Luc and FMOD Promoter-Luc reporters are higher in MGG8-DGCs than in MGG8-GSCs, and are inhibited upon SB431542 treatment (Supplementary Figures 5C, D).</p><p>6) pSMAD2 occupancy in FMOD promoter is higher in MGG8-DGCs than in MGG8GSCs and is reduced by SB431542treatment (Figure 1J)</p><p>All the above data are presented in pages no. 6 and 7, lines 166-188 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5) The authors bounce between cell lines. I am not clear why the authors use MGC lines for the discovery then use other cell types for all the experiments. The rationale for using LN229 and U251 is particularly weak, as these cells have been extensively cultured in serum. I would drop the studies with these lines or relegate them solely to supplemental figures.</p></disp-quote><p>In the revised manuscript, we have included experiments in an intracranial orthotopic tumor mouse model using one human GSC cell-line (MGG8; Figures 6 A-D), and a new murine glioma cell line (DBT-Luc; Supplementary Figure 23) in addition to the previously used murine (AGR53; Figures 5A-G) and human glioma cell lines (U251; Figure 6E –I). This data is described in page no. 12-14, lines no 363 to 402 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>6) To address the concerns about culture conditions complicating interpretation of comparing GSC and DGC, I would suggest performing more studies with cell sorting and comparison with the same culture conditions. MGC have been cultured for prolonged periods and may resemble cell lines.</p></disp-quote><p>We agree in principle with the reviewer. However, we cultured GSCs as neurospheres in neural stem cell media supplemented with growth factors so that the enrichment in CD133-positive cells of the neurospheres is maintained as reported by Suva et al., Cell 157, 580-594, 2014. The enrichment of CD133-positive cells was verified at regular intervals of culturing.</p><p>Further, we now show that the MGG8 GSC neurospheres used in our experiments (Figure 6) are indeed enriched in CD133-positive cells. This data is described in page no. 13, lines no 389 to 391 in the revised manuscript.</p><p>Moreover, the “DGC-specific” expression of FMOD was demonstrated when both GSCs and DGCs are grown as monolayers in Geltrex-coated cell culture dishes. More detail is given in answer to comment no # 2 of the reviewer</p><disp-quote content-type="editor-comment"><p>7) The studies only use single knockdown approaches (sometimes siRNA, sometimes shRNA, etc.). It would be helpful to demonstrate better controls and rescue.</p></disp-quote><p>In the previous version of the manuscript, siRNA was used to silence FMOD expression in U251 cells while shRNA was used in MGG8-DGCs for the purpose of collecting conditioned media to set up in vitro angiogenesis experiments. In the revised manuscript, silencing of FMOD was achieved by using shRNA in U251 cells and siRNA in MGG8-DGCs. (Supplementary Figures 13 B and E). This data is described in page no. 8, lines no 235 to 238, and page no. 9, lines no. 248-251 in the revised manuscript.</p><p>We had already illustrated the “rescue” experiments in U251/siFMOD and MGG8DGC/shFMOD cells (see Figures 3C, D) in the first version of the manuscript. In the revised manuscript, additional rescue experiments were carried out in human brain-derived primary endothelial cells (HBMECs) and mouse brain-derived immortalized endothelial cells (bEnd.3) (see Figure 3 E and F; Supplementary Figure 14F). In all these cellular modles, the reduced angiogenic network formation in presence of CM from FMOD-silenced cells is rescued by the exogenous addition of rhFMOD. This data is described in pages no. 8 and 9, lines no 224 to 257 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>8) I would strongly suggest consideration of FMOD analysis in the absence of culture. They should consider double staining of tumor specimens for stem/differentiation markers and FMOD. Also, FMOD expression should be near blood vessels and pFAK and Hes1.</p></disp-quote><p>To address this question, we used tissue samples from various intracranial tumor models (human and murine) to show that FMOD is indeed colocalized with GFAP (used as differentiation marker), to validate our initial finding that FMOD is “solely” secreted by the DGCs. These new data are illustrated on Supplementary Figures 24-26, described in page no. 14, lines no. 403 to 414 in the revised manuscript.</p><p>We also show a co-localization of CD31 and FMOD, CD31 and pFAK, CD31 and JAG1, and CD31 and HES1 in all three tumor models (Supplementary Figures 28A-C). This data is described in pages no. 14 and 15, lines no. 428 to 434 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>9) It would be helpful to consider the choice of lines with the studies of FMOD. FMOD appears to be lower in proneural tumors, which is not surprising due to the association with TGF-β. It would be important to consider the subtype of all the lines used.</p></disp-quote><p>We agree with the reviewer that FMOD expression is not associated with proneural tumors. We show in the revised manuscript that the expression of FMOD and the enrichment of TGFβ signaling gene set are more pronounced in mesenchymal subtype GBM (Supplementary Figures 5A and B). We also show that DGCs used in this study, which exhibit high FMOD expression, are also of the mesenchymal subtype, with an enrichment of genes of the TGF-β signaling pathway (Supplementary Figure 4). This data is described in pages no. 6 and 7, lines no. 166 to 188 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>10) ST1 cells are not ideal as endothelial cells, as they have been immortalized, which may change the signaling.</p></disp-quote><p>To address this issue, we have used two endothelial cells lines of brain origin, primary human brain microvascular endothelial cells (HBMECs) and murine immortalized brain endothelial cells (B.End3). Our results show that CM of MGG8-DGC/shNT cells is more efficient to promote angiogenic network formation by bEnd.3 and HBMECs than CM of MGG8DGC/shFMOD cells (Figures 3E and F; Supplementary Figure 14F), reminiscent of our initial observations using ST1 cells. Again, the effect of FMOD silencing was rescued by adding rhFMOD to both cell types (Figures 3 E and F; Supplementary Figure 14F). This indicates that the pro-angiogenic effect of FMOD is conserved across endothelial cells, irrespective of their tissue of origin, and confirms the validity of our initial findings using the human pulmonary microvascular endothelial cells (ST1). See page no. 9, lines no. 253 to 257 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>11) It would seem that the upstream regulation of FMOD should be better investigated to understand why DGC, not GSC, express FMOD</p><p>As suggested by the reviewer, we carried out several experiments to confirm that FMOD expression in DGCs is under the control of TGFβ signalling. The detail is provided in the answer to comment #3 above.</p><p>12) The key experiments would seem to be determining if over expression of FMOD in GSC could replace DGC with in vivo growth. This is the more important finding. I was particularly concerned with the design of Figure 6. The authors assume that the effects of FMOD are due to the DGC, but there is no direct evidence to this effect. I was not even sure why there was not greater study of the xenografts for expression of FMOD and the other signaling molecules.</p></disp-quote><p>While we show that FMOD is an important mediator of angiogenesis induced by DGCs, thereby contributing to tumor growth, DGCs may also influence tumor growth through FMODindependent mechanisms. For example, Wang et al. showed a reciprocal signaling between GSCs and DGCs in promoting tumor growth whereby DGC-secreted BDNF acts on NTRK2 receptors on the GSC membrane to activate self-renewal and activation of GSCs. (Wang et al., Cell Stem Cell, 22, 514-528, 2018). Hence, it is unlikely that overexpressing FMOD in GSCs would replace DGCs in tumor growth in vivo.</p><p>To address the reviewer’s other concerns, we utilized tissue samples from our various intracranial tumor models (human and murine) to show that FMOD is colocalized with GFAP (used as a differentiation marker) and thus validating our initial finding that FMOD is “solely” secreted by the DGCs in vitro. These data are illustrated on Supplementary Figures 24-26. We further demonstrate that the small tumors formed in FMOD-silenced conditions show GFAP staining, suggesting that differentiation has indeed occurred in the absence of FMOD, which supports our in vitro data indicating that FMOD is not needed for GSC differentiation to DGC.</p><p>Further analysis showed reduced angiogenesis in the small tumors formed in FMOD-silenced conditions (Figures 7A-L; Supplementary Figures 27 A-I). From these results, we conclude that compromised angiogenesis is indeed the main reason why tumor growth is reduced in FMOD-silenced condition. We also show the co-localization of CD31 and FMOD, CD31 and pFAK, CD31 and JAG1, and CD31 and HES1 in all three tumor models used in our study, which confirms (in addition to in vitro data) the activation of integrin-Notch signaling in FMOD-treated endothelial cells (Supplementary Figures 28 A-C). See pages no. 14 and 15, lines no. 403 to 434 for more detail in the revised manuscript</p><disp-quote content-type="editor-comment"><p>13) FMOD appears to be prognostic. This has been reported by the authors but could be better developed.</p></disp-quote><p>We have obtained the following data highlighting the prognostic significance of FMOD:</p><p>1) Significant upregulation of FMOD, JAG1, and HES1 in GBM in 5 data sets (Supplementary Figure 21 A-C)</p><p>2) Correlation between FMOD and HES1 transcripts and between FMOD and JAG1 transcripts in 8 data sets (Supplementary Figures 21 D and E)</p><p>3) Association of high FMOD transcript levels with poor prognosis in 5 data sets (Supplementary Figure 22 A)</p><p>4) Association of FMOD promoter hypomethylation with poor prognosis in 4 data sets (Supplementary Figure 22 B).</p><p>See page no. 12, lines no. 353 to 362 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>14) With FMOD already being reported to be connected to invasion, I was not sure why this was not examined. Also, the effects of FMOD on the immune system should be considered.</p></disp-quote><p>To address this issue, we performed invasion assays of ST1 cells treated with BSA vs. rhFMOD or CM of either MGG8-DGC/shNT or MGG8-DGC/shFMOD cells. We show that the presence of FMOD favors invasion of the ST1 cells (Supplementary Figures 14 C and D). See page no. 9, lines no. 251 to 253 for more detail in the revised manuscript.</p><p>We agree with the reviewer that investigating the effect of FMOD on the immune system would be of great interest and certainly warrants further exploration. However, we have been successful in addressing almost all comments by producing an important amount of new data both in vitro and in vivo. We would like to address this point in the future. We hope that the reviewer will share our opinion that it is beyond the main scoop of the current article.</p><disp-quote content-type="editor-comment"><p>15) The summary figure appears premature, as there are a number of molecules that have not been tested and the design of the Notch and KAK studies were not ideal. The authors should have engineered endothelial cells to have activated Notch and FAK to see if this rescues the effects of loss of FMOD in DGC.</p></disp-quote><p>To address the reviewer’s concerns, we carried out the following experiments in the revised manuscript.</p><p>1) We showed that αVβ1 and α6β1integrins play an important role in rhFMOD-mediated induction of pFAK levels (Supplementary Figures 18 D-I).</p><p>2) Pre-treatment of ST1 cells with FAK inhibitor or a Src inhibitor (PP2) reduced significantly the rhFMOD-mediated activation of CSL-Luc and HES-Luc (Supplementary Figures 19 AD), and induction of HES1 transcript and protein in ST1 cells (Supplementary Figure 19 E-</p><p>H).</p><p>3) Pre-treatment of ST1 cells with FAK inhibitor or PP2 (a Src inhibitor) significantly reduced the activation of JAG1 by rhFMOD (Supplementary Figures 20 B and C).</p><p>4) Silencing JAG1 in endothelial cells inhibited the ability of rhFMOD to activate CSL-Luc and HES-Luc (Supplementary Figures 20 D and E), increase HES1 transcript and protein levels, and induce angiogenic network formation by the ST1 cells (Figures 4 I-L).</p><p>5) We have identified KLF8 as the FAK-activated transcription factor responsible for JAG1 activation in rhFMOD-treated endothelial cells (Supplementary Figures 20 G and H).</p><p>6) We have also engineered ST1 cells exhibiting constitutively active Notch signaling. We stably expressed the Notch-intracellular domain (NICD) or the Vector Control (VC) in ST1 (ST1/NICD, ST1/VC) cells. (Supplementary Figure 17A and B). ST1/NICD cells showed higher capacity to form angiogenic networks by themselves, compared with ST1/VC cells (Supplementary Figures 17C and D). ST1 cells were then be subjected to angiogenesis network formation assay in the presence or absence MGG8-DGC/shNT vs. MGG8DGC/shFMOD CM. We observed that the lack of FMOD in MGG8-DGC/shFMOD CM caused a significant decrease in network formation by ST1/VC cells but not by ST1/NICD cells (Supplementary Figures 17 C and D). These results confirm that Notch activation is an essential step in FMOD-induced angiogenesis. <italic>See pages no. 9-12, lines no. 272 to 362 for more detail in the revised manuscript.</italic></p><p>7) We also show co-localization of CD31 with FMOD, pFAK, JAG1 and HES1 in the three tumor models used in our study, which confirms (in addition to in vitro data) the activation for integrin-Notch signalling in FMOD-treated endothelial cells (Supplementary Figures 28 AC). <italic>See page no. 14, lines no. 428 to 434 for more detail in the revised manuscript.</italic></p><disp-quote content-type="editor-comment"><p>Minor points:</p><p>1) The data presentation is not professional. The figures do not comply to Cell journal standards.</p></disp-quote><p>Efforts were made to make appropriate changes in the Figures and to improve their readability.</p><disp-quote content-type="editor-comment"><p>2) Better statistical testing with correction for multiple comparisons should be performed.</p></disp-quote><p>We have now systematically performed ANOVA in experiments where multiple samples were compared.</p><disp-quote content-type="editor-comment"><p>Answer to comments from Reviewer 3</p><p>1) The authors use 10% FBS to induce GSC differentiation into DGC, and the corresponding two types of conditioned medium were harvested and analyzed by mass spectrometry. It is unclear if these two cell types were cultured in same medium (stem cell medium or normal cancer cell medium?). Furthermore, FMOD was identified to be enriched in DGC-conditioned medium, which could be simply due to the effects of floating (cancer stem cells) vs adherent cells (differentiated cells). As this is the foundation of the whole study, the authors need to verify it in a well-controlled system, e.g., glioma stem cells (CD133+) vs non-stem glioma cells (CD133-), both cultured as neuro spheres, from the same patients. Since many datasets of global gene expression in GSCs and DGCs have been published, the authors could easily verify the specific mRNA expression of FMOD in DGCs.</p></disp-quote><p>Overall, we agree with the reviewer. However, we cultured GSCs as neurospheres in neural stem cell media supplemented with growth factors so that the enrichment of CD133-positive cells in neurospheres in was maintained (see Suva et al., Cell 157, 580-594, 2014). We also verify this point at regular intervals of culturing and show that the MGG8-GSC neurospheres used in our experiments (Figure 6A) are indeed enriched in CD133-positive cells.</p><p>Moreover, the DGC-specific expression of FMOD is also shown when both GSCs and DGCs are grown as monolayers in Geltrex-coated cell culture dishes. More detail is given in the answer to comment #2 of Reviewer #2.</p><p>2) Figure 3. The in vitro angiogenesis analysis is weak, solely depending on tube formation assay. The results need to be further verified by EC proliferation and migration assays.</p><p>To address the reviewer’s comment, we have included a number of new data:</p><p>1) We show that FMOD (rhFMOD or FMOD coming from MGG8-DGC/shNT CM) induces migration, invasion, but not proliferation of ST1 cells (Supplementary Figures 14A-E). See page no. 9, lines no. 249 to 251 for more detail in the revised manuscript.</p><p>2) Using two additional endothelial cell lines of brain origin (namely primary human brain microvascular endothelial cells (HBMECs) and murine immortalized brain endothelial cells (b.End3), we show that CM from MGG8-DGC/shNT cells promotes formation of angiogenic networks by HBMECs (Figures 3E and F) and B.End.3 (Supplementary Figure 14F) more efficiently than CM from MGG8-DGC/shFMOD cells. The effect of FMOD silencing was rescued by adding rhFMOD to both cell types (Figures 3 E and F; Supplementary Figure 14F). This indicates that the pro-angiogenic effect of FMOD is conserved across endothelial cells, irrespective of their tissue of origin, and confirms the validity of our initial findings using human pulmonary microvascular endothelial cells (ST1). See page no. 9, lines no. 253 to 258 for more detail in the revised manuscript.</p><p>3) The small size tumors formed by AGR53-GSC/miRFMOD cells after doxycycline treatment showed reduced staining for CD31 and vWF (von Willebrand factor) compared to tumors formed by AGR53-GSC/miRNT cells (Figures 7A-C; Supplementary Figures 27 A-C). Likewise, tumors formed by DBT-Luc GSC/miRFMOD cells in doxycycline-treated mice showed significantly reduced CD31 staining, compared with those developed by DBT-Luc GSC/miRFMOD cells in the absence of doxycycline treatment (Supplementary Figures 27 D-F). Like murine glioma tumors, tumors developed by MGG8-GSC/shFMOD cells showed reduced CD31 staining compared to tumors formed by MGG8-GSC/shNT cells (Figures 7 DF). We also tested the extent of blood vessel formation by TDECs (Tumor-derived endothelial cells). In all the three tumor models used, blood vessels formed by TDECs were significantly reduced in tumors formed in FMOD-silenced condition (Figures 7G-L; Supplementary Figures 27 G- I). See page no. 14, lines no. 414 to 428 for more detail in the revised manuscript.</p><p>These findings confirm our results in vitro, where the absence of FMOD decreased the ability of host-derived endothelial cells and TDECs to form angiogenic networks (Figure 3; Supplementary Figures 13-15). From these results, we conclude that angiogenesis induced by DGCsecreted FMOD is essential for glioma tumor growth.</p><p>4) We also show the co-localization of CD31 and FMOD, pFAK, JAG1, and HES1 in all the three tumor models used, which confirms (in addition to in vitro data) the activation of integrin-Notch signaling in FMOD-treated endothelial cells (Supplementary Figures 28 A-C). See page no. 14, lines no. 428 to 434 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>3) The mechanism study is relatively weak. The authors should identify the integrin that interacts with FMOD and test its role in FMOD-induced angiogenesis. To support the proposed model (Figure 7), the authors may define the precise mechanism by which FMOD induces FAK/Src activation and Jag1 expression, such as assays for dependency of Src/FAK on Jag1 expression, transcription factor/promoter binding, and transcriptional activation.</p></disp-quote><p>To address the reviewer’s comment, the following data have been included in the revised manuscript.</p><p>1) With respect to integrin signaling, we show that ITGA6, ITGAV and ITGB1 are highly expressed in endothelial cells (See supplementary information); Silencing experiments proved that all three integrins are important for the increase in pFAK levels induced by rhFMOD. This suggests the involvement of αVβ1 and α6β1 integrins in rhFMOD effects in endothelial cells (Supplementary Figures 18 D-I).</p><p>2) Pre-treatment of ST1 cells with FAK inhibitor or PP2 (Src inhibitor) significantly reduced the rhFMOD-mediated activation of CSL-Luc and HES-Luc (Supplementary Figures 19 AD), as well as induction of HES1 transcript and protein in ST1 cells (Supplementary Figures 19 E-H).</p><p>3) Pre-treatment of ST1 cells with FAK inhibitor or PP2 reduced the activation of JAG1 by rhFMOD (Supplementary Figures 20 B and C).</p><p>4) Silencing JAG1 in endothelial cells inhibited the ability of rhFMOD to activate CSL-Luc and HES-Luc (Supplementary Figures 20 D and E), induce HES1 transcript and protein, and induce angiogenic network formation by the ST1 cells (Figures 4 I-L).</p><p>5) We identified KLF8 as the FAK-activated transcription factor responsible for JAG1 activation in rhFMOD-treated endothelial cells (Supplementary Figures 20 G and H).</p><p>6) We engineered ST1 cells exhibiting constitutively active Notch signaling. We stably expressed the Notch-intracellular domain (NICD) or the Vector Control (VC) in ST1 (ST1/NICD, ST1/VC) cells (Supplementary Figures 17A and B). ST1/NICD cells showed higher capacity to form angiogenic networks by themselves, compared with ST1/VC cells (Supplementary Figures 17C and D). ST1 cells were then be subjected to in vitro angiogenesis network formation assay in the presence or absence of MGG8-DGC/shNT or MGG8-DGC/shFMOD CM. We observed that the lack of FMOD in MGG8-DGC/shFMOD CM caused a significant decrease in network formation by ST1/VC cells but not by ST1/NICD cells (Supplementary Figures 17 C and D). These results confirm that Notch activation is an essential step in FMODinduced angiogenesis. See pages no. 9-12, lines no 272 to 362 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4) The authors should validate their proposed molecular mechanism in the in vivo study, such as FMOD-induced and endothelial Jak1 expression in tumor ECs.</p></disp-quote><p>We show a co-localization of CD31 and FMOD, pFAK, JAG1, and HES1 in all three tumor models used in the studies, which confirms (in addition to in vitro data) the activation for integrin-Notch signaling in FMOD-treated endothelial cells (Supplementary Figures 28 A-C).</p><p>See page no. 14, lines no. 428 to 434 for more detail in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Other concerns:</p><p>1. Numerous mistakes/typos in references, e.g., Wang et al., 2918 (from future?) and Mondal et al., 2017 (could be seen in the ref list) in Page 6 and etc.</p></disp-quote><p>We carefully proofread the entire manuscript (including references) and corrected the mistakes.</p><disp-quote content-type="editor-comment"><p>2. Figure S1. The shRNA knockdown efficiency needs to be shown.</p></disp-quote><p>The knockdown of FMOD in MGG8 GSCs and DGCs is shown in the revised manuscript (Supplementary Figure 6A). In addition, FMOD-silencing in tumor models is shown on Figures 5 and 6, and Supplementary Figures 23-26.</p><disp-quote content-type="editor-comment"><p>3) Figure S2.D.E. The results of FMOD knockdown were not consistent in S2D and S2E, or the lanes were wrongly labeled.</p></disp-quote><p>This mistake has been rectified and shown in Supplementary Figure 7 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4) Figure S5. Considering several patient-derived GSCs are available in the authors' laboratory, why authors use U251 and mouse GSCs to test the role of FMOD in stemness and differentiation?</p></disp-quote><p>In the revised manuscript, we have included experiments in an intracranial orthotopic tumor model in the mouse using one human GSC cell-line (MGG8; Figures 6 A-D), and an additional murine glioma cell line (DBT-Luc; Supplementary Figure 23) in addition to existing experiments using murine (AGR53; Figures 5A-G) and human (U251; Figures 6E–I) glioma cell lines. This data is described in pages no. 12-14, lines no. 363 to 402.</p><disp-quote content-type="editor-comment"><p>5) Figure S10. The in vivo angiogenesis data is important for the whole study, and, therefore, is suggested to move to main figure. Furthermore, the main findings need to validate by additional assays, such as vessel perfusion or tumor hypoxia. In addition, the changes in representative images, but not in the quantified data, are not impressive. Additional staining with CD31 immunofluorescence would strengthen the results.</p></disp-quote><p>To address this concern, we have carried out the following experiments in the revised manuscript.</p><p>1) We have done additional angiogenesis-related experiments in vivo and the results are illustrated on Figure 7 and Supplementary Figure 27.</p><p>2) In the revised manuscript, we also demonstrate that FMOD induces angiogenic network formation by tumor-derived endothelial cells (TDECs) both in vitro and in vivo.</p><p>in vitro, we demonstrate that MGG8-DGCs and U87 cells readily differentiate to form endothelial cells (tumor-derived endothelial cells; TDECs) when grown in M199 media, which correlated with increased CD31 expression and decreased FMOD expression. In both cases, TDECs were induced to form angiogenic networks by the presence of rhFMOD. These new data are presented on Figures 3G-J and Supplementary Figure 15.</p><p>in vivo, we demonstrate that large tumors formed by MGG8-GSC, AGR53-GSC, and DBTLuc-GSC in FMOD+ condition show the presence of TDECs, as evidenced by significant colocalization of CD31 and GFAP (for MGG8), GFP (for AGR53 and DBT-Luc) on the blood vessels. This was significantly reduced in small tumors formed by the above cells in FMODsilenced conditions (Figures 7 G-L; Supplementary Figures 27 G-I).</p></body></sub-article></article>